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Abstract 
Background: South Africa has the fourth highest prevalence of Human Immunodeficiency 
Virus (HIV) in the world, with over 340 000 new infections in 2013 alone. Implementation of 
Highly Active Antiretroviral Treatment (HAART) regimens, has improved the lives of many HIV-
infected individuals, and has led to a decrease in the incidence of extreme forms of HIV-
associated dementia. However, the extended lifespan afforded by HAART has also resulted in 
an increase in the prevalence of milder forms of HIV-associated Neurocognitive Disorders 
(HAND). Clinical diagnosis of such cognitive decline currently relies on neurocognitive 
assessments, as no definitive biochemical test exists. A point-of-care test designed for use 
with easily accessible samples (e.g. blood) would be of great utility in both HAND research and 
clinical diagnosis, prognostication, and provision of timeous therapy. A blood-based 
biomarker test would also be less subjective than neurocognitive testing, which can be 
adversely affected by the patient’s level of education as well as operator competency. 
Recently, Professor Simon Lovestone (University of Oxford) developed a panel of blood-based 
biomarkers for the diagnosis of Alzheimer’s disease. Due to pathological similarities between 
HAND and Alzheimer’s disease, it is hypothesised that there may be applicability of this panel 
to diagnosis of HAND. The differential protein expression profile of patients with and without 
HAND is thus compared. 
Aims and Objectives: The aim of this study was to assess the applicability of a set of 
Alzheimer’s disease biomarkers to the diagnosis of HAND. In order to achieve this, targeted 
proteomic assays were developed to measure the markers in human serum. This assay was 
then applied to defined patient cohorts. 
Methods: Targeted proteomic assays were developed in order to quantify candidate markers 
in patient blood serum. Parallel Reaction Monitoring assays were developed on a Thermo Q 
Exactive Quadrupole-Orbitrap mass spectrometer, for application to defined patient samples 
collected from Groote Schuur Hospital (Cape Town, South Africa). Patient samples were 
divided into groups according to HAND severity (based on the HIV Dementia Scale), namely: 
Normal (HIV+), Minor Neurocognitive Disorders and HIV-associated Dementia. Discovery 
proteomic analysis was performed on pooled patient samples in order to determine the 
optimal peptides for identification and quantitation of candidate proteins. Targeted methods 
were then developed and refined using the same pooled samples. Finally, patient samples 
(N=81) from the three classes were analysed in a statistically rigorous manner. Data were 
normalised to correct for possible loading inconsistencies by two independent methods. 
Quantitative differences were investigated using t-tests and non-parametric statistical tests 
where appropriate.  
Results: Statistical assessment of final data indicated no significant differences in proteins 
between patient classes.  
Discussion & Conclusions: It is likely that the inflammatory nature of HIV itself influences the 
levels of these markers in HIV-positive patient samples to a greater degree than 
neurocognitive effects. Alternatively, possible co-infection by TB may have confounded the 
results. Regardless, it was concluded that the candidate Alzheimer’s biomarkers were not 
applicable to diagnosis of HAND. Further analysis on a larger sample cohort is recommended, 
utilising the assays optimised herein. Prospective studies to obtain viable biomarkers for 
definitive diagnosis may lie in proteomic analysis of model infection systems and 
cerebrospinal fluid. 
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Chapter 1  
Introduction 
CLINICAL AND EPIDEMIOLOGICAL OVERVIEW OF HIV ASSOCIATED 
NEUROCOGNITIVE DISORDERS 
Central nervous system (CNS) infection by human immunodeficiency virus (HIV) was first 
characterised as acquired immune deficiency syndrome (AIDS) dementia complex (ADC), and 
involved significant neurological pathologies.1,2 Common clinical features ranged from motor 
dysfunction, behavioural anomalies, as well as memory and concentration deficits in milder 
forms of the disease, to partial paralysis, uncontrollable muscle spasms, mutism, full-blown 
dementia, and death in more advanced forms.2–4 The median survival for an HIV infected 
individual with ADC was six months, with an annual ADC incidence of 7% following onset of 
AIDS.5 
The implementation of highly active antiretroviral treatment (HAART) regimens have greatly 
extended the lifespan of HIV infected individuals, while vastly improving their quality of life.6,7 
This includes patients diagnosed with ADC, where there has been a marked improvement in 
clinical prognosis, and increase in life expectancy.8,9 
The detrimental neurological effects of HIV are now collectively referred to as HIV-associated 
neurocognitive disorders (HAND). HAND is classified into three progressively more severe 
levels of neurocognitive impairment as defined by the HIV Neurobehavioral Research Centre 
at the University of California, San Diego: asymptomatic neurocognitive impairment (ANI), 
mild neurocognitive disorder/impairment (MND/MNI), and HIV-associated dementia (HAD).10 
HAART has led to a marked decrease in prevalence of the more severe forms of HAND but, 
due partly to the positive effect of HAART on survival, a high prevalence of the milder forms 
of the disease are still observed.11,12 Even in the HAART era, neurocognitive impairment 
caused by HIV infection has significant negative effects on adherence to HAART; job 
performance; employment; execution of simple tasks; and general quality of life.13–16 These 
effects may also impact negatively on the economy of countries, taking into account impacts 
on employment as well as the increased costs of specialised healthcare.14,17 
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MOLECULAR PATHOGENESIS OF HAND 
Due to compartmentalisation of the CNS, by virtue of the blood-brain barrier (BBB), it is 
protected from diffusional entry of deleterious substances from the systemic circulation, and 
is regarded as immune privileged.18 Despite this, CNS infection is a common cause of high 
morbidity and mortality rates in immunocompromised individuals.1,2 HIV itself is able to 
infiltrate the CNS with entry occurring early in infection, often prior to serodiagnosis or 
commencement of HAART, leading to neurological complications.19–21 
The mechanisms by which HIV gains entry into the CNS are not fully understood. Most 
evidence supports the ‘Trojan Horse’ hypothesis, which proposes that lentiviruses such as HIV 
enter the CNS within infected leukocytes, such as monocytes and T-cells.22 Indeed, CNS-
localised virions preferentially infect macrophages and microglia.23,24 
The major route by which HIV gains access to the CNS thus appears to be via infected 
macrophages, and to a lesser extent lymphocytes, from the systemic circulation.25–30 The CNS 
contains perivascular macrophages that reside along the endothelial cells of the BBB, whose 
population can be replenished by monocytes from the systemic circulation.29,31 These cells, in 
addition to microglia (macrophage-like glial cells) and astrocytes, are the primary targets for 
infection and viral replication following CNS infiltration by HIV.23,24,32–34 Indeed, HIV infection 
in the CNS upregulates release of chemokines such as monocyte chemotactic protein-1 from 
monocytes, microglia, and astrocytes; which promotes CNS infiltration by potentially HIV-
infected monocytes from the systemic circulation.25–28,35 Interestingly, a recent study by 
Louveau et al.36 has shown evidence of previously unknown lymphatic vessels supplying the 
CNS, and suggests these as efficient routes via which immune cells may gain access to the CNS 
and systemic circulation. This, by extension, may provide an optimal route for entry of HIV-
infected immune cells into the CNS. 
Another proposed but less well-characterised mechanism which may play a minor role in HIV 
entry into the CNS includes direct infection via BBB endothelial cells.37,38 
Neurons do not express CD4, the surface protein that facilitates HIV entry.39,40 Despite this, 
HIV is able to effect neuronal cell death in the CNS, probably without direct infection of the 
neurons themselves.41–44 To date, there is no evidence for productive HIV infection of 
neurons.45,46 It has been hypothesised instead that neuronal cell death results from response 
to various factors released during infection-related processes (Figure 1.1).47 One hypothesis 
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proposes that neurons are directly damaged by viral proteins released during infection.48 The 
other, more likely, scenario involves indirect neuronal cell death by chemokines released from 
microglia; macrophages; and astrocytes during the inflammatory response to the virus.48 
Direct neuronal injury is believed to be effected by HIV proteins such as transactivator of 
transcription (Tat), viral protein R (Vpr), and glycoprotein (gp)120.49–59 Vpr has been observed 
to directly cause apoptosis of neurons and astrocytes in vitro, possibly by caspase-8 mediated 
mechanisms.49–51 HIV gp120 has also been observed to cause neuronal apoptosis by activation 
of neuronal N-methyl-D-aspartate (NMDA) receptors on neurons.52–54 Excessive stimulation 
of NMDA receptors is believed to cause excessive Ca2+ influx as well as mitochondrial 
membrane depolarisation, both of which lead to apoptotic cell death.60,61 Studies have also 
implicated gp120-mediated activation of neuronal CXCR4 receptors, resulting in increased 
Ca2+ influx and subsequent excitotoxic cell death.55,56 Extracellular Tat has been implicated in 
neuronal apoptosis by direct stimulation of NMDA receptors.57,58 Evidence also exists for 
direct Tat-mediated hyper-activation of neuronal cyclin-dependent kinase 5 (CDK5), as well 
effecting its accumulation in the cytoplasm, resulting in neuronal cell death due to CDK5-
mediated cytoskeletal dysregulation.59 
Neuronal damage may also be effected indirectly by factors related to HIV-induced 
inflammatory processes.48 Release of soluble factors by microglia/macrophages is stimulated 
by either HIV infection or HIV protein binding, and may cause neuronal cell death directly or 
via astrocyte involvement.60–67 Binding of gp120 to CD4 receptors on macrophages results in 
release of arachidonic acid which inhibits glutamate uptake by astrocytes.62 Additionally, 
tumour-necrosis factor alpha (TNF-α) and arachidonic acid released by productively infected 
microglia/macrophages also causes increased release, and decreased reuptake of glutamate 
by astrocytes.63–65 Altogether, the increase in extracellular glutamate results in excessive 
stimulation of neuronal NMDA receptors, and eventual excitotoxic cell death (vide supra).60,61 
Productive macrophage infection by HIV has also been shown to cause direct NDMA receptor-
mediated neuronal cell death, by stimulating release of quinolinic acid.60,61,66,67  
Owing to the complexity of HIV infection and the inflammatory response, it is likely that the 
combination of both direct and indirect mechanisms are responsible for HIV 
neuropathogenesis.48 
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Despite releasing factors that are primarily responsible for pathogenic processes in HAND, 
microglia may also serve a protective role by regulating inflammatory processes in the CNS, 
possibly in concert with astrocytes and regulatory T lymphocytes.68–71 
Indeed, there is a complex immunological interplay in the CNS, which appears to be skewed 
towards neuropathogenic outcomes as evidenced by the prevalence of HAND.  
 
HAART AND HAND IN THE SOUTH AFRICAN CONTEXT 
The impact of HAND in a South African (SA) context is of particular concern, given the high 
local HIV prevalence. At last count (2013) SA had the fourth highest HIV prevalence in the 
world, with 19% of the adult population infected, bringing the number of people living with 
HIV to 6.3 million.72 In that year alone, 340 000 people were newly infected with the virus.72 
New infections however, have been steadily decreasing since 1999; and the number of AIDS-
related deaths have been rapidly decreasing from the highest recorded level of 410 000 in 
2010, to 200 000 in 2013.72 
FIGURE 1.1: MECHANISMS OF HIV PATHOGENESIS IN THE CNS. ADAPTED FROM GONZÁLEZ-SCARANO AND 
MARTÍN-GARCÍA47 
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The HIV burden in SA is still of significant importance, however, even 12 years after the 
implementation of HAART.73 The high prevalence of HIV highlights the potential impact of 
HAND on the SA populace. Indeed, neurocognitive impairment due to HAND has far reaching 
socio-economic consequences, with negative effects on employment; adherence to HAART; 
completion of daily tasks; and general quality of life.13–16 Definitive diagnostics, understanding, 
and treatment of this disorder is thus a matter of great urgency in an SA context. 
DIAGNOSTIC CHALLENGES 
Clinical diagnosis of HIV-induced cognitive decline currently relies on neurocognitive 
assessments as no definitive biochemical test exists.10,74 A biological marker or ‘Biomarker’ is 
defined by the National Institutes of Health as “A characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention”.75 Biomarkers exist for a multitude of 
diseases and influence diagnosis, disease characterisation, and design of appropriate 
treatment regimens.75,76 Several studies have attempted to identify HAND biomarkers in body 
fluids such as blood serum and cerebrospinal fluid (CSF).77–82 However, none of the markers 
that have shown promise have been approved, presumably due to complexities inherent in 
the biomarker development pipeline as well as possible sub-optimal specificity for HAND.82–84 
Indeed, a point-of-care test designed for use with easily accessible biological samples (e.g. 
blood) would be of great utility in HAND research, clinical diagnosis, prognostication, and 
provision of timeous and appropriate therapy. A blood-based biomarker test would also be 
less subjective than neurocognitive testing, which can be adversely affected by the patient’s 
level of education as well as operator competency, and would be ideally suited to diagnosis of 
HAND in the SA context.74,85–88 Biochemical confirmation of diagnosis in combination with 
neurocognitive examination would be ideal.74 
PROTEOMIC MASS SPECTROMETRY 
Mass spectrometry (MS) involves characterisation of ions or charged molecules in gas phase 
based on their mass, charge and/or structure.89 The mass spectrometer is able to measure the 
mass-to-charge ratio (m/z) of a charged molecule, from which the atomic mass (in Dalton) and 
molecular structure can be determined.89 
Ionisation is the mechanism by which molecules form charged ions.90 The two most widely 
used methods of ionisation used in biological MS analyses are matrix-assisted laser desorption 
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ionisation (MALDI), and electrospray ionisation (ESI).91–95 ESI is commonly used in conjunction 
with high performance liquid chromatography (HPLC) for the analysis of complex mixtures.96,97 
This technique often involves separation of sample analytes on a liquid chromatography (LC) 
column, thereby reducing complexity and aiding analysis.98 ESI is pertinent to the present 
study, and will be discussed briefly. ESI is a complex mechanism that involves formation of gas 
phase ions, from aerosolisation of ionised molecules in solution.89 Although not fully 
understood, a popular model for describing the ESI process is the ‘Ion Evaporation 
Model’.95,99,100 Briefly, a considerable charge applied across the capillary tip causes the liquid 
to nebulise due to the Coulomb forces overcoming surface tension (Raleigh limit).95 The 
positively charged droplets are drawn toward the entry orifice of the mass spectrometer by 
the potential difference between the spray needle and the entry capillary.95 As the droplets 
desolvate and decrease in size, the protons within them move to the surface of the molecule.95 
These protons aggregate until the Raleigh limit is reached, and the repulsive force causes the 
droplets to explode into smaller droplets by a process known as ‘Coulombic explosion’.95 This 
process continues, until the droplet becomes so small that ions are ejected from the droplet 
due to the field strength at the surface.95  
The development of nanoelectrospray ionisation (nESI) has led to a significant gain in 
sensitivity due to vastly improved ionisation efficiency.101,102 Nanoelectrospray MS is a 
significantly scaled-down form of classical ESI; wherein flow rates as low as 20 nl/min, as well 
as spray needles approximately 1-2 µm in diameters are used.102 The significant decrease in 
spray size is accompanied by a concomitant decrease in the size of solvent droplets 
formed.101,102 This increases ionisation efficiency by several orders of magnitude since the 
droplets evaporate much more rapidly, allowing for faster transfer of charge to analyte 
molecules.101,102  
Determination of a molecule’s m/z is made by a mass analyser.103 The simplest type of mass 
analyser is the time-of-flight (TOF), which involves measurement of the time taken for a 
charged molecule to travel the fixed length of an evacuated tube, and enables estimation of 
its m/z based on linear velocity.104,105  
Tandem MS involves mass analysis at two levels: the first being the identification, and often 
quantitation, of the m/z of the ‘parent’ (entire) molecule; while the second involves controlled 
fragmentation of the molecule and subsequent measurement of the fragment m/z 
values.89,106 Measured m/z values of parent molecules and their fragments are known as a 
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tandem mass spectrum: where intensity measurements pertaining to the m/z values of parent 
molecules in the sample are known as the MS1 spectrum, and those of the fragments form the 
MS2 spectrum.89,107 Predictable fragmentation enables reliable structural elucidation of the 
analyte.106 The most common types of fragmentation are collision-induced dissociation (CID) 
and high-energy collision dissociation (HCD) – a modified form of CID.108,109 CID involves the 
fragmentation of molecules by accelerating them into a stream of inert gas (e.g. Argon, 
Helium) to prevent chemical reactions during collision.108  
Of particular importance to the current study are Quadrupole and Orbitrap mass analysers. 
Quadrupoles function as mass filters such that, based on a combination of accurately timed 
adjustment of both direct current and alternating current potentials across opposing sets of 
quadrupole pairs, selectively allow molecules within a narrow m/z range through to the 
detector.110,111 Quadrupoles are able to discard all masses except those within a narrow range 
of interest, and are therefore utilised primarily for detection of molecules of known m/z.110 
The high resolution Orbitrap mass analyser is similar to ion cyclotron mass analysers, which 
determine the m/z of ions based on their rotation within a static magnetic field.112,113 In an ion 
cyclotron, the m/z is calculated by taking a Fourier transformation of the signal measured from 
ion cycling.112 m/z analysis in the Orbitrap is carried out by measurement of the lateral motion 
of ions, orbiting around a central spindle-shaped electrode within an electrostatic field.113 This 
signal is then converted to mass spectra using Fourier transform.113 Orbitrap mass analysers 
can also act as ion detectors.113 
Proteomic MS is the utilisation of MS technologies in the analysis of peptide and proteins.97 
Shotgun proteomic MS involves analysis of enzymatic digests of complex protein samples, to 
enable protein identification and quantitation.96,97 Digestion is commonly performed by 
trypsin to yield predictable peptide products, although other enzymes may also be used.96,97 
These peptides are separated by online HPLC (vide supra), ionised by ESI (vide supra), and 
analysed by tandem MS.96 Reversed-phase liquid chromatography (RPLC) is generally used as 
the on-line separation method for shotgun MS analyses.97 RPLC primarily involves separation 
of analytes based on their hydrophobicity.98  During gradient elution, the hydrophobicity of 
the mobile phase gradually increases, allowing peptides of increasing hydrophobicity to elute 
off the chromatography column and be analysed by the mass spectrometer.98 Figure 1.2 below 
shows the output from a reference shotgun mass spectrometric analysis conducted ‘in-house’. 
The upper panel shows a graphical representation of the total MS1 ion chromatogram (MS1-
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TIC), depicting all peptide ion intensities over the chromatographic elution; while the centre 
panel shows the total MS2 ion chromatogram (MS2-TIC), or fragment ions. The signal intensity 
at each time point on either chromatogram contains the summed intensities for all ions in 
each spectrum (MS1 or MS2).103 For example, the lower panel in Figure 1.2 shows the ions 
detected at MS2 level at 25.88 minutes, for the 491.76m/z parent ion. 
 
The measured mass spectral data are then compared to theoretical mass spectra generated 
from in silico digestion of known protein sequences.114 Theoretical peptide fragmentation 
outlines possible fragmentation sites of a peptide molecule based on Roepstorff-Fohlman-
Biemann nomenclature.114–116 The most common type of fragments seen with CID and HCD 
are y- and b-type ions, which are produced from fragmentation at the peptide bond.109,115–117 
Generally the m/z values of these fragments, including adducts and neutral losses, are used 
to construct theoretical mass spectra for identification of peptides by MS.114 Software 
packages, such as MaxQuant and the Andromeda search engine, used in the present study, 
are designed to assess experimental mass spectra and compare them to in silico-derived 
versions, thereby identifying peptides in the sample.114,118,119 Protein identity can then be 
inferred based on peptide composition.114 False identifications are detected based on matches 
to a decoy database, which is usually a reversed version of the reference protein sequence 
FIGURE 1.2: EXAMPLE OF A SHOTGUN MASS SPECTROMETRIC CHROMATOGRAM. UPPER PANEL: MS1 ION 
CHROMATOGRAM; CENTRE PANEL: MS2 ION CHROMATOGRAM; LOWER PANEL: MS2 MASS SPECTRUM FOR A 
491.76 M/Z PEPTIDE 
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database.120 Peptide abundances are calculated based on the signal over time for peptide ions 
extracted from the MS1 chromatogram.118 Protein abundances are then calculated from 
peptide abundances using established algorithms.118 
Targeted proteomic analysis involves the detection and quantitation of pre-selected peptides 
by tandem MS. Specifically, parent ions of predefined m/z are selected and fragmented, prior 
to selection and quantitation of predefined product ions.121 This type of analysis is referred to 
as selected reaction monitoring (SRM), whereas the measurement of multiple product ions 
per parent is known as multiple reaction monitoring (MRM).89,121–123 When this analysis is 
applied to peptides, fragment ions can be predicted based on their theoretical amino acid 
sequence.124 Triple quadrupole instruments are specifically designed for targeted analyses, 
owing to the mass filtering ability of the quadrupoles.125,126 Triple quadrupole mass 
spectrometers are comprised of three quadrupole mass filters in series.125 The basic layout of 
a triple quadrupole mass spectrometer is illustrated in Figure 1.3.127  
 
In this instrument ionised peptides of a predefined m/z are allowed to pass through the first 
quadrupole (Q1) while the remaining peptides are filtered out.125 These selected peptides are 
then accelerated into a stream of inert gas particles (e.g. Argon) in the second quadrupole 
(Q2), resulting in fragmentation of the peptides – where the kinetic energy applied to the 
peptides determine the fragments produced.125,128 Fragments are transferred to the third 
quadrupole (Q3) where fragments of a preselected m/z are allowed to pass, while the 
remaining ions are ejected from the instrument.125 The selected fragment ions reach a 
detector, usually an electron multiplier, which amplifies the signal that is recorded by the 
FIGURE 1.3: SCHEMATIC OF A TRIPLE QUADRUPOLE MASS ANALYSER. Q1: QUADRUPOLE 1, Q2: QUADRUPOLE 
2. Q3: QUADRUPOLE 3. ADAPTED FROM BOJA ET AL.127 
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instrument control software.125,129 MRM enables confident identification of peptides – and 
other – molecules as any ambiguity resulting from measurement of only the precursor mass 
is eliminated by measurement of several fragments.121 
Parallel reaction monitoring (PRM) is a similar analytical technique to SRM, except during PRM 
analysis all detectable product ions are measured for each parent ion.130 In addition to its full 
scan capabilities, the Q Exactive Quadrupole-Orbitrap mass spectrometer is also able to 
perform PRM analyses (Figure 1.4).131 In this instrument the quadrupole acts as the precursor 
mass filter, and the Orbitrap provides high resolution detection of product ions.131 Briefly, 
selected precursor ions are filtered through by the quadrupole and accumulated in the HCD 
collision cell – acting as an ion trap.131,132 Once the ions have accumulated for the pre-set 
injection time (IT), they are fragmented into product ions.131,132 These product ions are then 
injected, via the C-trap, into the Orbitrap for mass determination and quantitation.131,132  
 
FIGURE 1.4: SCHEMATIC OF THE Q EXACTIVE QUADRUPOLE-ORBITRAP MASS SPECTROMETER. ADAPTED 
FROM MICHALSKI ET AL.187 
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This process can be applied to single precursors in sequence, as illustrated in Figure 1.5-A, 
where each precursor is successively selected and its product ions quantified.131,132 It is also 
possible to quantify multiple precursors simultaneously to increase analytical throughput as 
shown in Figure 1.5-B.131,132 In the latter scenario, each precursor is selected by the 
quadrupole and successively accumulated in the HCD cell.131,132 Once the final set of precursor 
ions have accumulated, all the ions in the cell are fragmented and injected into the Orbitrap 
for analysis.131,132 Regarding triple quadrupole instruments, every precursor can be tied back 
to each product ion as selection at both MS levels occurs in sequence, thus preventing 
‘crosstalk’.125 This is not the case with multiplexed PRM analyses, as all product ions are 
analysed simultaneously.130 It should be noted that this restricts the product ions that can be 
multiplexed such that no two precursors may have product ions with the same mass.  
  
FIGURE 1.5: SCHEMATICS OF SINGLE- (A) AND MULTI-PLEXED (B) PARALLEL 
REACTION MONITORING ON Q-EXACTIVE MASS SPECTROMETER. ADAPTED 
FROM GALLIEN ET AL.132 
B 
A 
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The data output from PRM and MRM assays are expressed as product ion signal over the 
chromatographic elution time (Figure 1.6). Specialised software, such as Skyline, used in the 
present study, is used to read and display this data in graphical form.133  The signal of each 
measured fragment, collectively known as the MS2 spectrum in tandem MS (Figure 1.6-B), is 
linked to its parent. This pair or ions is known as a parent to product ion ‘transition’ (Figure 
1.6-C).134 
 
The graphical data output is expressed as quantitative data by calculating the areas under the 
intensity vs retention time chromatogram for each transition (Figure 1.7).127,133,135 These areas 
can then be summed to yield a representative area value for the parent peptide, which can 
then be used for comparative quantitation.127 
  
A 
A 
B 
C 
FIGURE 1.6: DATA VISUALISATION OF A TARGETED MASS SPECTROMETRIC EXPERIMENT. A: PEPTIDE IONS; B: 
MS2 SPECTRUM; C: TRANSITION CHROMATOGRAM OF INTENSITY OVER TIME 
B
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MASS SPECTROMETRY BASED BIOMARKER ASSESSMENT 
The utilisation of MS for the discovery, and high throughput validation of disease markers in 
biological fluids is an attractive prospect that has gained significant attention since the advent 
of proteomic MS.136 The recent advances in mass spectrometric technologies has led to a 
burgeoning in the field of MS-based proteomics, and in turn to growth in the field of systems 
biology.96 It is now possible to identify and accurately quantify several thousands of proteins 
in complex biological samples.96 This provides significant utility for the identification of 
markers of disease. Targeted analyses allow for accurate quantitation and validation of 
prospective markers, in a large number of biological replicates at high throughput.127,137–139  
Targeted proteomic MS possesses major advantages over classical quantitative techniques 
such as enzyme-linked immunosorbent assays (ELISAs) for biomarker screening, as mass 
spectrometric assays are high throughput; allow for high multiplexing without extensive 
optimisation; and are highly automatable.138–140 Targeted proteomic assays are also less costly 
to develop, as expensive antibodies are not required.138,139 Addition of markers to an existing 
method requires minimal optimisation. Ideally, the endpoint of MS-based screening of 
potential biomarkers would be an easily administered point-of-care test.141 
A B 
FIGURE 1.7: QUANTITATION IN TARGETED MASS SPECTROMETRIC EXPERIMENTS. A: TRANSITION 
CHROMATOGRAM; B: PEAK AREA BAR PLOT 
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THE ‘ALZHEIMER’S DISEASE BIOMARKER IN HAND’ HYPOTHESIS 
Alzheimer’s disease (AD) is a complex neuro-inflammatory disorder characterised by intra-
neuronal amyloid beta (Aβ) plaques, extracellular accumulation of soluble Aβ oligomers, and 
intra-neuronal neurofibrillary tangles composed of hyper-phosphorylated tau protein.142–146 
Although the neuropathogenesis of AD is not completely understood, these protein are 
believed to be involved in the inflammatory pathology characteristic of AD.142,144,146 
There appear to be some similarities between the inflammatory mechanisms underlying 
neuropathogenesis in HAND and AD. Indeed, Inflammatory mechanisms mediated by 
microglia and CNS macrophages are thought to be responsible for, or at the very least 
contribute to, inflammation-related neuronal cell death in these disorders.23,24,33,34,147–151 Aβ 
plaques have also been found in the brains of HAND patients.152,153 
We hypothesised that this inflammatory similarity may provide a suitable starting point for 
the development of molecular diagnostic tests aimed at HAND. A panel of serum-based 
protein markers would be of significant utility in the diagnosis of HAND, and could perhaps be 
based on established markers for neurodegenerative disorders with a similar inflammatory 
basis. Utilisation of markers previously associated with AD was proposed. It should be noted 
that any biomarker expression profile seen in HAND must be compared with that in other 
neuroinflammatory disorders, especially AD, in order to differentiate between disorders with 
similar inflammatory pathogeneses. Indeed, utilisation of a panel of markers with an 
expression signature specific for HAND subtypes would allow for differentiation between 
other disorders with similar underlying pathologies. 
Recently, Professor Simon Lovestone (Department of Psychiatry, University of Oxford) 
reported a panel of blood-based biomarkers for the diagnosis of AD.154–159 Accuracy, 
sensitivity, and specificity of the final panel for conversion from mild neurocognitive 
dysfunction to AD was estimated at 94.9%, 73.6%, and 94.9% respectively.154 These diagnostic 
indicators were assisted by Apolipoprotein E genotype-based prediction of progression to 
AD.154 We hypothesised that there may be applicability of this panel to diagnosis of HAND. At 
the initial stages of the present study, twelve protein candidates were proposed from within 
the AD biomarker panel, based on suggestions by Professor Lovestone:  alpha-1-acid 
glycoprotein (A1AG), alpha-1-antitrypsin (A1AT), alpha-2-macroglobulin (A2M), 
apolipoprotein A-I (ApoA-I), apolipoprotein E (ApoE), ceruloplasmin (CERU), clusterin (CLU), 
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complement C3 (C3), complement C4 (C4), complement factor H (CFH), gelsolin (GSN), serum 
amyloid P-component (SAP). Differential marker expression profiling between patients with 
intermediate and severe forms of HAND, as well as without HAND, forms the basis of the 
present study.  
AIMS AND OBJECTIVES OF STUDY 
The aim of this study was to assess the applicability of a set of AD biomarkers to the diagnosis 
of HAND. Objectives included: 
1. Shotgun proteomic analyses on pooled samples to identify representative peptides 
for marker proteins, 
2. Development and optimisation of PRM assays for markers and internal reference 
peptides, 
3. Application of PRM assays to clinical samples across representative disease groups. 
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Chapter 2  
Sample Preparation for Mass 
Spectrometric Analyses 
2.1. Introduction 
Bottom up proteomic MS is primarily concerned with identification of proteins by inference 
from identified peptides (see Chapter 3). Sample preparation for this type of analysis involves 
generation of peptides by a specific protease, usually trypsin, and is equivalent to that 
required for targeted proteomic analyses. 
Modern shotgun analyses that employ full mass range scanning are able to detect analytes up 
to 104 orders of dynamic range.160 Targeted mass spectrometric assays such as MRM, which 
utilise non-scanning methods, increase the dynamic range to 4-5 orders of magnitude.124,134,161 
This however, is insufficient in detecting all the constituents of a complex biological matrix 
exceeding 105 orders of dynamic range. Proteomic analysis of blood serum and plasma is 
therefore difficult, owing to the fact that human plasma proteins span an abundance range of 
approximately 12 orders of magnitude, with albumin alone comprising up to 55% of total 
protein.162 It is for this reason that affinity depletion and extensive fractionation is routinely 
employed to enable identification of lower abundance plasma proteins in discovery 
analyses.163–165 
For the purposes of the present study however, depletion and fractionation were deemed 
unnecessary, since the proteins of interest belong to the high to medium abundance portion 
of the plasma proteome.137,162,166,167 Extensive fractionation and depletion would also 
negatively impact high throughput analysis of clinical samples168,169. Kuzyk et al.137 provide a 
list of 45 quantifiable plasma proteins quantifiable by MRM in crude plasma, of which eight of 
the 13 markers of interest were represented. It was therefore deemed likely that the markers 
of interest would be quantifiable in serum, due to lack of abundant coagulation related 
proteins. Additionally, in order to increase the likelihood of detecting and quantifying the 
markers of interest, depletion of albumin alone was performed by means of gel-based removal 
of the dominant 67 kDa band. This Chapter outlines albumin depletion and sample 
preparation for analysis by targeted MS. 
17 
 
2.2. Materials and Methods 
2.2.1. Cohort Collection and Serum Isolation 
This study was approved by the University of Cape Town Human Research Ethics Committee 
of the Faculty of Health Sciences as an amendment to approval for the study “Characterisation 
of HIV Dementia among individuals starting antiretroviral therapy in South Africa”.170 (HREC 
023/2008). 
Patients who met recruitment criteria, outlined in the primary publication by Dr John Joska170, 
and who provided written informed consent were enrolled into the study. Participants were 
predominantly female (75%), ranging from 18 to 35 years of age. Other recruitment criteria 
included recent confirmation of HIV status (<6 months prior to study commencement), and at 
least 7 years of formal education. Ethnicity data was not available. The 170 enrolled patients, 
including HIV-positive control patients, were subjected to various neuropsychological tests, 
and HAND statuses were determined based on the American Academy of Neurology 
criteria.10,170 
Venous blood samples were collected in Vacutainer serum-separating tubes (SST, BD 
Biosciences, for serum isolation). Phlebotomy and clinical characterisations were performed 
by the Department of Psychiatry (Groote Schuur Hospital) for ApoE genotyping as part of the 
larger project headed by Dr John Joska (PI: Dr Dan Stein), entitled “Characterisation of HIV 
Dementia among individuals starting antiretroviral therapy in South Africa”.170,171 Groote 
Schuur hospital is a large tertiary hospital in the Western Cape at which a substantial 
proportion of patients are HIV-infected.  
Samples were transported at room temperature to a biosafety level two facility at the Institute 
of Infectious Disease and Molecular Medicine (IDM) for processing. Dr Kathryn Wood 
(Professor Robert Wilkinson's Group, CIDRI. IDM) and Tariq Ganief (Blackburn Group, IDM) 
were responsible for isolating and storing serum. Serum from a total of 138 patients were 
isolated. For serum isolation, SST tubes were centrifuged (1500 x g, 10 minutes, room 
temperature) and serum fractions collected and stored at -80˚C. 
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2.2.2. Sample Selection and Stratification 
Serum samples were selected based on their HAND status. Of the 138 isolated patient 
samples, 81 were selected for analysis. These comprised of 27 Normal (HIV positive), 27 MNI, 
and 27 HAD patient samples. These samples were derived from patients ranging from 23-30 
years of age. Of the 81 samples selected, 67 (83%) were derived from female participants. 
Normal, MNI, and HAD groups consisted of 24 (89%), 22 (81%), and 21 (78%) samples from 
female participants respectively. All selected samples Serum samples were randomised for 
processing in batches of nine, comprising three samples from each disease group (normal, 
MNI, HAD) (Appendix A: Table 8.1).  
2.2.3. Depletion Strategy 
Non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
utilised to effect the depletion of abundant proteins. Samples were separated on a 4-20% Tris-
Glycine pre-cast gradient gel (Mini-PROTEAN TGX Precast Gel, Bio-Rad Laboratories, Cat#: 
456-1093) to maximise band resolution and minimise concomitant removal of proteins other 
than albumin. Albumin (±67 kDa) was the only abundant protein depleted, by band excision. 
2.2.4. Sample Loading Determination 
Gel loading amounts were determined by trial and error. Maximal loading was preferred, with 
overlap of protein bands between lanes as the limiting factor. At this stage, serum total 
protein concentration was estimated at approximately 70 mg/ml. Upon running several serum 
loads (23 µg, 25 µg and 30 µg) on a 10% SDS-PAGE gel, a final concentration of 1.53 µg/µl in 
18 µl (23 µg per well) was chosen as it provided maximal loading without compromising band 
resolution. 
2.2.5. Sample Preparation for Pilot Analysis 
Total protein in serum samples was estimated using the Bicinchoninic acid assay (BCA, 
Thermo-Pierce), according to manufacturer instructions. Briefly, samples were incubated at 
60°C for 1 hour to deactivate HIV in plasma. Samples were then diluted 100-fold, to allow the 
protein concentration to fall within the linear range (20-2000 µg/ml) of the micro-plate BCA 
assay. Total protein concentration was then estimated by extrapolation from a BSA standard 
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curve ranging from 0.02 to 2 µg/µl. Crude concentrations were calculated for all samples by 
multiplying calculated concentrations by the dilution factor.  
2.2.6. Sample Preparation for Mass Spectrometric Analysis 
2.2.6.1. Sample Normalisation 
Raw serum sample randomised batches (as discussed above in Section 2.2.2), were processed 
independently. Serum samples were normalised based on total protein to a final 
concentration of 1.53 µg/µl (Appendix A: Table 8.1). Samples were diluted with Milli-Q water 
(Merck Millipore), on ice. 
2.2.6.2. Gel-based Separation 
45 µl of sample was dispensed into sterile screw-top polypropylene vials (Greiner Bio-One), 
and 9 µl of 6x SDS-PAGE sample buffer (4× Tris Cl/SDS [pH 6.8], 3.0 ml glycerol [30% final], 1 g 
SDS [10% final], 0.93 g DTT [0.6 M final], 1.2 mg bromphenol blue [0.012% final], H2O to 10 
ml)172 was added. The vials were kept on ice. Once all samples in the batch were dispensed 
and sample buffer added, vials were vortexed briefly and heated at 95°C for 5 minutes to 
denature proteins. Samples were left to cool at room temperature, vortexed briefly at low 
speed, and centrifuged (10000 x g, 2 minutes, room temperature) to ensure no loss of 
condensate. 18 µl of each sample/sample buffer mixture was loaded onto each gel, which was 
organised into one molecular weight marker lane containing 5 µl of PageRuler Plus standard 
(mass range 10-250 kDa, Thermo Scientific) and nine sample lanes (one gel per batch). Gels 
were run in a BioRad Mini Protean 4 system (Bio-Rad Laboratories) with SDS running buffer 
(25 mM Tris, 192 mM glycine, 0.1% SDS)173 prepared in-house. Each gel was run individually, 
at a constant voltage of 100V until the Bromophenol dye front approached the end of the gel 
(approximately 1.5hrs). 
2.2.6.3. Zinc Reversible Gel Staining 
Each gel was rinsed briefly and stained using a zinc-imidazole reversible stain (Thermo-Pierce, 
Cat#: 24582) as per the manufacturer’s protocol. Briefly, the gel was incubated in 
approximately 25 mL of zinc stain solution (Imidazole-SDS solution174) on an orbital shaker at 
low speed for 10 minutes. The zinc-imidazole stain renders the gel opaque while leaving 
protein bands unstained. This “negative staining” procedure is advantageous in that unbound 
proteins facilitate downstream analysis flexibility. This, in contrast to Coomassie-stained gels, 
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eliminates the need for intensive removal of stain from protein during the in-gel digest 
procedure. The stain was removed and replaced by 25 mL of zinc developer solution (Zinc 
sulphate solution174), and developed for 30 seconds. The developer was quickly removed and 
the gel rinsed three times with Milli-Q water for 1 minute on an orbital shaker at low speed. 
The gel was then photographed on a glass plate with a black background to visualise the clear 
protein bands (Appendix A: Figure 8.1). 
2.2.6.4. In-gel Digest 
An in-gel digest protocol for Coomassie-stained gels175, was modified to extract tryptic 
peptides from the gel: 
GEL DISSECTION 
 Each lane was dissected from the gel and divided into fractions according to Figure 2.1. Each 
fraction was cut into smaller blocks (approximately 1 mm x 1 mm) to maximise surface area 
for tryptic digestion. To prevent cross-contamination, scalpels and forceps were rinsed with 
FIGURE 2.1: FRACTIONATION OF GEL LANE FOR IN-GEL DIGEST. FRACTION 4 IS PRESUMED TO BE THE ALBUMIN 
BAND. MOLECULAR WEIGHT MARKER BAND WEIGHTS IN RED. 
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50% methanol in water following isolation of each individual fraction. Fractions were then 
transferred to 1.5 mL flip-top polypropylene vials and submerged in Milli-Q water.  
 
The water was removed using a 200 µl micro-pipette, and 250 µl of Tris-Glycine buffer (50 mM 
Tris, 192 mM Glycine, in Milli-Q water) was added to all vials (500 µl for Fraction 5, due to the 
larger gel volume) using a HandyStep (Brand GmbH & Co. KG) liquid dispenser with PD-tips 
(Brand GmbH & Co. KG) for rapid dispensing across all fraction vials. The vials were then 
vortexed at low speed for 10 minutes. The Tris-Glycine buffer chelates zinc precipitate from 
the gel to de-stain it. The buffer was then exchanged for 250 µl (500 µl for Fraction 5) of 50 
mM Ammonium Bicarbonate (ABC, Sigma-Aldrich), after which the vials were briefly vortexed 
at low speed and incubated at room temperature for 10 minutes.  
ABC was exchanged for 250 µl 100% Acetonitrile (ACN, Gradient grade, Merck) and vials were 
incubated while vortexing at low speed for 30 minutes.  ACN was replaced with fresh ACN and 
incubated while vortexing at low speed for 10 minutes, or until gel pieces turned opaque. ACN 
was removed and gel pieces dehydrated in a SpeedVac (Savant, Thermo Scientific) for 30 
minutes (or until completely dry). Vials were stored at -20°C for further processing. Fraction 4 
(the presumed albumin fraction) was not taken to the next phase of processing, in the interest 
of efficiency. 
REDUCTION AND ALKYLATION 
Gel pieces were equilibrated to reach room temperature before subsequent processing. 
Disulphide bonds between cysteine residues were reduced by addition of 250 µl 2 mM Tris(2-
carboxyethyl)phospine hydrochloride (TCEP•HCl, Sigma-Aldrich). Samples were then 
incubated at 37°C for 30 minutes, TCEP was removed, and 250 µl 50 mM ABC was added to all 
vials (500 µl for Fraction 5) for 1 minute. ABC was removed, and 250 µl 50% ACN was added 
to all vials for 1 minute. ACN was removed, and 200 µl 55 mM Iodoacetamide (IAA, Sigma-
Aldrich) was added to all vials (300 µl for Fraction 5) and incubated at room temperature in 
the dark for 60 minutes in order to  block exposed sulfhydryl groups of reduced cysteine 
residues by addition of a carbamidomethyl group to prevent reformation of disulphide bonds. 
IAA was removed and 200 µl 50 mM ABC was added to all vials for 10 minutes. ABC was 
replaced with 250 µl 50% ACN (500 µl for Fraction 5) for 20 minutes. ACN was removed and 
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samples were completely dehydrated in a SpeedVac (approximately 1 hour) to remove 
residual ACN. 
TRYPTIC DIGEST 
During dehydration, sequencing-grade modified porcine trypsin (Promega) was prepared by 
reconstituting 20 µg lyophilised trypsin in 100 µl 50 mM acetic acid to yield a 0.2 µg/µl 
solution. Prior to adding trypsin to gel pieces, 900 µl 50 mM ABC was added to the 
reconstituted trypsin to activate it (optimal pH: 7-9) and yield a final concentration of 20 ng/µl. 
Trypsin was kept at 4°C prior to addition to gel pieces to minimise enzyme autolysis and 
maximise activity. Trypsin was added to dehydrated gel pieces until the enzyme solution just 
covered the pieces (100 µg of trypsin per gel, due to reagent constraints). Generally, the 
volumes used for each vial were as follows (allowing for “topping up” of vials where 
necessary): fraction 1 ~125 µl, fraction 2 ~50 µl, fraction 3 ~125 µl, fraction 5 ~250 µl. Vials 
were incubated for 17 hours at 37°C in a wet box to maintain even heat distribution and 
minimise evaporation. 
PEPTIDE EXTRACTION 
Following tryptic digest, 100 µl 70% ACN was added to all vials, which were incubated at room 
temperature for 30 minutes. Supernatant was transferred to clean vials. This step was 
repeated and the new supernatant was harvested and added to the original supernatant. The 
supernatant (peptide extract) was dehydrated in a CentriVap concentrator (LabconCo) at 35°C 
for ~150 minutes. Peptides were stored at -20°C prior to downstream processing. 
PEPTIDE CLEAN-UP 
Silica beads with functionalised 18-carbon chains (which bind peptides via hydrophobic 
interactions) were utilised to remove MS-incompatible buffers, salts, and contaminants from 
prepared peptides. The peptides were then eluted with a highly hydrophobic solvent, which 
disrupts the hydrophobic interactions. Samples were ‘cleaned’ using C18 spin columns packed 
in-house102,176: empty spin columns that fit into 1.5/2.0 mL polypropylene vials (Appendix A: 
Figure 8.2, 30 µm pore size, Thermo-Pierce) were packed with 8 mg C18 reversed phase beads 
(Supelco Discovery C18, 50 µm particle size, Sigma-Aldrich) to bind 30 µg of peptide.177 The 
samples were cleaned according to the manufacturer’s instructions for Thermo-Pierce C18 
spin columns.177  
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Stored samples were allowed to reach room temperature before 100 µl 5% ACN/0.5% Formic 
Acid (FA, MS grade, Sigma-Aldrich) in Milli-Q water was added to each vial. The vials were then 
vortexed at low speed for 5 minutes to resolubilise peptides, and centrifuged (10000 x g, 2 
minutes, room temperature) to collect condensed droplets and sediment gel particulates. 
Each column was tapped to settle C18 resin and inserted into clean 2 mL flip-top 
polypropylene vials. This was followed by addition of 200 µl activation solution (50% ACN) 
using a 200 µl gel-loading pipette tip (Sigma-Aldrich) to prevent air bubble formation and resin 
disturbance. Columns were centrifuged (1500 x g, 1 minute, room temperature) to activate 
beads, and flow-through was discarded. These steps were repeated with an additional 200 µl 
activation solution. Equilibration solution (200 µl 0.5% FA in 5% ACN) was added, columns 
were centrifuged (1500 x g, 1 minute, room temperature) to equilibrate beads, and flow-
through was discarded. These steps were repeated with an additional 200 µl equilibration 
solution.  
Each column was transferred to a clean 2 mL flip-top polypropylene vial. All fractions 
belonging to each individual sample were loaded on a single column with the aim of 
recombining them into a single final fraction: for each sample, each fraction was dispensed in 
a step-wise manner onto the corresponding column after centrifugation (1500 x g, 1 minute, 
room temperature) with the previous fraction until all fractions had been added and without 
discarding the flow-through. Each column was then transferred to a clean 2 mL flip-top 
polypropylene vial. The flow-through was then run through each column again to ensure 
sample binding: 2 x 200 µl of each sample was centrifuged (1500 x g, 1 minute, room 
temperature). Flow-through was stored at -20°C for future quality control assessment of 
sample binding. Each column was transferred to a clean 2 mL flip-top polypropylene vial. Wash 
solution (200 µl 0.5% FA in 5% ACN) was added to each column prior to centrifugation (1500 
x g, 1 minute, room temperature) to remove contaminants, and flow-through was discarded. 
These steps were repeated with an additional 200 µl of wash solution per column. Each 
column was transferred to a sterile, un-autoclaved 2 mL screw-cap polypropylene vial. Elution 
buffer (25 µl 0.1% FA in 70% ACN) was added to each column prior to centrifugation (1500 x 
g, 1 minute, room temperature) to release and elute bound peptides from the column. These 
steps were repeated with an additional 25 µl of elution buffer per column. The samples were 
dehydrated in a CentriVap concentrator at 35°C for ~60 minutes. Vials were stored at -20°C 
until analysis.  
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Chapter 3  
Optimisation A: Identification of Candidate 
Peptides for Parallel Reaction Monitoring 
Assays through Shotgun Proteomic 
Analysis of Pooled Sera 
3.1. Introduction 
In order to be useful in biomarker validation, targeted MS analysis of biological samples 
requires a priori identification of ideally-performing (vide infra) peptides with which to infer 
protein quantities. It is feasible to predict all possible tryptic peptides in silico, then assess 
each via multiple rounds of targeted MS. This method, however, is labour intensive and 
inefficient. As an alternative, SRMatlas (www.srmatlas.org) is an online repository of targeted 
proteomic data, and includes empirically determined peptide lists for given proteins, as well 
as associated instrument parameters. However, this route to peptide selection may result in 
peptides and parameters that are not the most effective, given the in-house instrument 
configuration. A further route of optimal peptide selection, therefore, is via shotgun 
proteomic MS of pilot samples which are representative of final analytical samples. 
During shotgun MS,  tryptic peptides are separated by online liquid chromatography and 
analysed by tandem mass spectrometry (LC-MS/MS).97 These peptides are sequenced by 
matching their masses, as well as the masses of their fragment ions, obtained by MS to a 
theoretical peptide database which was generated in silico.114 Peptides are then mapped to 
parent proteins in the original sample and can also be utilised to infer parent protein 
abundance.114 
In the present study, sample depletion followed by fractionation were not employed, contrary 
to the norm for shotgun proteomic analysis of human serum. Instead, gel fractionation was 
employed to remove albumin, after which fractions were recombined for targeted proteomic 
analysis. Re-pooling of the fractions after removal of albumin was due to the initial intent of 
the study, where no shotgun proteomic analysis was planned. MRM assays, based on peptides 
and parameters provided by Dr Malcolm Ward (Proteome Sciences), were to be applied to 
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minimally depleted samples without fractionation to increase throughput. Discovery 
proteomic analysis was subsequently performed due to failure of these initial MRM assays in 
pilot experiments (data not included). 
This Chapter therefore describes MS-based identification of the peptides present in pooled 
patient samples, and subsequent selection of a set of optimally performing peptides 
representing candidate biomarkers of neurodegeneration. The ultimate intention is utilisation 
of this peptide set to develop a PRM assay for these biomarkers. 
3.2. Materials and Methods 
3.2.1. Sample Pooling 
Table 3.1 shows sample selection for discovery analysis, including disease group and batch 
membership, as well as pooling assignments. Nine samples from each cohort (n=9) were 
randomly selected for shotgun analysis. One sample was selected from each batch, per 
disease group (described in Chapter 2 and Appendix A: Table 8.1), to ensure equivalent 
representation across all batches. Within each disease group, samples were combined into 
three pools of three. Pooling was employed to minimise initial analysis time, given limited 
instrument time. Three biological replicates were run per disease group, and all disease groups 
were represented to ensure that candidate peptides would be detected independently of 
disease state.  
TABLE 3.1: RANDOMISED SAMPLE POOLING FOR DISCOVERY PROTEOMIC ANALYSIS 
Pool Disease Group Sample Batch 
POS_1 HIV-positive Control 
J061 1 
J204 2 
J0231 3 
POS_2 HIV-positive Control 
J0203 4 
J009 5 
J0260 6 
POS_3 HIV-positive Control 
J035 7 
J068 8 
J0233 9 
MNI_1 MNI J0179 1 
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Pool Disease Group Sample Batch 
J0193 2 
J0125 3 
MNI_2 MNI  
J063 4 
J020 5 
J0167 6 
MNI_3 MNI 
J079 7 
J074 8 
J0207 9 
HAD_1 HAD 
J0149 1 
J030 2 
J206 3 
HAD_2 HAD 
J0148 4 
J097 5 
J0236 6 
HAD_3 HAD 
J005 7 
J0132 8 
J216 9 
HAD: HIV Associated Dementia, MNI: Minor Neurocognitive Impairment, POS: HIV positive control.  
 
Stored samples (Section 2.2.6) were re-suspended in 25 µl 2% ACN/0.1% FA to an estimated 
concentration of 0.4 µg/µl (assuming no loss during in-gel digests) per stock solution. Stock 
solutions were pooled, as per Table 3.1, and adjusted to a final concentration of 25 ng/µl by 
addition of 2% ACN/0.1% FA. Samples were transferred to 2 ml autosampler vials fitted with 
tapered 100 µl glass inserts (Macherey-Nagal) and stored at 4°C prior to mass spectrometric 
analysis. 
3.2.2. LC/MS Instrumentation and Parameters 
Discovery proteomic analysis was performed on a Q Exactive Quadrupole-Orbitrap mass 
spectrometer (Thermo Scientific), coupled to a Dionex UltiMate 3500 RSLC nano-LC system 
(Thermo Scientific). A standardised LC gradient, developed in our laboratory for use with 
mammalian peptide extracts, was used for all MS analyses unless otherwise stated.  
Approximately 250 ng of pooled sample was introduced by partial loop injection onto a trap 
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column packed in-house with Luna C18 coated silica beads (75 µm x 2 cm fused silica: New 
Objective; 5 µm Luna C18 resin: Phenomenex). Separation was performed by reversed phase 
chromatography on a nanoscale analytical column, also packed in-house (5 µm Luna C18 
beads, 75 µm x 50 cm). Ionisation was attained by application of charge over a steel emitter 
(Thermo Scientific, Cat#: TFES542) affixed to the end of the analytical column.  
Solvent A comprised 0.1% FA (LC-MS Ultra, Eluent Additive, Sigma) in UHPLC grade H2O (LC-
MS Ultra, Sigma), while Solvent B – hereafter referred to as B - comprised 0.1% FA (LC-MS 
Ultra, Eluent Additive) in ACN (LC-MS Ultra, Sigma). Samples were eluted using a linear 177 
minute gradient at a constant flow rate of 300 nl/min, as follows: 2% B for 10 minutes, 2-25% 
B over 115 minutes, 25-35% B over 5 minutes, 35-80% B over 5 minutes, held at 80% B for 20 
minutes, before returning to 2% B in 2 minutes, followed by re-equilibration at 2% B for 20 
minutes. Each disease group replicate was run successively, with different groups separated 
by an 80 minute wash. The linear wash gradient was run at a constant flow rate of 300 nl/min, 
as follows: 2-35% B over 10 minutes, 35-50% B over 5 minutes, 50-80% B over 5 minutes, held 
at 80% B for 25 minutes, before returning to 2% B in 5 minutes, followed by re-equilibration 
at 2% B for 20 minutes. Because the intrinsic analytic gradient wash interval (80% B) was 
sufficient to prevent carry over for up to three consecutive samples, and in order to reduce 
instrument usage time, extended washes were inserted between disease groups only. 
Mass spectrometric analysis was controlled by Xcalibur software (Thermo Scientific; v2.2). 
Mass spectrometric acquisition parameters were developed in-house and based on initial 
settings from Pirmoradian et al.178 They are the default for all discovery analyses conducted 
in our laboratory.  Acquisition was performed in ‘Top 10’, data-dependent, positive ion mode. 
MS1 settings included resolution at 70 000, automatic gain control (AGC) target of 3x106, and 
an ion injection time of 250 ms. At the MS2 level, resolution was set at 17 500, AGC target of 
2x105, ion injection time of 120 ms, isolation window of 4.0 m/z and a normalised collision 
energy (NCE) of 25. Data dependent settings included an underfill ratio of 1% (which equates 
to an intensity threshold of 1.7x104 for triggering of MS2 scan), peptide match set to 
“preferred”, isotopic exclusion, and a dynamic exclusion of 30 s. Charge exclusion was set to 
all unassigned charges, as well as all charges other than 2 or 3.  
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3.2.3. Protein/Peptide Identification and Quantitation 
Data analysis was performed using MaxQuant version 1.3.0.5, which utilises the Andromeda 
search engine.118,119 Masses and intensities for all detected peptide and fragment ions were 
extracted using default MaxQuant settings (Appendix B: Table 9.1), with the following 
adjustments. Briefly, multiplicity was set to 1 since no labelling strategy was employed. 
Peptide and protein false discovery rate (FDR) cut-offs of 0.01 were used for identification. 
Protein identification was ‘lenient’, with a minimum of one peptide required for protein 
identification. Peptides unique to a protein group were not required for protein inference. 
Label-free quantitation (LFQ) was enabled with a minimum ratio count of 2. Finally, Fast LFQ 
was enabled. The UniProt complete human proteome .fasta file (downloaded on 9/01/2014) 
was selected for sequence database searching, with sequence reversal used to construct the 
decoy database. Each replicate was treated as a separate experiment in the 
experimentalDesignTemplate.txt file. 
The Andromeda search engine matched extracted MS1 and MS2 masses to an in silico digested 
human proteome sequence file consisting of known human protein sequences. Peptides were 
identified by matching theoretical peptide masses as well as the masses of resultant MS2 
fragments, to best-fit experimental MS1 and MS2 spectra. False identifications were estimated 
by matching measured masses to a reversed version of the human proteome sequence. 
Protein identities were inferred based on peptide sequence matching. Confidence in protein 
identity increased with increasing unique peptide identifications. Unique peptides are defined 
as peptides that belong to only one protein or protein group, and do not share complete 
sequence homology with any other protein or protein group. 
Data quality and identification statistics were summarised by an R-script kindly provided by Dr 
Karsten Krug (Proteome Centre, University of Tübingen, Germany).  
3.2.4. Preliminary Peptide Selection 
The proteingroups.txt and peptides.txt Maxquant output files were interrogated manually to 
ascertain the presence of the candidate biomarkers. The proteingroups.txt file provided 
details on sequence coverage of proteins. Data for candidate proteins were assessed for the 
potential to extract representative peptides. 
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Data related to detected peptides contributing to the sequence of the candidate proteins 
were extracted from the peptides.txt output file. To obtain a set of representative peptides 
for downstream targeted analysis, 10 peptides were selected for each protein, or all identified 
peptides in the case of proteins with fewer than 10 identified peptides. A2M, C3 and CFH were 
exceptions, with 12, 12 and 15 peptides respectively as an unsatisfactory number of peptides 
satisfied the selection criteria (vide infra). Primary peptide selection criteria included good PEP 
(posterior error probability) scores (≤0.01) and, as a secondary criteria, the presence of the 
peptide in all or most of the samples. The PEP score is essentially a p value that represents the 
probability of a false identification118, where a low score indicates a more reliable 
identification. Only peptides unique to a protein group were chosen, to ensure definitive 
protein identification.  
Exclusion criteria included: peptides containing amino acid residues susceptible to variable 
modifications, peptides containing histidine and methionine residues (due to their tendency 
to become oxidised), cysteine-containing peptides (in the event of incomplete alkylation), and 
peptides containing missed cleavages (due to the possibility of inter-sample digest 
inconsistency).  
3.3. Results and Discussion  
3.3.1. Protein Identification and Quantitation 
A total of 175 protein groups were identified by MaxQuant, with 22 of these categorised as 
contaminants and reverse hits (Appendix B: Table 9.2). A total of 1178 non-redundant 
peptides were identified, of which 204 were contaminants and reverse hits (Data not shown). 
Of the 381780 peptide spectra recorded, only 4.75% were assigned. 
This number of protein identifications may seem low, when compared to the average 
identifications of up to 4000 proteins seen in proteomic experiments conducted in our 
laboratory. Plasma proteomic analysis however, cannot be compared to that of biological 
samples possessing lower dynamic range (despite albumin-depletion, as other high-
abundance plasma proteins remain). Serum and plasma samples routinely require extensive 
processing prior to mass spectrometric analysis. Depletion of abundant proteins, preferably 
by antibody affinity chromatography, is required to reduce plasma’s broad dynamic range.163 
However, depletion of abundant proteins alone is not adequate, and extensive fractionation 
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via techniques orthogonal to the reversed phase chromatographic separation online with MS 
– such as isoelectric focusing (IEF) or strong cation exchange (SCX) chromatography, are also 
required.164,165  
The Human Proteome Organisation Plasma Proteome Project identified 3020 proteins in 
serum and plasma from data acquired in 35 laboratories, employing various depletion and 
fractionation strategies, as well as analysis by various mass spectrometer types.179 In a recent 
study comparing serum analysis between several high resolution mass spectrometers, 
samples were subjected to two rounds of abundant protein depletion, followed by extensive 
IEF fractionation into 30 fractions. The highest number of identifications were obtained from 
a Q Exactive mass spectrometer with 1349 proteins (≥2 peptides per protein, FDR=1%).180 
Extensive fractionation, however, does not guarantee identifications in excess of 1000 protein 
identifications, as shown by another study employing Multiple Affinity Removal System 
(MARS) depletion coupled with SCX fractionation and analysis by a relatively low resolution Q-
TOF mass spectrometer, which identified 125 proteins (≥2 peptides per protein, peptide 
FDR=0.6%, protein FDR=0%).181 The same study also detected 63 proteins in crude plasma. 
The rudimentary depletion strategy employed in the present study served to remove only 
albumin, with remaining fractions recombined thereafter. It would therefore be reasonable 
to expect that protein identification would not be on par with analyses employing extensive 
depletion and fractionation strategies.  
Despite limited protein coverage, the proteins identified in the shotgun proteomic analysis did 
indeed identify the candidate biomarkers of interest, with acceptable peptide coverage, and 
therefore served its purpose in the context of the present study. Assessment of additional 
protein biomarkers would indeed require more optimised sample preparation in subsequent 
studies. 
3.3.2. Preliminary Peptide Selection 
Data output files from MaxQuant analysis were manually interrogated to locate protein 
biomarkers identified by Professor Simon Lovestone: A1AG, A1AT, A2M, ApoA-I, ApoE, CERU, 
CLU, C3, C4, CFH, GSN, and SAP. All candidate biomarkers were found to be represented in the 
total list of 175 identified proteins. These proteins (Table 3.2) were extracted from the 
proteingroups.txt file (Appendix B: Table 9.2). Table 3.2 includes Uniprot IDs, peptides 
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belonging to the protein identified, as well as percentage sequence coverage. Most of the 
identified proteins’ sequence coverage was adequate, except proteins such as A1AG, for 
which only two peptides were identified (10.9% coverage). Despite poor protein coverage for 
proteins such as SAP, CLU, GSN, and the apolipoproteins; there were sufficient peptides from 
which to obtain candidate peptides for PRM analysis.  
TABLE 3.2: CANDIDATE BIOMARKERS REPRESENTED IN DISCOVERY ANALYSIS RESULTS.  
 Protein IDs Protein names Peptides Sequence coverage [%] 
1 P02763 Alpha-1-acid glycoprotein (A1AG) 2 10.9 
2 P01009 Alpha-1-antitrypsin (A1AT) 18 47.8 
3 P01023 Alpha-2-macroglobulin (A2M) 58 51.8 
4 P02647 Apolipoprotein A-I (ApoA-I) 12 48.3 
5 P02649 Apolipoprotein E (ApoE) 7 27.8 
6 P00450 Ceruloplasmin (CERU) 22 24.7 
7 P10909-2 Clusterin (CLU) 7 19.4 
8 P01024 Complement C3 (C3) 75 49.2 
9 P0C0L4 Complement C4-A (C4A) 45 32.9 
10 P0C0L5 Complement C4-B (C4B) 43 30.4 
11 P08603 Complement factor H (CFH) 21 24.1 
12 P06396 Gelsolin (GSN) 10 19.1 
13 P02743 Serum amyloid P-component (SAP) 5 23.8 
PEP: Posterior Error Probability 
 
The set of 106 preliminarily selected peptides, in order of increasing PEP score, are shown in 
Table 3.3. Missed cleavages, uniqueness between protein groups, as well as charge states and 
PEP scores are shown. These peptides were selected primarily on the basis of uniqueness to a 
protein group to ensure that PRM quantitation applies only to the protein of interest. Shared 
peptides are not representative of a single protein of interest, and therefore would skew 
quantitation if included in analyses. Selection of peptides possessing good PEP scores 
increases the likelihood of finding adequately-performing peptides in subsequent PRM-based 
validation.  
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TABLE 3.3: PRELIMINARILY SELECTED PEPTIDES FOR TARGETED ASSAY METHOD DEVELOPMENT 
Protein 
name 
Sequence 
Missed 
cleavages 
Unique 
(Groups) 
Charge 
States 
PEP 
Raw Intensity 
HAD 
1 
HAD 
2 
HAD 
3 
MNI 
1 
MNI 
2 
MNI 
3 
POS 
1 
POS 
2 
POS 
3 
A1AG TEDTIFLR 0 no 2 4.28E-13 1.73E+07 1.18E+07 0.00E+00 9.07E+06 0.00E+00 0.00E+00 8.90E+06 0.00E+00 0.00E+00 
A1AG 
EQLGEFYEALDCLR
* 
0 yes 2 1.31E-02 
0.00E+00 5.60E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
A1AT 
TLNQPDSQLQLTT
GNGLFLSEGLK 
0 yes 2,3 4.61E-188 
4.99E+07 6.70E+07 6.50E+06 5.57E+07 1.37E+07 1.64E+06 2.85E+07 1.28E+07 1.81E+06 
A1AT 
VFSNGADLSGVTE
EAPLK 
0 yes 2,3 1.54E-111 
2.69E+08 1.73E+08 2.51E+07 2.66E+08 0.00E+00 0.00E+00 2.26E+08 1.17E+08 0.00E+00 
A1AT AVLTIDEK 0 yes 2 1.03E-67 1.93E+08 0.00E+00 0.00E+00 0.00E+00 0.00E+00 7.96E+07 1.49E+08 1.29E+08 0.00E+00 
A1AT LSITGTYDLK 0 yes 2 1.21E-15 2.56E+08 2.49E+08 9.02E+06 2.48E+08 1.93E+07 8.25E+06 1.72E+08 1.29E+08 0.00E+00 
A1AT FLENEDRR* 1 yes 2,3 1.21E-08 9.63E+06 6.08E+06 0.00E+00 2.68E+07 0.00E+00 1.57E+07 2.16E+07 1.43E+07 0.00E+00 
A1AT ITPNLAEFAFSLYR 0 yes 2,3 6.61E-06 1.81E+07 5.58E+06 1.23E+06 6.46E+07 2.57E+06 0.00E+00 2.25E+07 4.46E+06 0.00E+00 
A1AT QINDYVEK 0 yes 2 8.86E-05 1.05E+08 6.60E+07 4.56E+07 9.94E+07 6.00E+07 7.14E+07 8.84E+07 6.98E+07 4.12E+06 
A1AT SVLGQLGITK 0 yes 2 3.59E-04 3.57E+08 2.20E+08 1.77E+07 2.73E+08 2.24E+07 1.76E+07 2.21E+08 1.40E+08 2.75E+07 
A1AT DTVFALVNYIFFK 0 yes 2 6.65E-04 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 1.75E+06 0.00E+00 0.00E+00 
A1AT FLENEDR 0 yes 2 3.77E-02 2.60E+07 9.73E+06 0.00E+00 0.00E+00 1.23E+07 1.58E+07 1.37E+07 0.00E+00 0.00E+00 
A2M 
QFSFPLSSEPFQGS
YK 
0 yes 2,3 1.64E-145 
4.06E+07 9.02E+07 2.57E+07 7.58E+07 2.85E+07 1.89E+07 2.83E+06 3.82E+06 1.80E+07 
A2M NEDSLVFVQTDK 0 yes 2 8.08E-124 1.52E+08 1.49E+08 1.92E+07 2.81E+08 2.52E+07 2.02E+07 1.24E+08 1.34E+08 2.43E+07 
A2M 
AAQVTIQSSGTFSS
K 
0 yes 2 5.71E-75 
2.96E+07 7.15E+06 1.51E+07 7.34E+07 1.07E+07 1.43E+07 3.59E+07 4.94E+07 3.87E+06 
A2M AIGYLNTGYQR 0 yes 2 7.04E-52 1.84E+08 1.77E+08 2.37E+07 3.15E+08 2.08E+07 2.85E+07 1.23E+08 2.05E+08 3.11E+07 
A2M 
IAQWQSFQLEGGL
K 
0 yes 2 2.91E-47 
7.03E+06 1.02E+08 1.13E+07 7.44E+07 1.70E+07 7.64E+06 2.22E+07 2.24E+07 6.04E+06 
A2M 
VSVQLEASPAFLAV
PVEK 
0 yes 2,3 3.59E-41 
2.11E+07 1.46E+08 1.70E+07 4.52E+07 1.75E+07 1.45E+07 1.28E+07 1.98E+07 1.13E+07 
A2M 
ALLAYAFALAGNQ
DK 
0 yes 2,3 1.90E-36 
7.09E+06 1.37E+07 0.00E+00 2.97E+07 2.59E+06 7.72E+05 1.15E+07 4.01E+06 0.00E+00 
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Protein 
name 
Sequence 
Missed 
cleavages 
Unique 
(Groups) 
Charge 
States 
PEP 
Raw Intensity 
HAD 
1 
HAD 
2 
HAD 
3 
MNI 
1 
MNI 
2 
MNI 
3 
POS 
1 
POS 
2 
POS 
3 
A2M FEVQVTVPK 0 yes 2 4.32E-22 8.18E+07 1.01E+08 1.06E+07 1.77E+08 1.33E+07 6.15E+06 5.96E+07 7.32E+07 7.17E+06 
A2M FQVDNNNR 0 yes 2 1.93E-19 1.56E+07 9.50E+06 1.37E+07 2.66E+07 1.29E+07 1.43E+07 9.87E+06 1.51E+07 0.00E+00 
A2M QTVSWAVTPK 0 yes 2 1.74E-10 9.14E+07 7.26E+07 1.67E+07 1.49E+08 1.42E+07 1.66E+07 5.76E+07 8.78E+07 0.00E+00 
A2M 
LLIYAVLPTGDVIGD
SAK 
0 yes 2,3 3.50E-10 
1.87E+07 8.60E+07 1.35E+07 6.46E+07 2.19E+07 7.84E+06 1.78E+07 1.51E+07 3.04E+06 
A2M LPPNVVEESAR 0 yes 2 8.16E-06 1.07E+08 8.60E+07 3.32E+07 1.71E+08 2.96E+07 3.29E+07 7.96E+07 1.35E+08 2.49E+07 
ApoA-I DYVSQFEGSALGK 0 yes 2 7.99E-185 1.05E+08 8.32E+07 0.00E+00 1.32E+08 0.00E+00 0.00E+00 1.19E+08 7.47E+07 0.00E+00 
ApoA-I 
LLDNWDSVTSTFS
K 
0 yes 2 8.52E-74 
2.87E+07 7.32E+07 1.07E+07 4.28E+07 1.09E+07 1.35E+07 3.26E+07 1.57E+07 1.02E+07 
ApoA-I 
EQLGPVTQEFWD
NLEK 
0 yes 2 3.04E-68 
1.55E+07 0.00E+00 4.42E+06 1.81E+07 6.89E+06 6.61E+06 1.08E+07 5.13E+06 2.73E+06 
ApoA-I VSFLSALEEYTK 0 yes 2 4.38E-47 3.39E+07 7.55E+07 6.93E+06 6.20E+07 1.00E+07 6.29E+06 3.89E+07 1.22E+07 2.55E+06 
ApoA-I DLATVYVDVLK 0 yes 2 2.96E-14 1.68E+07 4.96E+07 8.27E+06 5.74E+07 0.00E+00 6.75E+06 2.51E+07 1.12E+07 2.80E+06 
ApoA-I AKPALEDLR* 1 yes 2,3 1.40E-09 5.03E+07 1.52E+07 0.00E+00 2.29E+07 0.00E+00 0.00E+00 1.83E+07 1.71E+07 0.00E+00 
ApoA-I QGLLPVLESFK 0 yes 2 4.02E-04 2.83E+07 3.74E+07 1.53E+07 4.28E+07 1.69E+07 1.49E+07 2.69E+07 9.27E+06 0.00E+00 
ApoA-I VQPYLDDFQK 0 yes 2 9.66E-04 1.16E+08 8.47E+07 8.08E+06 1.06E+08 0.00E+00 9.30E+06 1.02E+08 6.06E+07 1.83E+07 
ApoA-I VKDLATVYVDVLK* 1 yes 3 5.69E-02 0.00E+00 0.00E+00 0.00E+00 6.07E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
ApoE LEEQAQQIR 0 yes 2 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
ApoE 
SELEEQLTPVAEET
R 
0 yes 2 4.25E-19 
1.05E+07 2.83E+06 0.00E+00 7.17E+06 0.00E+00 0.00E+00 5.59E+06 3.98E+06 0.00E+00 
ApoE 
AATVGSLAGQPLQ
ER 
0 yes 2 1.30E-03 
1.04E+07 5.92E+06 0.00E+00 6.99E+06 8.87E+05 0.00E+00 6.59E+06 6.45E+06 0.00E+00 
ApoE VEQAVETEPEPELR 0 yes 2 2.02E-02 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
ApoE LGPLVEQGR 0 yes 2 2.08E-02 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
ApoE LAVYQAGAR 0 yes 2 2.75E-02 4.61E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
CERU VNKDDEEFIESNK* 1 yes 2,3 2.00E-122 6.21E+07 3.79E+07 0.00E+00 4.70E+07 0.00E+00 0.00E+00 4.45E+07 5.34E+07 0.00E+00 
CERU 
NNEGTYYSPNYNP
QSR 
0 yes 2 1.62E-61 
2.42E+07 1.39E+07 4.02E+06 1.74E+07 6.17E+06 6.77E+06 2.46E+07 1.60E+07 2.19E+06 
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Protein 
name 
Sequence 
Missed 
cleavages 
Unique 
(Groups) 
Charge 
States 
PEP 
Raw Intensity 
HAD 
1 
HAD 
2 
HAD 
3 
MNI 
1 
MNI 
2 
MNI 
3 
POS 
1 
POS 
2 
POS 
3 
CERU ALYLQYTDETFR 0 yes 2 2.07E-36 1.45E+07 6.81E+07 2.73E+06 3.47E+07 4.07E+06 2.62E+06 3.38E+07 1.10E+07 0.00E+00 
CERU EYTDASFTNR 0 yes 2 3.12E-29 6.26E+07 4.66E+07 2.20E+07 5.28E+07 2.57E+07 4.17E+07 6.41E+07 5.22E+07 3.30E+06 
CERU GAYPLSIEPIGVR 0 yes 2 3.51E-26 5.08E+07 5.18E+07 9.49E+06 6.05E+07 1.09E+07 1.12E+07 6.92E+07 2.70E+07 1.50E+07 
CERU DDEEFIESNK 0 yes 2 4.86E-11 0.00E+00 0.00E+00 0.00E+00 0.00E+00 1.07E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
CERU QSEDSTFYLGER 0 yes 2 1.97E-05 4.25E+07 3.54E+07 1.59E+06 3.69E+07 2.01E+06 2.05E+06 4.05E+07 3.75E+07 8.92E+05 
CERU QYTDSTFR 0 yes 2 1.09E-02 2.47E+07 1.69E+07 1.36E+07 2.44E+07 1.69E+07 2.48E+07 2.24E+07 2.29E+07 0.00E+00 
CERU GEFYIGSK 0 yes 2 2.49E-02 2.01E+07 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
CERU PVWLGFLGPIIK 0 yes 2 4.65E-02 0.00E+00 0.00E+00 0.00E+00 1.46E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
CLU ASSIIDELFQDR 0 yes 2 2.65E-26 5.99E+06 2.16E+07 2.98E+06 1.48E+07 5.04E+06 2.64E+06 6.16E+06 3.43E+06 0.00E+00 
CLU 
LFDSDPITVTVPVE
VSR 
0 yes 2 8.44E-12 
0.00E+00 1.48E+07 0.00E+00 8.71E+06 1.86E+06 0.00E+00 3.72E+06 0.00E+00 0.00E+00 
CLU EIQNAVNGVK 0 yes 2 2.00E-04 2.72E+06 0.00E+00 0.00E+00 4.74E+06 2.87E+06 2.85E+06 3.03E+06 2.96E+06 0.00E+00 
CLU IDSLLENDR 0 yes 2 1.81E-03 1.52E+07 1.08E+07 4.19E+06 1.95E+07 5.59E+06 7.77E+06 1.51E+07 1.07E+07 0.00E+00 
CLU TLLSNLEEAK 0 yes 2 6.13E-03 1.00E+07 8.72E+06 1.55E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 2.15E+06 
C3 APSTWLTAYVVK 0 yes 2 0.00E+00 9.09E+06 6.82E+07 0.00E+00 3.12E+07 0.00E+00 0.00E+00 2.09E+07 2.35E+07 0.00E+00 
C3 GVFVLNK 0 no 1,2 0.00E+00 2.39E+07 3.02E+07 7.54E+06 5.33E+07 1.23E+07 7.79E+06 3.46E+07 7.24E+07 0.00E+00 
C3 
VPVAVQGEDTVQS
LTQGDGVAK 
0 yes 2,3 1.02E-285 
1.88E+07 1.06E+08 0.00E+00 1.06E+08 3.21E+07 0.00E+00 1.12E+08 4.64E+07 4.10E+07 
C3 
DYAGVFSDAGLTF
TSSSGQQTAQR 
0 yes 2,3 1.15E-145 
1.62E+07 3.98E+07 4.85E+06 2.70E+07 6.73E+06 5.37E+06 1.97E+07 2.58E+07 2.86E+06 
C3 
AYYENSPQQVFSTE
FEVK 
0 yes 2 3.44E-94 
0.00E+00 3.26E+07 7.74E+06 2.17E+07 1.33E+07 8.60E+06 1.58E+07 2.16E+07 1.01E+07 
C3 SGSDEVQVGQQR 0 yes 2 2.07E-89 1.09E+07 1.06E+07 1.21E+07 1.92E+07 2.30E+07 1.92E+07 2.05E+07 2.35E+07 2.21E+06 
C3 
SNLDEDIIAEENIVS
R 
0 yes 2,3 5.71E-76 
3.43E+07 1.10E+08 1.26E+07 8.53E+07 2.58E+07 3.13E+06 6.94E+07 6.50E+07 1.88E+07 
C3 QELSEAEQATR 0 yes 2 3.98E-61 1.68E+07 1.50E+07 1.05E+07 2.22E+07 2.22E+07 1.90E+07 2.62E+07 2.93E+07 0.00E+00 
C3 TIYTPGSTVLYR 0 no 2 2.06E-47 1.12E+08 1.54E+08 0.00E+00 1.66E+08 2.16E+07 1.34E+07 1.64E+08 1.87E+08 2.70E+07 
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1 
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HAD 
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POS 
1 
POS 
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C3 
EDIPPADLSDQVPD
TESETR 
0 yes 2 9.42E-36 
4.16E+06 6.76E+06 2.65E+06 6.90E+06 7.88E+06 4.03E+06 5.46E+06 1.11E+07 5.35E+06 
C3 IPIEDGSGEVVLSR 0 yes 2,3 1.39E-35 1.01E+08 1.18E+08 1.15E+07 1.56E+08 2.38E+07 1.21E+07 1.46E+08 1.72E+08 2.20E+07 
C3 TGLQEVEVK 0 yes 2 1.22E-33 8.35E+07 8.54E+07 4.67E+07 1.21E+08 7.68E+07 7.88E+07 1.23E+08 1.41E+08 8.86E+06 
C4A 
PVAFSVVPTAAAA
VSLK 
0 yes 2,3 2.47E-50 
1.85E+06 2.08E+07 2.09E+06 5.25E+06 2.66E+06 3.02E+06 4.99E+06 3.11E+06 1.46E+06 
C4A 
LQETSNWLLSQQQ
ADGSFQDPCPVLD
R* 
0 yes 3 7.10E-08 
0.00E+00 4.85E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
C4A DSSTWLTAFVLK 0 yes 2 2.01E-02 0.00E+00 3.15E+06 0.00E+00 3.50E+06 2.62E+06 0.00E+00 3.66E+06 0.00E+00 0.00E+00 
C4B 
VLSLAQEQVGGSP
EK 
0 no 2 6.66E-175 
6.75E+07 7.22E+07 1.50E+07 7.51E+07 4.78E+06 1.02E+07 6.58E+07 7.39E+07 0.00E+00 
C4B 
VTASDPLDTLGSEG
ALSPGGVASLLR 
0 no 2,3 4.29E-106 
1.72E+07 4.68E+07 7.58E+06 1.84E+07 4.58E+06 1.16E+07 9.88E+06 1.09E+07 9.75E+06 
C4B TTNIQGINLLFSSR 0 no 2 1.75E-60 2.78E+06 4.51E+07 6.00E+06 1.26E+07 5.29E+06 3.74E+06 8.64E+06 7.81E+06 1.30E+06 
C4B 
ALEILQEEDLIDEDD
IPVR 
0 no 2 1.31E-44 
0.00E+00 0.00E+00 2.77E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 6.79E+06 0.00E+00 
C4B QGSFQGGFR 0 no 2 2.49E-15 1.54E+07 1.16E+07 8.41E+06 1.89E+07 5.55E+06 9.53E+06 1.54E+07 1.61E+07 0.00E+00 
C4B DFALLSLQVPLK 0 no 2 2.64E-13 8.41E+06 2.19E+07 5.30E+06 1.10E+07 6.02E+06 2.12E+06 8.27E+06 4.31E+06 6.71E+05 
C4B VGDTLNLNLR 0 no 2 1.71E-11 0.00E+00 6.24E+07 0.00E+00 8.45E+07 5.08E+06 0.00E+00 4.76E+07 3.43E+07 4.53E+06 
C4B AEFQDALEK 0 no 2 3.09E-06 3.29E+07 3.10E+07 1.42E+07 3.99E+07 9.99E+06 1.62E+07 3.04E+07 3.79E+07 0.00E+00 
C4B PVQGVAYVR 0 no 2 3.35E-06 8.55E+06 1.03E+07 3.37E+06 2.02E+07 3.26E+06 2.94E+06 1.16E+07 1.35E+07 0.00E+00 
C4B GSSTWLTAFVLK 0 yes 2 5.90E-02 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 4.25E+06 0.00E+00 0.00E+00 
CFH 
LGYVTADGETSGSI
TCGK* 
0 yes 2 1.66E-40 
7.43E+06 1.25E+07 0.00E+00 1.29E+07 3.35E+06 1.69E+06 1.29E+07 1.13E+07 0.00E+00 
CFH 
AGEQVTYTCATYY
K* 
0 yes 2 1.33E-26 
1.21E+07 2.34E+07 0.00E+00 2.19E+07 2.93E+06 1.12E+06 1.96E+07 2.33E+07 7.34E+05 
CFH 
VSVLCQENYLIQEG
EEITCK* 
0 yes 2,3 1.58E-15 
2.83E+06 1.33E+07 2.97E+06 1.25E+07 3.05E+06 3.30E+06 9.27E+06 6.16E+06 1.29E+06 
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CFH 
AVYTCNEGYQLLG
EINYR* 
0 yes 2 1.49E-06 
0.00E+00 1.02E+07 0.00E+00 3.54E+06 2.08E+06 0.00E+00 2.20E+06 2.79E+06 0.00E+00 
CFH 
SSIDIENGFISESQY
TYALK 
0 yes 2 1.94E-06 
0.00E+00 2.80E+06 0.00E+00 2.88E+06 0.00E+00 0.00E+00 0.00E+00 1.16E+06 0.00E+00 
CFH LSYTCEGGFR* 0 yes 2 9.26E-05 2.20E+07 2.16E+07 0.00E+00 2.48E+07 4.80E+06 0.00E+00 2.34E+07 2.53E+07 2.10E+06 
CFH SSNLIILEEHLK* 0 yes 2,3 6.62E-04 0.00E+00 0.00E+00 0.00E+00 1.58E+07 0.00E+00 0.00E+00 1.65E+07 0.00E+00 0.00E+00 
CFH 
EQVQSCGPPPELL
NGNVK* 
0 yes 2 1.72E-03 
8.15E+05 7.63E+05 0.00E+00 1.71E+06 0.00E+00 0.00E+00 1.20E+06 1.31E+06 0.00E+00 
CFH 
WSSPPQCEGLPCK
* 
0 yes 2 2.18E-03 
4.04E+06 6.20E+06 0.00E+00 5.28E+06 0.00E+00 0.00E+00 5.00E+06 7.18E+06 0.00E+00 
CFH 
CFEGFGIDGPAIAK
* 
0 yes 2 3.20E-03 
4.76E+06 8.66E+06 1.26E+06 2.54E+06 2.98E+06 3.77E+06 9.18E+06 1.56E+06 0.00E+00 
CFH IDVHLVPDR* 0 yes 2 3.64E-03 7.37E+06 8.93E+06 0.00E+00 8.12E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
CFH 
NTEILTGSWSDQT
YPEGTQAIYK 
0 yes 2 4.23E-03 
0.00E+00 0.00E+00 0.00E+00 1.76E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
CFH 
DTSCVNPPTVQNA
YIVSR* 
0 yes 2 4.35E-03 
0.00E+00 0.00E+00 0.00E+00 1.58E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
CFH 
SCDNPYIPNGDYSP
LR* 
0 yes 2 5.50E-03 
2.14E+06 0.00E+00 0.00E+00 2.37E+06 0.00E+00 0.00E+00 2.12E+06 0.00E+00 0.00E+00 
CFH KGEWVALNPLR* 1 yes 3 5.63E-03 0.00E+00 6.66E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
GSN 
TPSAAYLWVGTGA
SEAEK 
0 yes 2 4.20E-16 
0.00E+00 5.43E+06 0.00E+00 5.78E+06 0.00E+00 0.00E+00 5.17E+06 0.00E+00 0.00E+00 
GSN 
QTQVSVLPEGGET
PLFK 
0 yes 2 3.62E-08 
2.62E+06 6.26E+06 0.00E+00 8.74E+06 2.76E+06 1.48E+06 6.08E+06 1.96E+06 1.99E+06 
GSN 
EVQGFESATFLGYF
K 
0 yes 2 7.65E-07 
1.50E+06 5.17E+06 0.00E+00 4.19E+06 1.64E+06 0.00E+00 3.03E+06 9.55E+05 0.00E+00 
GSN 
AQPVQVAEGSEPD
GFWEALGGK 
0 yes 2 1.78E-06 
0.00E+00 1.88E+06 0.00E+00 1.87E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
GSN AGALNSNDAFVLK 0 yes 2 4.08E-04 0.00E+00 1.11E+07 0.00E+00 1.35E+07 0.00E+00 0.00E+00 1.23E+07 7.21E+06 0.00E+00 
GSN PALPAGTEDTAK 0 yes 2 7.97E-03 0.00E+00 1.03E+06 0.00E+00 3.18E+06 0.00E+00 0.00E+00 3.45E+06 0.00E+00 0.00E+00 
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Protein 
name 
Sequence 
Missed 
cleavages 
Unique 
(Groups) 
Charge 
States 
PEP 
Raw Intensity 
HAD 
1 
HAD 
2 
HAD 
3 
MNI 
1 
MNI 
2 
MNI 
3 
POS 
1 
POS 
2 
POS 
3 
GSN EPGLQIWR 0 yes 2 3.76E-02 0.00E+00 0.00E+00 0.00E+00 4.82E+06 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
SAP IVLGQEQDSYGGK 0 yes 2 6.40E-04 0.00E+00 9.38E+06 0.00E+00 7.40E+06 0.00E+00 0.00E+00 0.00E+00 8.68E+06 0.00E+00 
SAP AYSLFSYNTQGR 0 yes 2 1.12E-03 7.95E+06 1.02E+07 0.00E+00 0.00E+00 0.00E+00 0.00E+00 3.48E+06 9.08E+06 0.00E+00 
SAP QGYFVEAQPK 0 yes 2 5.26E-03 8.02E+06 6.10E+06 0.00E+00 5.57E+06 0.00E+00 0.00E+00 2.09E+06 0.00E+00 0.00E+00 
SAP VGEYSLYIGR 0 yes 2 5.26E-03 0.00E+00 0.00E+00 0.00E+00 6.48E+06 0.00E+00 0.00E+00 0.00E+00 4.80E+06 0.00E+00 
SAP DNELLVYK 0 yes 2 1.01E-02 4.69E+06 0.00E+00 0.00E+00 4.09E+06 0.00E+00 0.00E+00 2.25E+06 2.61E+06 0.00E+00 
*: Does not adhere to selection criteria 
PEP: Posterior Error Probability 
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3.4. Conclusion 
As a means to identify precursor ions suitable for PRM analysis of our candidate biomarkers, 
discovery proteomic analysis of pooled patient samples yielded an acceptable number of 
protein identifications, considering the low degree of abundant protein depletion. Analysis 
successfully identified all candidate biomarker proteins, with varying degrees of peptide 
coverage. Peptide identifications provided an adequate number of prospective target 
peptides for almost all candidate biomarkers. Peptides unique to a protein group were 
selected based on suitability for downstream screening by PRM analysis, and a final set of 106 
peptides were chosen for validation by PRM analysis. Screening by PRM analysis would also 
serve to exclude false hits, regardless of assessment of quality based on discovery proteomic 
data analysis. The best peptides from this validation can then be used to construct a PRM 
assay for high throughput analysis of patient serum samples. 
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Chapter 4  
Optimisation B: Optimisation of 
Instrument Parameters for Parallel 
Reaction Monitoring Assays  
4.1. Introduction 
PRM is a targeted mass spectrometric method, that when applied to a Q Exactive quadrupole-
Orbitrap mass spectrometer, possesses several advantages over classical SRM assays 
conducted on triple quadrupole instruments.130 Both methods entail selection of precursors 
by the first quadrupole, however, PRM involves high resolution detection of all fragment ions 
in the Orbitrap detector; while SRM assays entail selection and detection of predefined 
fragment ions.125,126,130 The high resolution capability, coupled with the ability to detect all 
possible fragments, make PRM analysis well suited to high throughput, high resolution 
targeted analysis.130 
Previously developed PRM assay parameters have been outlined in the literature, which 
include suggested ion injection times, AGC target values, and isolation list sizes at various 
resolution settings.132,182 Multiplexing considerations such as injection time and isolation list 
modification have also been outlined.132 These settings however require verification to ensure 
their validity, as well as to gain a more practical understanding of PRMs. 
This Chapter is thus concerned with determination of optimal mass spectrometer parameters 
for proteomic PRM assays using our Q Exactive mass spectrometer. Analysis in duplex mode 
(i.e.: two peptides analysed simultaneously), at a resolution of 35 000, and requisite cycle time 
of 2 seconds, has been reported to allow a maximum 32 peptides to be measured.132 In the 
present study an isolation list of 36 precursors would be analysed with an average of 3 
peptides per protein, and a list of 12 proteins – with consideration for at least 5 internal 
reference peptides. Factoring in retention time scheduling should theoretically improve 
quantitation.138 A resolution of 35 000 resolution was therefore selected for optimisation. 
In order to further optimise instrument parameters for PRMs, a laboratory reference sample 
– for which LC and data-dependent acquisition parameters had already been established – 
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was initially utilised. The reference sample consists of a tryptic digest of total protein extracted 
from SHSY-5Y neuroblastoma cells, processed according to a modified filter-aided sample 
preparation (FASP) protocol.183 Peptides detected in this sample were used as surrogates for 
determination of optimal instrument parameters for further PRM analyses. 
4.2. Materials and Methods 
4.2.1. Identification of Reference Sample Peptides for Method 
Development 
Data files from 11 LC-MS/MS analyses were interrogated to identify proteins present in the 
sample.  Discovery proteomic analysis was performed as outlined in Section 3.2.2, with 50 ng 
of reference sample loaded onto the LC column. Three samples were chromatographically 
separated using an 85 minute gradient (vide infra), while the remaining eight were separated 
on a 45 minute gradient (vide infra). The former was run on the Dionex UltiMate 3500 RSLC 
nano-LC instrument equipped with a nanoscale analytical column, packed in-house with Luna 
C18 coated silica beads (75 µm x 50 cm). The gradient comprised a constant flow rate of 300 
nl/min over a linear gradient: 2% B for 10 minutes, 2-35% B over 23 minutes, 35-50% B over 5 
minutes, 50-80% B over 5 minutes, held at 80% B for 20 minutes, before returning to 2% B in 
2 minutes, followed by re-equilibration at 2% B for 20 minutes. The latter was run on a Proxeon 
Easy nLC (Thermo Scientific) instrument equipped with a nanoscale analytical column, packed 
in-house with Luna C18 coated silica beads (75 µm x 20 cm).  The gradient comprised a 
constant flow rate of 300 nl/min: 5-35% B over 30 minutes, 35-80% B over 5 minutes, and held 
at 80% B for 10 minutes. Equilibration at 5% B is conducted pre-run. Data analysis was 
performed as described in Section 3.2.3. 
4.2.2. Parameter Optimisation 
4.2.2.1. Baseline Settings 
ISOLATION LIST CONSTRUCTION 
Skyline (v3.1) – an open source targeted proteomic software tool – was used to prepare 
methods and to visualise PRM data.133 It was also subsequently used to process and export 
data for statistical analysis (Chapter 7). 
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The software settings used here for analysis of instrument parameter optimisation data were 
used throughout the present study for all other PRM analyses, as these settings correspond 
to characteristics of the target peptides used throughout the study. Trypsin was chosen as the 
enzyme, with one accepted missed cleavage. The UniProt complete human proteome .fasta 
file (downloaded on 9/01/2014) was used to construct the background proteome. The 
minimum and maximum allowed peptide lengths were set to 6 and 25 amino acids 
respectively, while no N-terminal amino acids were excluded. Cysteine, methionine and 
histidine residues were permitted in peptide sequences. Peptides possessing consensus 
glycosylation sites (NXT/NXS) were excluded since glycosylated peptides are not easily 
identified or consistently quantifiable.184 Proline residues flanking cleavage sites (KP/RP) were 
also excluded due to their inhibition of tryptic cleavage.185 Carbamidomethyl cysteine (57m/z) 
was defined as the only fixed structural modification (www.unimod.org). The default 
monoisotopic precursor ion charges states were set to 3 and 2, while the product ion (b and 
y) charge states were set to 1. The mass range was adjusted to reflect Q Exactive instrument 
capabilities, with a minimum and maximum m/z of 50 and 3000 respectively. Remaining 
settings were retained as default.  
The aforementioned settings may be used at any level of PRM analysis, with the option to 
disregard them by manually adding or removing precursor or product ions.  The Full Scan 
settings are the most influential in PRM analyses, and required adjustment when exporting 
and importing isolation lists and data respectively. When exporting isolation lists, the 
precursor isotope peaks were set to ‘Count’, with one peak chosen. The Orbitrap was chosen 
as the MS1 mass analyser with resolution set to 35 000 at 200m/z. The Targeted MS2 
acquisition method was chosen with the Orbitrap mass analyser resolution also set to 35 000 
at 200m/z. When importing data files into Skyline, the precursor mass analyser was set to 
quadrupole ion trap (QIT) with a resolution of 1m/z (the closest match to the Q Exactive 
quadrupole mass filter). 
Once Skyline settings were adjusted, reference peptides selected from data-dependent 
analysis (Section 4.3.1) were imported into Skyline by manual sequence entry. The 
unscheduled isolation list (Table 4.1) was then exported as a .csv file for import into Xcalibur. 
Empty columns are intentional, as this is the format required by Xcalibur for isolation list 
import and applies to all isolation lists used hereafter. 
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TABLE 4.1: ISOLATION LIST FOR UNSCHEDULED PRM ANALYSIS OF REFERENCE SAMPLE PEPTIDES.  
Mass [m/z] 
Formula 
[M] 
Species 
CS 
[z] 
Polarity 
Start 
[min] 
End 
[min] 
NCE Comment 
1081.991 
  
2 
Positive   27 
AENNSEVGASGYGVPGPTWDR 
(light) 
1243.065 
  
2 
Positive   27 
KAAAPAPEEEMDEC[+57.0]EQ
ALAAEPK (light) 
1280.628 
  
2 
Positive   27 
LVQDVANNTNEEAGDGTTTAT
VLAR (light) 
786.9458   2 Positive   27 TLTDELAALQITGVK (light) 
956.4396   2 Positive   27 VDSAATSGYEIGNPPDYR (light) 
1189.087 
  
2 
Positive   27 
QVQSLTC[+57.0]EVDALKGTNE
SLER (light) 
1257.525 
  
2 
Positive   27 
NADMSEEMQQDSVEC[+57.0]
ATQALEK (light) 
652.3099   2 Positive   27 SPEEVDKESQR (light) 
1058.994 
  
2 
Positive   27 
DQQEAALVDMVNDGVEDLR 
(light) 
754.3823 
  
2 
Positive   27 
VIQC[+57.0]FAETGQVQK 
(light) 
1147.574 
  
2 
Positive   27 
EAFLNTEDKGDSLDSVEALIK 
(light) 
1179.546 
  
2 
Positive   27 
MQEAMTQEVSDVFSDTTTPIK 
(light) 
607.3142   2 Positive   27 DSPSVWAAVPGK (light) 
931.4423   2 Positive   27 SPSDSSTASTPVAEQIER (light) 
922.9493   2 Positive   27 EAFSLFDKDGDGTITTK (light) 
980.966 
  
2 
Positive   27 
DATNVGDEGGFAPNILENK 
(light) 
1246.059 
  
2 
Positive   27 
LC[+57.0]SLLDSEDYNTC[+57.0
]EGAFGALQK (light) 
640.3192   2 Positive   27 SVNSSTMVAQQK (light) 
448.7366   2 Positive   27 ALTTMGFR (light) 
648.807   2 Positive   27 GGELVYTDSEAR (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
INSTRUMENT PARAMETERS 
In order to develop PRM assays for specific peptides, baseline instrument parameters had to 
be established. Several publications provided a general outline of the PRM assay parameters 
applicable to the Q Exactive mass spectrometer.131,132,182 The major parameters involved in 
PRM methods – referred to in the software as Targeted MS2 (tMS2) – are: Lock Mass, 
Chromatographic Peak Width, Resolution, AGC Target, Max Injection Time (Max IT), Multiplex 
Level (MSX), Isolation Window, and NCE. 
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Baseline settings (some of which are evident in Table 4.2) were obtained from Schroeder et 
al.182 The lock mass function instructs the instrument to begin scanning at a predefined m/z 
value. Lock masses were set to ‘off’ during PRM analysis as the start of each scan is instead 
determined by the inclusion list. Chromatographic peak width was set to 15 s, this being the 
average width of peaks on the LC gradient in our laboratory. The charge state for each 
precursor is indicated in the isolation list. A resolution setting of 35 000 (at 200m/z) was 
chosen. The AGC target limits the amount of ions allowed to enter the Orbitrap – by varying 
ITs – to avoid space charging effects which adversely affect detection.186 The highest setting 
was selected to prevent inconsistent ITs, which could impact quantitation. Max IT is the 
amount of time that the instrument spends collecting each precursor in the collision cell for 
subsequent Orbitrap analysis. Higher ITs result in greater sensitivity since more ions are 
injected into the detector.  
MSX indicates the number of precursors that are analysed together after fragmentation in the 
collision cell. It was not clear from the literature however, whether increasing MSX requires a 
concomitant reduction of Max IT, assuming IT is assigned to each precursor when 
multiplexing, and was therefore established experimentally. Isolation Window indicates the 
‘margin of error’ allowed by the quadrupole when selecting precursor masses. A wider 
window increases the number of different precursor ions that enter the Orbitrap, including 
isotopes, but also permitting entry of untargeted peptides. An isolation width of 2m/z was 
therefore used as this permitted relatively high selectivity of the quadrupole, without 
significantly sacrificing signal intensity, since signal intensity has been found to be comparable 
when using either a 2 or 4m/z isolation window.132 The NCE value influences collision energy 
based on the mass of the precursor. Essentially, increasing the NCE will increase the effective 
collision energy to a varying extent for precursors of different masses. The Skyline default NCE 
of 27 was used.  
TABLE 4.2: TABLE OF BASE SETTINGS FOR PRM ANALYSIS.  
Lock masses Off 
Chrom. peak width 15 s 
Charge state 2 
Resolution 35000 
AGC Target 5.00E+06 
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Max IT 110 ms 
MSX 1 
ISO Window 2 m/z 
NCE 27 
AGC: Automatic Gain Control, MSX: Multiplex level, ISO: Isolation, NCE: Normalised Collision Energy, 
Max IT: Maximum Injection time. 
 
4.2.2.2. LC/MS Instrumentation and Parameters 
Parallel reaction monitoring analysis was performed on the Q Exactive, coupled to the Dionex 
UltiMate 3500 RSLC nano-LC system. Approximately 100 ng of reference sample was loaded 
onto the reversed phase chromatography column as outlined in Section 3.2.2. Samples were 
eluted with an 85 minute gradient as described in Section 4.2.1. A Targeted MS2 method was 
constructed starting with the baseline instrument settings as outlined in Table 4.2, using the 
.csv file in Table 4.1 as an inclusion list. Xcalibur instrument settings were then varied between 
optimisation steps, with remaining LC/MS parameters remaining constant unless otherwise 
stated. 
4.2.2.3. Injection Time Optimisation 
Correct IT is integral to an efficient PRM experiment. A short IT compromises sensitivity by 
unnecessarily limiting the number of ions entering the mass analyser.187 On the other hand, 
excessively long ITs extend cycle time (time taken to cycle though the target list), impeding 
quantitation by limiting the number of sampling points on the chromatogram.134 It stands to 
reason that this may also cause the Orbitrap to idle between injections, if the injection time is 
too long, thereby wasting analysis time. Ideally, IT should be balanced with the scanning time 
of the Orbitrap, ensuring minimal time is wasted between scan cycles.   
A transient is the time domain signal of an oscillating molecule detected over time, which is 
converted by Fourier Transform into a mass spectrum in the frequency domain.113,188 Higher 
resolution is correlated with higher transient measurement times.188 Schroeder et al.148 
maintain that IT should not exceed the theoretical transient time of the Orbitrap detector, and 
provide suggested ITs for each resolution setting (Table 4.3). Gallien et al.132 predict that the 
IT should be calculated by dividing the transient time by MSX, therefore assigning an IT of 128 
ms at a resolution of 35 000 in single-plex mode. However, they do not adhere to this claim as 
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their instrument parameters reflect an IT of 120 ms under the previously mentioned 
conditions.  
TABLE 4.3: TABLE OF ORBITRAP SCAN TIME PARAMETERS BASED ON RESOLUTION SETTING. ADAPTED FROM 
SCHROEDER ET AL.148 
Resolution 
at m/z 200 
Scan speed (Hz) 
Transient length 
(ms) 
Suggested Max Fill 
Time (ms) 
17 500 13 64 50 
35 000 7 128 110 
70 000 3 256 240 
140 000 1.5 512 500 
 
Determination of optimal injection time was performed due to the lack of consensus on this 
baseline parameter, as incorrect IT may adversely affect sensitivity and quantitation (vide 
supra). The following experiments served to ascertain the optimal injection time necessary to 
maximise sensitivity whilst maintaining sufficiently high quantitative ability.  
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SCAN EVENT ANALYSIS 
In order to assess the effect of alterations in IT, scan events were examined in each .RAW file. 
The total MS2 chromatogram was set to show scan events as vertical lines (or ‘sticks’), each 
labelled with scan number and retention time (Figure 4.1). The time between scan events 
indicates scan time and was used to compare different IT settings. Changes in scan time may 
indicate injection time causing varying delays between successive scans. According to our 
current knowledge, the application of this method of scan time evaluation to PRM analysis is 
novel. 
 
For all applicable optimisation steps, scans were taken from random retention time points on 
the chromatogram and average scan time calculated. 
ESTABLISHING THE RELATIONSHIP BETWEEN MSX AND INJECTION TIME 
It was initially unclear whether increasing MSX required a concomitant reduction of Max IT. It 
was hypothesised that Max IT was assigned to each precursor independently when 
multiplexing. To test this hypothesis, all settings (Table 4.2) were kept constant while MSX was 
varied. For each consecutive analysis, MSX was varied from 1 to 4 inclusive. 
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FIGURE 4.1: EXAMPLE OF A SCAN DIAGRAM OUTLINING SCAN PARAMETERS. SCAN TIME (IN SECONDS) IS 
CALCULATED BY MULTIPLYING THE TIME BETWEEN SCANS (IN MINUTES) BY 60 
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ASSESSMENT OF SUGGESTED INJECTION TIME SETTINGS  
In order to assess the effect of increasing multiplexing degree on scan times, MSX levels as 
well as Max IT settings were varied concomitantly (other baseline settings remained constant 
as in Table 4.2). Multiplex levels were set to 1, 2, and 3; while Max IT was set to 110, 55 and 
36 ms respectively (i.e. Max IT at single-plex was divided by MSX level). 
DETERMINATION OF OPTIMUM INJECTION TIME 
To test the optimal IT (110 ms) suggested by Schroeder et al.182, and establish the highest 
permissible IT that would permit only the Orbitrap scanning time to influence overall scan 
time, overall scan time solely dependent on Orbitrap scanning time was established. A short 
IT and associated delays does not influence total scan time. ITs of 50 ms and 100 ms 
respectively were evaluated at 35 000 resolution in single-plex mode, with all other settings 
kept constant (Table 4.2). These ITs were chosen for their proximity to and position below the 
suggested value.  
VALIDATION OF INJECTION TIMES AT OTHER MULTIPLEX LEVELS 
The optimal IT for single-plex PRM analysis was confirmed to be 100 ms. This information, 
together with Equation 1 (p. 54), was used to predict the IT settings for higher multiplex levels, 
which were then validated for single- and duplex assays, confirming the predictive ability of 
Equation 1 when optimum single-plex IT is known. ITs of 45 ms and 27 ms were used at MSX 
levels of 2 and 3 respectively, with all other settings kept constant (Table 4.2).  
4.2.2.4. Multiplexing Considerations 
Multiplexing in PRM facilitates analysis of multiple precursors in a single scan, significantly 
increasing the number of peptides that can be measured in a single assay. It also increases the 
number of sampling scans over the chromatographic peak by shortening the time taken for 
the mass spectrometer to cycle through the isolation list. One drawback to multiplexing lies 
in the reduction in IT afforded to each precursor. Data files from the 100 ms single-plex and 
45 ms duplex evaluations were used to assess these aspects by comparing peptide 
VDSAATSGYEIGNPPDYR (Table 4.4) in the two MSX modes. Isolation lists were identical in both 
analyses. Data were visualised in Skyline, and the chromatogram was reconstructed in Excel 
to visualise the points on the curve. Data were copied from Skyline, consisting of each data 
point used to generate the chromatogram, and were pasted into Microsoft Excel. The data 
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points were used to construct a line graph with multiple markers, each representing an 
individual scan.  
4.3. Results and Discussion 
4.3.1. Identification of Reference Sample Peptides for Method 
Development 
 
Following MaxQuant analysis of ideal reference LC-MS/MS data files (Figure 4.2), the output 
was interrogated to identify ideal peptides for instrument optimisation. The number of 
protein groups identified, including contaminants and reverse hits, totalled 2499 across 11 
data files (Data not shown). Excluding contaminants and reverse hits reduced the total to 2451 
protein groups. Of 73643 identified peptides, 20 were selected for instrument method 
development (Table 4.4). Peptides with good PEP scores were preferred and were randomly 
selected, with three relatively low-scoring peptides included to avoid bias. Peptides with 
variable modifications such as oxidation and N-terminal acetylation were excluded, as they 
may not be reliably detected at high abundance. Additionally, detection of these variants were 
not necessary for the purposes of instrument optimisation. Peptides containing cysteine and 
methionine residues, as well as missed cleavages were allowed.  
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FIGURE 4.2: REPRESENTATIVE MASS SPECTROMETRIC CHROMATOGRAM OF A SINGLE REFERENCE SAMPLE. UPPER 
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TABLE 4.4: TABLE OF CHOSEN PEPTIDES FOR INSTRUMENT METHOD DEVELOPMENT.  
Sequence Protein Names PEP 
AENNSEVGASGYGVPGPTWDR ATP-dependent RNA helicase A 0 
KAAAPAPEEEMDECEQALAAEPK Elongation factor 1-gamma 0 
LVQDVANNTNEEAGDGTTTATVLAR 60 kDa heat shock protein, mitochondrial 0 
TLTDELAALQITGVK Estradiol 17-beta-dehydrogenase 11 0 
VDSAATSGYEIGNPPDYR Low molecular weight phosphotyrosine protein 
phosphatase 
2.62E-291 
QVQSLTCEVDALKGTNESLER Vimentin 2.37E-279 
NADMSEEMQQDSVECATQALEK Dynein light chain 1, cytoplasmic 7.00E-256 
SPEEVDKESQR Nestin 5.68E-249 
DQQEAALVDMVNDGVEDLR Glutathione S-transferase P 2.50E-150 
VIQCFAETGQVQK Clathrin heavy chain 1 2.61E-144 
EAFLNTEDKGDSLDSVEALIK Spectrin alpha chain, brain 9.45E-144 
MQEAMTQEVSDVFSDTTTPIK Vinculin 2.25E-143 
DSPSVWAAVPGK Profilin-1 1.93E-141 
SPSDSSTASTPVAEQIER Drebrin 1.84E-140 
EAFSLFDKDGDGTITTK Calmodulin 2.11E-139 
DATNVGDEGGFAPNILENK Alpha-enolase 2.08E-133 
LCSLLDSEDYNTCEGAFGALQK Transportin-1 2.89E-96 
SVNSSTMVAQQK Septin-7 0.003154 
ALTTMGFR Sorcin 0.003363 
GGELVYTDSEAR Plectin 0.10254 
PEP: Posterior Error Probability 
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4.3.2. Parameter Optimisation 
4.3.2.1. Injection Time Optimisation 
ESTABLISHING THE RELATIONSHIP BETWEEN MSX AND INJECTION TIME 
IT was kept constant at 110 ms, while MSX level was varied. Samples of scan diagrams (Figure 
4.3) show the scan time changes associated with an increase in MSX.  
 
Summarised in Table 4.5 are the scan time changes associated with changes in degree of MSX. 
The significant scan time increase of 120 ms, as degree of multiplexing increases, indicates 
that the Max IT value is indeed assigned to each precursor when multiplexing. Therefore, 
when multiplexing, the IT used during single-plex analysis needs to be adjusted based on the 
level of multiplexing. For example, a duplex assay would have a Max IT of 55 ms when the 
FIGURE 4.3: SCAN DIAGRAMS SHOWING SCAN TIMES WITH INCREASING MSX LEVEL. A: MSX=1, B: MSX=2, 
C: MSX=3, D: MSX=4. IMAGE NOT TO SCALE, *: AGC PRESCAN 
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single-plex Max IT is 110 ms. This relationship between IT and MSX was unclear at the outset 
of PRM analysis, although it had previously been inferred by Gallien et al.132 It should be noted, 
for all subsequent scan diagrams, that a scan approximately twice as long as an average scan 
is periodically observed (*: Figure 4.3). We hypothesised that this additional scan was the AGC 
prescan, and it is excluded from our calculations as it is a built-in mass spectrometer function. 
TABLE 4.5: SUMMARY OF SCAN TIME CHANGES ASSOCIATED WITH CHANGE IN MSX 
Parameters Scan Times 
Resolution Max IT MSX 
Transient 
Time 
Ave. Scan Time Δ Scan Time 
35 000 110 ms 
1 
128 ms 
145 
120 
  
2 265 
120 
 
3 385  
120 
4 505   
 
This experiment also revealed an unexpected additional change in scan time between 
consecutive multiplex levels was identified. It would be reasonable to assume that the overall 
scan time should increase by multiples of the Max IT value. This is clearly not the case 
however, as the observed change in scan time was calculated to be approximately 120 ms 
rather than 110 ms (Table 4.5). It would appear that there is an additional 10 ms scan delay – 
in addition to the expected 110 ms – associated with each increase in multiplex level.  
The average scanning time of the Orbitrap at 35 000 resolution was measured at   
approximately 145 ms (single-plex). Calculating the inverse of scan speed (Hz or 
cycles/second) results in overall scan time (seconds/cycle) as shown in Table 4.6.182 The 
measured scan time very nearly agrees with the predicted overall scan time. However, optimal 
IT has yet to be determined. An IT that results in a total scan time equal to or lower than the 
predicted scan time in Table 4.6 would be deemed optimal. 
TABLE 4.6: TABLE SHOWING OVERALL SCAN TIME. ADAPTED FROM SCHROEDER ET AL.148 
Resolution 
at m/z 200 
Scan speed (Hz) Transient length (ms) 
Scan time  
(1/scan speed, ms) 
17 500 13 64 77 
35 000 7 128 143 
70 000 3 256 333 
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140 000 1.5 512 667 
 
ASSESSMENT OF SUGGESTED INJECTION TIME SETTINGS 
Having established that Max IT requires adjustment when increasing MSX level, MSX level was 
therefore increased, while Max IT was adjusted for each level by dividing the single-plex Max 
IT by its respective MSX level. Scan times were measured for each set of conditions (Figure 
4.4).  
 
Decreasing Max IT proportionately with increasing MSX was predicted to result in a constant 
overall scan time. However, with an increase in MSX, an increase in overall scan time was 
FIGURE 4.4: SCAN DIAGRAMS SHOWING SCAN TIMES WITH CONCOMITANTLY ADJUSTED MSX AND MAX IT. A: 
SINGLE-PLEX & 110MS, B: DUPLEX & 55MS, C: TRIPLEX AND 36MS. IMAGE NOT TO SCALE 
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unexpectedly observed (Table 4.7). This can be interpreted as IT-related delays between 
successive scans, an additional 10 ms delay being observed with each increase in MSX. This 
observation is contrary to the assertion by Gallien et al.132 that the Max IT for higher MSX 
levels simply equates to the transient time divided by MSX. 
TABLE 4.7: SUMMARY OF SCAN TIMES ASSOCIATED WITH CONCOMITANT CHANGES IN MSX AND MAX IT 
Parameters Scan Times 
Resolution Max IT MSX 
Transient 
Time 
Ave. Scan Time Δ Scan Time 
35 000 
110 ms 1 
128 ms 
145 
10 
 
55 ms 2 155 
8 
36 ms 3 163  
 
With increasing MSX, there are no additional Orbitrap scans since all multiplexed ions are 
scanned simultaneously.132 It can therefore be assumed that the 10 ms delay is independent 
of Orbitrap scanning and is an artefact of additional injections. A portion of this delay could 
be attributed to the 6 ms it takes for the quadrupole to switch to the next mass in the isolation 
list.187 With the absence of definitive reasoning for this additional delay in the literature, 
considerations for future assessment is recommended. 
If the scan delay is related to ion injection and fragmentation, it is likely that the delay also 
applies to the IT in single-plex mode. The actual IT (effective IT) for a Max IT setting of 110 ms 
in single-plex mode would therefore be 120 ms. The effective IT values for MSX greater than 
one must equal the effective IT at single-plex.  
It is apparent that simply dividing the single-plex IT by MSX is not sufficient to eliminate 
additional scan delays between multiplex levels; this additional delay needs to be taken into 
account for each level of multiplexing. 
In order to maintain a constant effective IT at each multiplex level that is equal to the effective 
IT at single-plex, the Max IT would need to be adjusted for each MSX level based on the 
effective IT at single-plex, cumulative delay, and multiplex level. A general equation can be 
expressed as:  
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EQUATION 1: EQUATION TO CALCULATE INJECTION TIME SETTINGS FOR A GIVEN MULTIPLEX LEVEL 
𝑀𝑎𝑥 𝐼𝑇 =  
((𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝐼𝑇 @ 𝑠𝑖𝑛𝑔𝑙𝑒 𝑝𝑙𝑒𝑥) − (10𝑚𝑠 × 𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥 𝑙𝑒𝑣𝑒𝑙))
𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑒𝑥 𝑙𝑒𝑣𝑒𝑙
 
 
 
Table 4.8 illustrates application of Equation 1 to predict IT values for higher MSX based on an 
effective single-plex IT of 120 ms 
TABLE 4.8: TABLE OF ADJUSTED IT VALUES BASED ON MULTIPLEX LEVEL AND ADDITIONAL DELAY 
MSX Effective IT Adjustment Adjusted Max IT 
1 120 ms N/A 110 ms 
2 120 ms* (120-20)/2 50 ms 
3 120 ms* (120-30)/3 30 ms 
*Effective IT of single-plex injection is the target of the adjustment 
 
These assumptions only hold assuming the single-plex IT of 110 ms is optimal, which can be 
easily verified. 
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DETERMINATION OF OPTIMAL INJECTION TIME 
To establish the total scan time when Orbitrap scanning time was the limiting factor, a 
significantly shorter IT was evaluated, as well as one 10 ms lower than that suggested by 
Schroeder et al.182 (Figure 4.5).  
 
In the event that the suggested IT was in fact correct, the average scan time would remain the 
same as previously measured (Table 4.7). As can be seen in Table 4.9 below, the overall scan 
time for the 50 ms IT is approximately 140 ms. This suggests that the recommended IT of 110 
ms was not optimal. When an IT of 100 ms was assessed, the overall scan time was the same 
as that for 50 ms. It can therefore be concluded that an IT of 100 ms is optimal.  
The determination of optimal IT at 35 000 resolution of 110 ms here differs from IT parameters 
reported by Gallien et al.132 (120 ms) and Schroeder et al.182 (110 ms). Considering IT 
parameters used in those studies were determined by theoretical transient times of the 
Orbitrap analyser, the empirically determined IT parameter in the present study can be 
regarded as more reliable. 
TABLE 4.9: SUMMARY OF SCAN TIMES FOR INJECTION TIME OPTIMISATION 
Parameters Scan Times 
Resolution Max IT MSX 
Transient 
Time 
Ave. Scan Time Δ Scan Time 
35 000 
50 ms 
1 128 ms 
139-140 
0 
 
100 ms 139-140 ~5 
RT: 0.04866 - 0.10179
0.050 0.055 0.060 0.065 0.070 0.075 0.080 0.085 0.090 0.095 0.100
Time (min)
0
10
20
30
40
50
60
70
80
90
100
R
el
at
iv
e 
A
bu
nd
an
ce
33
0.08385
30
0.07519
20
0.05023
28
0.0705426
0.06589
39
0.09780
35
0.0885022
0.05488 34
0.0861727
0.06822
36
0.0908231
0.07752 32
0.0798523
0.05721
25
0.06356 370.0931529
0.07287
24
0.05953 40
0.10012380.09548
NL:
1.14E5
TIC F: ms2   
MS 
140706_BM_DI
ONEX_85mpar
t_tMS2_35K_1
plex_50ms
RT: 0.05180 - 0.10595
0.055 0.060 0.065 0.070 0.075 0.080 0.085 0.090 0.095 0.100 0.105
Time (min)
0
2
4
6
8
10
12
14
16
18
20
22
24
R
el
at
iv
e 
A
bu
nd
an
ce
39
0.10200
33
0.08805
30
0.07856
20
0.05276 31
0.08088
35
0.09270
28
0.07391
22
0.05741
21
0.05508
37
0.09735
26
0.06925
34
0.0903723
0.05974 40
0.10432
29
0.07623
27
0.07158
25
0.06692
32
0.08321
38
0.09967
24
0.06207
NL:
2.83E5
TIC F: ms2   
MS 
140706_BM_DI
ONEX_85mpart
_tMS2_35K_1p
lex_100ms
14
0m
s 
13
9m
s 
14
0m
s 
14
0m
s 
13
9m
s 
14
0m
s 
13
9m
s 
14
0m
s 
14
0m
s 
13
9m
s 
14
0m
s 
14
0m
s 
14
0m
s 
14
0m
s 
14
0m
s 
13
9m
s 
14
0m
s 
13
9m
s 
14
0m
s 
140ms 
A B 
FIGURE 4.5: SCAN DIAGRAMS SHOWING SCAN TIMES FOR INJECTION TIME OPTIMISATION. A: MAX IT=50MS, 
B: MAX IT=100MS. IMAGE NOT TO SCALE 
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Parameters Scan Times 
Resolution Max IT MSX 
Transient 
Time 
Ave. Scan Time Δ Scan Time 
110 ms 145  
 
Utilising the scan delay equation above, together with the optimum single-plex, Max IT 
settings for higher multiplex levels could now be calculated. The Max IT settings can be seen 
in Table 4.10 below, where effective IT was maintained across increasing multiplex levels by 
using Equation 1. Injection times for duplex and triplex assays were calculated at 45- and 27 
ms respectively.  
TABLE 4.10: TABLE OF OPTIMUM INJECTION TIMES FOR EACH MSX LEVEL AT 35 000 RESOLUTION 
MSX Effective IT Calculation Max IT Setting 
1 110 (110-10)/1 100 ms 
2 110 (110-20)/2 45 ms 
3 110 (110-30)/3 27 ms 
 
The IT for a single-plex assay was thus established, but predicted injection times for other 
multiplex levels require validation. 
VALIDATION OF INJECTION TIMES AT OTHER MULTIPLEX LEVELS 
The hypothesised ITs for single and duplex assays were verified to confirm IT settings for these 
multiplex levels and assess the predictive ability of Equation 1. Sample scans were assessed 
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and scan times measured for multiplex levels 2 and 3, with ITs of 45- and 27 ms respectively 
(Figure 4.6).  
 
It was observed that overall scan times are equivalent between duplex and triplex scans with 
predicted ITs (Table 4.11). The scan times are equivalent to the minimum scan time previously 
established, so predicted ITs can therefore be accepted as optimal.  
TABLE 4.11: SUMMARY OF SCAN TIMES RESULTING FROM PREDICTED INJECTION TIMES IN SINGLE AND DUPLEX 
MODES 
Parameters Scan Times 
Resolution Max IT MSX 
Transient 
Time 
Ave. Scan Time Δ Scan Time 
35 000 
45 ms 2 
128 ms 
139-140 
0 
27 ms 3 139-140 
 
As an extension of the predictive ability of the IT equation (Equation 1), Max IT settings for 
multiplex levels four to six can be calculated (Table 4.12). However, 4-plex was selected as the 
highest feasible multiplex level as markedly short ITs result in a significant loss in sensitivity.132 
Isolation list size allowance was calculated based on a requisite cycle time of 2 s, as this 
translates to at least six sampling points on a 12-second chromatographic peak. The 
assumption, based on previous experiments in our laboratory, is that peaks elute in 12-18 
seconds on average. The calculation for number of precursors is as follows: 
RT: 0.02561 - 0.05389
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FIGURE 4.6: SCAN DIAGRAMS SHOWING SCAN TIMES FOR PREDICTED INJECTION TIMES AT VARYING MSX LEVELS. 
A: MSX = 2, MAX IT = 45MS; B: MSX = 3, MAX IT = 27MS 
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EQUATION 2: EQUATION TO ESTIMATE MAXIMUM NUMBER OF PRECURSORS IN A GIVEN PRM ASSAY  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑃𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟𝑠 = ( 
𝑅𝑒𝑞𝑢𝑖𝑠𝑖𝑡𝑒 𝐶𝑦𝑐𝑙𝑒 𝑇𝑖𝑚𝑒
𝑆𝑐𝑎𝑛 𝑇𝑖𝑚𝑒
) × 𝑀𝑆𝑋 𝐿𝑒𝑣𝑒𝑙 
 
Table 4.12 shows the calculated isolation list size based on Equation 2. Gallien et al.132 
conducted sensitivity assessments on a concentration range of peptide standards spiked into 
a biological matrix, at varying injection times (70 000 resolution, in single-plex mode). They 
found that decreasing IT resulted in a marked decrease in the number of reliably quantifiable 
product ions, and this decrease was exacerbated by decrease in the amount of spiked in 
peptide.  It can be inferred that to maintain a reasonable level of quantitative ability, IT should 
be kept as high as possible. Limits on IT should therefore be decided on a per-experiment 
basis, taking into account the inherent aims as well as sample type. Extensive multiplexing can 
also be avoided by implementation of retention time scheduling, which essentially decreases 
the isolation list size by segregating it according to the retention times of the analytes.138  
TABLE 4.12: TABLE OF INJECTION TIME ESTIMATIONS FOR MULTIPLEXING UP TO 6X, AND ISOLATION  LIST 
LENGTHS FOR A PREDEFINED CYCLE TIME OF 2 S 
Requisite 
Cycle Time 
Resolution MSX Max IT 
Scan Time 
(Total) 
Precursors 
Actual 
Cycle Time 
2000 ms 35 000 
1 100 ms 
140 ms 
14 
2002 ms 
2 45 ms 28 
3 27 ms 42 
4 18 ms 56 
5 12 ms 70 
6 8 ms 84 
 
In conclusion, optimal Max ITs were determined for analysis at 35 000 resolution, at multiple 
MSX levels. Isolation list sizes were also calculated for an ideal cycle time of 2 seconds. These 
parameters may be utilised in any proteomic PRM assay, and were applied to detection of the 
candidate serum biomarkers in subsequent stages of the present study. 
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4.3.2.2. Multiplexing Considerations 
The effects of multiplexing were assessed by comparing single-plex and duplex scans in Skyline 
(Figure 4.7(A) and Figure 4.7(B) respectively). The effective ITs for the VDSAATSGYEIGNPPDYR 
peptide in single-plex and duplex modes were 100- and 45 ms respectively. 
 
It is observed that the duplex chromatogram appears smoother than the single-plex 
counterpart, suggesting fewer sampling points on the latter curve. Peak intensity for the 
single-plex experiment appears to be approximately twice that of the duplex experiment. For 
example, the y5 ion appears to have a peak height of approximately 510x103 at single-plex, 
compared to 260x103 at duplex. This observation supports the assumption that multiplexing 
results in decreased sensitivity; this can be attributed to the lower IT associated with 
multiplexing, which results in fewer ions being collected for detection. 
Sampling rate was assessed by visualising the chromatogram in Microsoft Excel. Line markers 
in Figure 4.8 represent individual data sampling points taken over the chromatographic peak. 
 
 
FIGURE 4.7: SKYLINE CHROMATOGRAMS OF SINGLE-PLEX VS DUPLEX ANALYSES OF 
VDSAATSGYEIGNPPDYR. A: SINGLE-PLEX, B: DUPLEX 
B A 
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The single-plex experiment yielded an average of five points on the curve, whereas its duplex 
counterpart had approximately ten. This suggests that multiplexing increases the sampling 
points on a chromatographic peak, due to the isolation list being essentially halved by 
measuring two precursors per scan, resulting in approximately twice as many sampling points 
on the precursor elution curve. The higher number of sampling points on the curve allow for 
a more accurate representation of analyte elution – illustrated by a more smoothly defined 
curve, which increases quantitative accuracy.124 
It is important to note that isolation list order should be carefully assessed when multiplexing 
peptides. Owing to the mechanism by which the Q Exactive performs multiplexing, it should 
be ensured that peptides which are multiplexed together do not have fragment ions with 
identical m/z values. Each precursor ion is selected by the quadrupole and consecutively 
accumulated in the HCD cell.131,132 Once all precursors have been accumulated, they are 
fragmented and transferred to the Orbitrap for analysis.131,132 It can be inferred that this 
mechanism renders it impossible for the mass spectrometer to relate each fragment ion back 
to its parent. In the event that precursors being multiplexed together have fragment ions of 
0.00E+00
5.00E+04
1.00E+05
1.50E+05
2.00E+05
2.50E+05
3.00E+05
3
0
.5
3
0
3
0
.5
5
5
3
0
.5
8
1
3
0
.6
0
7
3
0
.6
3
3
3
0
.6
5
9
3
0
.6
8
4
3
0
.7
1
0
3
0
.7
3
6
3
0
.7
6
2
3
0
.7
8
8
3
0
.8
1
3
3
0
.8
3
9
In
te
n
si
ty
 (
A
U
)
Retention Time (mins)
0.00E+00
1.00E+05
2.00E+05
3.00E+05
4.00E+05
5.00E+05
6.00E+05
7.00E+05
In
te
n
si
ty
 (
A
U
)
Retention Time (mins)
A B 
FIGURE 4.8: EXCEL-GENERATED CHROMATOGRAMS OF SINGLE-PLEX VS DUPLEX ANALYSES OF 
VDSAATSGYEIGNPPDYR. MARKERS REPRESENT MASS-SPECTROMETRIC SAMPLING POINTS. A: SINGLE-PLEX, 
B: DUPLEX 
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the same m/z, the total signal for that ion would be incorrectly attributed to both parent ions, 
as was observed in our pilot PRM analyses (data not shown). Additionally, when assessing 
different charge states of a given peptide, the precursors should not be multiplexed if the 
product ions are both presumed to be singly charged. Indeed, it is difficult to avoid 
multiplexing peptides containing either arginine or lysine residues, since all tryptic peptides 
will end in either one of these amino acids. It is for this reason that product ions of arginine or 
lysine should be excluded from analyses. 
In conclusion, multiplexing has definitive advantages for high throughput PRM analysis, as well 
as improving quantitative accuracy. These advantages come though at the price of significant 
loss in sensitivity at higher multiplex levels. Therefore, multiplexing must be balanced against 
isolation list and quantitative requirements, carefully considering the loss of sensitivity at high 
multiplexing levels. Isolation list order must also be carefully considered to avoid ambiguity in 
identification of detected product ions, which could have a detrimental effect on the PRM 
assay as a whole. 
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4.4. Conclusion 
Instrument parameters were successfully optimised for PRM analysis at 35 000 resolution, and 
are summarised in Table 4.13 below. Lock masses, Chromatographic peak width, Charge state, 
AGC Target, ISO Window, and NCE values remained at baseline. Max IT settings optimised for 
each MSX level are shown, together with the recommended maximum number of precursors 
per analysis.  
TABLE 4.13: FINAL SETTINGS FOR PRM ANALYSES AT 35 000 RESOLUTION. AGC: AUTOMATIC GAIN CONTROL, 
ISO: ISOLATION, NCE: NORMALISED COLLISION ENERGY, MSX: MULTIPLEX LEVEL, MAX IT: MAXIMUM 
INJECTION TIME. 
Resolution 35000 
Lock masses Off 
Chrom peak width 15 s 
Charge state 2 
AGC Target 5.00E+06 
ISO Window 2 m/z 
NCE 27 
MSX 1 2 3 4 
Max IT 100 ms 45 ms 27 ms 18 ms 
Precursors 14 28 42 56 
 
These final instrument settings should be used for selection of optimal representative 
peptides, internal reference peptides, and final PRM analysis. They may also be applied to 
PRM assays in general, as they improve on the currently accepted IT and MSX settings.132,182 
These improvements may significantly affect sensitivity and quantitation in currently accepted 
proteomic PRM assays. Although IT and MSX parameters for other resolutions may be inferred 
based on the optimal values determined in the present study, it is recommended that 
empirical determination of optimal parameters be performed. 
  
63 
 
Chapter 5  
Optimisation C: Selection of Final Peptides 
for Final Parallel Reaction Monitoring 
Assay 
5.1. Introduction 
Targeted proteomic MS is up to two orders of magnitude more sensitive than shotgun 
methods, given that particular masses are targeted rather than scanning the entire mass 
range.134 As such, it is ideally suited to selection of the best peptides for inclusion in the final 
PRM assay. It is generally accepted that at least three peptides – with three to five transitions 
each – are required for confident protein inference in the development of MRM assays (vide 
infra) using triple quadrupole instruments.124,189 
PRM assays differ from MRM analyses in that the former detect all MS2 spectra, whereas the 
latter target predefined MS2 ions.125,126,130 Therefore, confirmation of peptide identity is more 
reliable in PRM analyses, since full MS2 spectra is stronger evidence than several MS2 ions. This 
also simplifies selection of ideal peptides and product ions:  MRM product ion selection entails 
extensive optimisation of collision energies to obtain the strongest product ion signal.189 The 
best PRM product ions are immediately apparent following initial analysis. 
This Chapter focuses on PRM-based evaluation of peptides identified by shotgun proteomic 
analysis, with the aim of selecting the three best peptides per protein for inclusion in the final 
PRM assay. PRM analysis is able to facilitate highly-sensitive verification of discovery peptide 
identification. Evaluation of preliminarily selected peptides is conducted on pooled samples, 
analysed previously by discovery MS and using previously-optimised PRM instrument 
parameters (Chapter 4).  
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5.2. Materials and Methods 
5.2.1. Sample Selection 
Prospective peptides identified during discovery proteomic analysis of pooled samples (Table 
3.3) were selected for verification by PRM analysis. Analyses were conducted on pooled 
samples used previously for discovery analysis (Table 3.1). Samples were chosen based on the 
most comprehensive membership of the preliminarily selected peptides (Table 3.3): POS_1, 
POS_2, MNI_1, MNI_2, MNI_3, HAD_1, and HAD_2. 
5.2.2. LC/MS Instrumentation and Parameters 
Targeted proteomic analysis was performed on a Q Exactive Quadrupole-Orbitrap Mass 
Spectrometer, coupled to a Dionex UltiMate 3500 RSLC nano-LC system. Approximately 125 
ng of pooled sample peptides were injected onto the same LC setup described in Section 3.2.2, 
with the exception of the analytical column dimensions which were 75 µm x 15 cm. A 
shortened 72 minute linear gradient, developed for rapid targeted analysis, ran at a constant 
flow rate of 300 nl/min as follows: 2% B for 5 minutes, 2-35% B over 35 minutes, 35-80% B 
over 5 minutes, held at 80% B for 15 minutes, before returning to 2% B in 2 minutes, followed 
by re-equilibration at 2% B for 10 minutes. 
Previously-developed baseline instrument parameter settings (Table 5.1) were utilised 
(Chapter 4), with appropriate modifications as isolation list size decreased. Multiplex level and 
injection time were varied with each round of optimisation. Skyline software settings for 
analysis and data input are described in Section 4.2.2.1. 
TABLE 5.1: INITIAL SETTINGS FOR OPTIMAL PEPTIDE SELECTION BY PRM ASSAY AT 35 000 RESOLUTION.  
Lock masses Off 
Chrom. peak width 15 s 
Charge state 2 
Resolution 35000 
AGC Target 5.00E+06 
ISO Window 2 m/z 
NCE 27 
AGC: Automatic Gain Control, ISO: Isolation, NCE: Normalised Collision Energy 
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5.2.3. Optimal Peptide Selection 
A total of 106 prospective peptides were selected from the discovery analysis. Due to the 
multiple charge states assessed for certain peptides, the final isolation list consisted of 124 
precursor ions. Peptides were pasted manually into Skyline, with detection of the source 
protein facilitated by automated comparison of imported sequences to a human proteome 
database. To maintain an overall cycle time of 2 seconds for each individual unscheduled 
analysis, isolation list sizes must obey the constraints outlined in Table 4.12 for a resolution 
setting of 35 000. After each round of optimisation, results were assessed via manual 
chromatogram inspection in Skyline according to several exclusion criteria (see Section 5.3.1). 
For example: poor peak shape, significant transition misalignment, low number of transitions, 
low signal-to-noise ratio, and missing peaks. Mass accuracy of identified peaks, as calculated 
by Skyline, was also taken into account.  
5.2.3.1. Round 1 
The master Skyline file was divided into two unscheduled isolation lists due to the large 
number of precursors, and these were exported for initial analyses. List A (Table 5.2) consisted 
of 72 precursors belonging to A2M, ApoE, CLU, C3, CFH, GSN, and SAP. List B (Table 5.3) 
comprised of 52 precursors belonging to A1AG, A1AT, CERU, C4A, and C4B. The numerical 
disparity was not realised until after initial analyses were conducted. Certain isolation list 
columns were left blank intentionally, as this is the required format from Xcalibur. 
TABLE 5.2: ISOLATION LIST A, ROUND 1 (UNSCHEDULED) 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
388.7369   2 Positive   27 GVFVLNK (light) 
465.9329   3 Positive   27 SSNLIILEEHLK (light) 
474.7667   2 Positive   27 LAVYQAGAR (light) 
484.7798   2 Positive   27 LGPLVEQGR (light) 
490.9315   3 Positive   27 IPIEDGSGEVVLSR (light) 
497.2662   2 Positive   27 DNELLVYK (light) 
499.7745   2 Positive   27 EPGLQIWR (light) 
501.7769   2 Positive   27 TGLQEVEVK (light) 
503.7387   2 Positive   27 FQVDNNNR (light) 
522.6156   3 Positive   27 ALLAYAFALAGNQDK (light) 
523.7977   2 Positive   27 FEVQVTVPK (light) 
532.2984   2 Positive   27 IDVHLVPDR (light) 
536.2933   2 Positive   27 EIQNAVNGVK (light) 
537.7749   2 Positive   27 IDSLLENDR (light) 
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Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
557.7962   2 Positive   27 LEEQAQQIR (light) 
558.806   2 Positive   27 QTVSWAVTPK (light) 
559.3086   2 Positive   27 TLLSNLEEAK (light) 
578.8035   2 Positive   27 VGEYSLYIGR (light) 
583.7957   2 Positive   27 QGYFVEAQPK (light) 
585.8037   2 Positive   27 PALPAGTEDTAK (light) 
595.269   2 Positive   27 LSYTC[+57.0]EGGFR (light) 
605.825   2 Positive   27 LPPNVVEESAR (light) 
606.3023   3 Positive   27 SNLDEDIIAEENIVSR (light) 
615.6838   3 Positive   27 
LLIYAVLPTGDVIGDSAK 
(light) 
616.9649   3 Positive   27 QFSFPLSSEPFQGSYK (light) 
628.3251   2 Positive   27 AIGYLNTGYQR (light) 
628.6874   3 Positive   27 
VSVQLEASPAFLAVPVEK 
(light) 
631.3046   2 Positive   27 QELSEAEQATR (light) 
641.867   2 Positive   27 KGEWVALNPLR (light) 
645.3077   2 Positive   27 SGSDEVQVGQQR (light) 
660.3513   2 Positive   27 AGALNSNDAFVLK (light) 
668.369   2 Positive   27 APSTWLTAYVVK (light) 
685.8694   2 Positive   27 TIYTPGSTVLYR (light) 
697.3515   2 Positive   27 ASSIIDELFQDR (light) 
697.3515   2 Positive   27 IVLGQEQDSYGGK (light) 
697.8435   2 Positive   27 NEDSLVFVQTDK (light) 
698.3957   2 Positive   27 SSNLIILEEHLK (light) 
703.8386   2 Positive   27 AYSLFSYNTQGR (light) 
733.3815   3 Positive   27 
VPVAVQGEDTVQSLTQGDG
VAK (light) 
735.8936   2 Positive   27 IPIEDGSGEVVLSR (light) 
741.3583   2 Positive   27 
C[+57.0]FEGFGIDGPAIAK 
(light) 
749.4046   2 Positive   27 AATVGSLAGQPLQER (light) 
756.3886   2 Positive   27 AAQVTIQSSGTFSSK (light) 
773.3449   2 Positive   27 
WSSPPQC[+57.0]EGLPC[+5
7.0]K (light) 
783.4197   2 Positive   27 ALLAYAFALAGNQDK (light) 
802.9252   2 Positive   27 IAQWQSFQLEGGLK (light) 
804.7189   3 Positive   27 
VSVLC[+57.0]QENYLIQEGE
EITC[+57.0]K (light) 
813.4045   2 Positive   27 VEQAVETEPEPELR (light) 
827.8745   2 Positive   27 
AGEQVTYTC[+57.0]ATYYK 
(light) 
832.0542   3 Positive   27 
DYAGVFSDAGLTFTSSSGQQ
TAQR (light) 
861.9223   2 Positive   27 EVQGFESATFLGYFK (light) 
865.9258   2 Positive   27 SELEEQLTPVAEETR (light) 
908.4251   2 Positive   27 
LGYVTADGETSGSITC[+57.0]
GK (light) 
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Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
908.9498   2 Positive   27 SNLDEDIIAEENIVSR (light) 
915.4858   2 Positive   27 
QTQVSVLPEGGETPLFK 
(light) 
919.452   2 Positive   27 
TPSAAYLWVGTGASEAEK 
(light) 
923.022   2 Positive   27 
LLIYAVLPTGDVIGDSAK 
(light) 
924.9438   2 Positive   27 QFSFPLSSEPFQGSYK (light) 
934.4176   2 Positive   27 
SC[+57.0]DNPYIPNGDYSPL
R (light) 
937.4989   2 Positive   27 
LFDSDPITVTVPVEVSR 
(light) 
942.5275   2 Positive   27 
VSVQLEASPAFLAVPVEK 
(light) 
983.4886   2 Positive   27 
EQVQSC[+57.0]GPPPELLNG
NVK (light) 
1010.991   2 Positive   27 
DTSC[+57.0]VNPPTVQNAYI
VSR (light) 
1082.012   2 Positive   27 
AVYTC[+57.0]NEGYQLLGEI
NYR (light) 
1083.505   2 Positive   27 
AYYENSPQQVFSTEFEVK 
(light) 
1099.569   2 Positive   27 
VPVAVQGEDTVQSLTQGDG
VAK (light) 
1107.506   2 Positive   27 
EDIPPADLSDQVPDTESETR 
(light) 
1133.05   2 Positive   27 
SSIDIENGFISESQYTYALK 
(light) 
1136.548   2 Positive   27 
AQPVQVAEGSEPDGFWEAL
GGK (light) 
1206.575   2 Positive   27 
VSVLC[+57.0]QENYLIQEGE
EITC[+57.0]K (light) 
1247.578   2 Positive   27 
DYAGVFSDAGLTFTSSSGQQ
TAQR (light) 
1301.619   2 Positive   27 
NTEILTGSWSDQTYPEGTQA
IYK (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
TABLE 5.3: ISOLATION LIST B, ROUND 1 (UNSCHEDULED) 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
338.1977   3 Positive   27 AKPALEDLR (light) 
360.1807   3 Positive   27 FLENEDRR (light) 
444.7555   2 Positive   27 AVLTIDEK (light) 
450.7267   2 Positive   27 GEFYIGSK (light) 
461.7169   2 Positive   27 FLENEDR (light) 
488.2887   3 Positive   27 VKDLATVYVDVLK (light) 
492.2383   2 Positive   27 QGSFQGGFR (light) 
494.7824   2 Positive   27 PVQGVAYVR (light) 
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Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
497.7638   2 Positive   27 TEDTIFLR (light) 
504.7535   2 Positive   27 QINDYVEK (light) 
506.7929   2 Positive   27 AKPALEDLR (light) 
508.3109   2 Positive   27 SVLGQLGITK (light) 
509.2354   2 Positive   27 QYTDSTFR (light) 
522.9143   3 Positive   27 VNKDDEEFIESNK (light) 
525.7587   2 Positive   27 AEFQDALEK (light) 
539.7674   2 Positive   27 FLENEDRR (light) 
543.3188   3 Positive   27 
PVAFSVVPTAAAAVSLK 
(light) 
547.9594   3 Positive   27 ITPNLAEFAFSLYR (light) 
555.8057   2 Positive   27 LSITGTYDLK (light) 
557.8144   2 Positive   27 VGDTLNLNLR (light) 
602.2675   2 Positive   27 EYTDASFTNR (light) 
611.9791   3 Positive   27 
VFSNGADLSGVTEEAPLK 
(light) 
613.2646   2 Positive   27 DDEEFIESNK (light) 
615.8583   2 Positive   27 QGLLPVLESFK (light) 
618.3477   2 Positive   27 DLATVYVDVLK (light) 
626.8141   2 Positive   27 VQPYLDDFQK (light) 
655.3612   2 Positive   27 GSSTWLTAFVLK (light) 
670.4105   2 Positive   27 PVWLGFLGPIIK (light) 
672.4003   2 Positive   27 DFALLSLQVPLK (light) 
684.3639   2 Positive   27 DSSTWLTAFVLK (light) 
686.3852   2 Positive   27 GAYPLSIEPIGVR (light) 
693.8612   2 Positive   27 VSFLSALEEYTK (light) 
700.8383   2 Positive   27 DYVSQFEGSALGK (light) 
716.323   2 Positive   27 QSEDSTFYLGER (light) 
760.375   2 Positive   27 ALYLQYTDETFR (light) 
771.4121   2 Positive   27 VLSLAQEQVGGSPEK (light) 
782.4281   2 Positive   27 TTNIQGINLLFSSR (light) 
783.8677   2 Positive   27 VNKDDEEFIESNK (light) 
788.9241   2 Positive   27 DTVFALVNYIFFK (light) 
806.8963   2 Positive   27 LLDNWDSVTSTFSK (light) 
814.4745   2 Positive   27 
PVAFSVVPTAAAAVSLK 
(light) 
821.4354   2 Positive   27 ITPNLAEFAFSLYR (light) 
828.4378   3 Positive   27 
VTASDPLDTLGSEGALSPGG
VASLLR (light) 
858.7852   3 Positive   27 
TLNQPDSQLQLTTGNGLFLS
EGLK (light) 
871.9063   2 Positive   27 
EQLGEFYEALDC[+57.0]LR 
(light) 
917.4651   2 Positive   27 
VFSNGADLSGVTEEAPLK 
(light) 
952.4139   2 Positive   27 
NNEGTYYSPNYNPQSR 
(light) 
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Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
966.9705   2 Positive   27 
EQLGPVTQEFWDNLEK 
(light) 
1044.828   3 Positive   27 
LQETSNWLLSQQQADGSFQ
DPC[+57.0]PVLDR (light) 
1113.063   2 Positive   27 
ALEILQEEDLIDEDDIPVR 
(light) 
1242.153   2 Positive   27 
VTASDPLDTLGSEGALSPGG
VASLLR (light) 
1287.674   2 Positive   27 
TLNQPDSQLQLTTGNGLFLS
EGLK (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
During the first round of optimisation the cycle time was allowed to exceed 2 seconds in the 
interests of maintaining sensitivity, with a concomitant insignificant decrease in quantitative 
ability. Lists A and B were imported into Xcalibur with settings as described in Table 5.1, an 
MSX of 4, and a Max IT of 18 ms. This equated to an effective cycle time of 2.5 and 2 seconds 
for lists A and B respectively. Sample MNI_1 was used to assess list A, while list B was 
evaluated by analysing sample POS_1.  
Following PRM analysis, data files were imported into Skyline according to settings outlined in 
Section 4.2.2.1. Chromatograms were assessed for elimination of low-quality peptides. 
5.2.3.2. Round 2 
To rule out the hypothesis that lower sensitivity at a high multiplex level (4-plex) was 
responsible for the low quality of some peptides from the analysis of List A, these were re-
analysed at a lower MSX, and higher per-precursor ITs to further increase sensitivity. An 
unscheduled isolation list of 23 precursors (Table 5.4) was assayed with settings as described 
in Table 5.1, in duplex mode, and with a Max IT of 45 ms. This resulted in an effective cycle 
time of 1.61 seconds.  Sample HAD_2 was re-analysed, while MNI_1 was also analysed in the 
event that the low-quality peptide signal was sample-related. 
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TABLE 5.4: ISOLATION LIST A REPEAT, ROUND 2 (UNSCHEDULED) 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
813.4045   2 Positive   27 VEQAVETEPEPELR (light) 
865.9258   2 Positive   27 SELEEQLTPVAEETR (light) 
474.7667   2 Positive   27 LAVYQAGAR (light) 
484.7798   2 Positive   27 LGPLVEQGR (light) 
749.4046   2 Positive   27 AATVGSLAGQPLQER (light) 
557.7962   2 Positive   27 LEEQAQQIR (light) 
536.2933   2 Positive   27 EIQNAVNGVK (light) 
559.3086   2 Positive   27 TLLSNLEEAK (light) 
537.7749   2 Positive   27 IDSLLENDR (light) 
697.3515   2 Positive   27 ASSIIDELFQDR (light) 
937.4989   2 Positive   27 
LFDSDPITVTVPVEVSR 
(light) 
585.8037   2 Positive   27 PALPAGTEDTAK (light) 
499.7745   2 Positive   27 EPGLQIWR (light) 
861.9223   2 Positive   27 EVQGFESATFLGYFK (light) 
915.4858   2 Positive   27 
QTQVSVLPEGGETPLFK 
(light) 
660.3513   2 Positive   27 AGALNSNDAFVLK (light) 
919.452   2 Positive   27 
TPSAAYLWVGTGASEAEK 
(light) 
1136.548   2 Positive   27 
AQPVQVAEGSEPDGFWEAL
GGK (light) 
703.8386   2 Positive   27 AYSLFSYNTQGR (light) 
497.2662   2 Positive   27 DNELLVYK (light) 
578.8035   2 Positive   27 VGEYSLYIGR (light) 
583.7957   2 Positive   27 QGYFVEAQPK (light) 
697.3515   2 Positive   27 IVLGQEQDSYGGK (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
Following PRM analysis, data files were imported into Skyline. Chromatograms were assessed 
for elimination of low-quality peptides. 
5.2.3.3. Round 3 
High-quality peptides resulting from round 2 were recombined with their counterparts from 
Round 1, to yield adjusted lists A and B, consisting of 39 and 26 precursors respectively. In 
order to equalise the number of precursors in each list, seven C3 peptides were transferred 
from list A to list B, resulting in final list sizes of 32 and 33 precursors respectively (Table 5.5 
and Table 5.6).  Disparate list sizes were equalised to maintain consistency and prevent the 
results from the analysis with the shorter isolation list from appearing misleadingly superior. 
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TABLE 5.5: ISOLATION LIST A, ROUND 3 (UNSCHEDULED) 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
697.8435   2 Positive   27 NEDSLVFVQTDK (light) 
802.9252   2 Positive   27 IAQWQSFQLEGGLK (light) 
523.7977   2 Positive   27 FEVQVTVPK (light) 
923.022   2 Positive   27 
LLIYAVLPTGDVIGDSAK 
(light) 
558.806   2 Positive   27 QTVSWAVTPK (light) 
605.825   2 Positive   27 LPPNVVEESAR (light) 
628.3251   2 Positive   27 AIGYLNTGYQR (light) 
756.3886   2 Positive   27 AAQVTIQSSGTFSSK (light) 
865.9258   2 Positive   27 SELEEQLTPVAEETR (light) 
474.7667   2 Positive   27 LAVYQAGAR (light) 
484.7798   2 Positive   27 LGPLVEQGR (light) 
749.4046   2 Positive   27 AATVGSLAGQPLQER (light) 
559.3086   2 Positive   27 TLLSNLEEAK (light) 
537.7749   2 Positive   27 IDSLLENDR (light) 
697.3515   2 Positive   27 ASSIIDELFQDR (light) 
937.4989   2 Positive   27 
LFDSDPITVTVPVEVSR 
(light) 
908.4251   2 Positive   27 
LGYVTADGETSGSITC[+57.0]
GK (light) 
532.2984   2 Positive   27 IDVHLVPDR (light) 
698.3957   2 Positive   27 SSNLIILEEHLK (light) 
804.7189   3 Positive   27 
VSVLC[+57.0]QENYLIQEGE
EITC[+57.0]K (light) 
595.269   2 Positive   27 LSYTC[+57.0]EGGFR (light) 
741.3583   2 Positive   27 
C[+57.0]FEGFGIDGPAIAK 
(light) 
827.8745   2 Positive   27 
AGEQVTYTC[+57.0]ATYYK 
(light) 
499.7745   2 Positive   27 EPGLQIWR (light) 
861.9223   2 Positive   27 EVQGFESATFLGYFK (light) 
915.4858   2 Positive   27 
QTQVSVLPEGGETPLFK 
(light) 
660.3513   2 Positive   27 AGALNSNDAFVLK (light) 
919.452   2 Positive   27 
TPSAAYLWVGTGASEAEK 
(light) 
703.8386   2 Positive   27 AYSLFSYNTQGR (light) 
497.2662   2 Positive   27 DNELLVYK (light) 
578.8035   2 Positive   27 VGEYSLYIGR (light) 
697.3515   2 Positive   27 IVLGQEQDSYGGK (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
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TABLE 5.6: ISOLATION LIST B, ROUND 3 (UNSCHEDULED) 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
497.7638   2 Positive   27 TEDTIFLR (light) 
504.7535   2 Positive   27 QINDYVEK (light) 
461.7169   2 Positive   27 FLENEDR (light) 
555.8057   2 Positive   27 LSITGTYDLK (light) 
508.3109   2 Positive   27 SVLGQLGITK (light) 
917.4651   2 Positive   27 
VFSNGADLSGVTEEAPLK 
(light) 
611.9791   3 Positive   27 
VFSNGADLSGVTEEAPLK 
(light) 
444.7555   2 Positive   27 AVLTIDEK (light) 
618.3477   2 Positive   27 DLATVYVDVLK (light) 
700.8383   2 Positive   27 DYVSQFEGSALGK (light) 
806.8963   2 Positive   27 LLDNWDSVTSTFSK (light) 
626.8141   2 Positive   27 VQPYLDDFQK (light) 
615.8583   2 Positive   27 QGLLPVLESFK (light) 
693.8612   2 Positive   27 VSFLSALEEYTK (light) 
760.375   2 Positive   27 ALYLQYTDETFR (light) 
602.2675   2 Positive   27 EYTDASFTNR (light) 
686.3852   2 Positive   27 GAYPLSIEPIGVR (light) 
952.4139   2 Positive   27 
NNEGTYYSPNYNPQSR 
(light) 
716.323   2 Positive   27 QSEDSTFYLGER (light) 
509.2354   2 Positive   27 QYTDSTFR (light) 
782.4281   2 Positive   27 TTNIQGINLLFSSR (light) 
525.7587   2 Positive   27 AEFQDALEK (light) 
557.8144   2 Positive   27 VGDTLNLNLR (light) 
655.3612   2 Positive   27 GSSTWLTAFVLK (light) 
492.2383   2 Positive   27 QGSFQGGFR (light) 
494.7824   2 Positive   27 PVQGVAYVR (light) 
685.8694   2 Positive   27 TIYTPGSTVLYR (light) 
735.8936   2 Positive   27 IPIEDGSGEVVLSR (light) 
733.3815   3 Positive   27 
VPVAVQGEDTVQSLTQGDG
VAK (light) 
908.9498   2 Positive   27 SNLDEDIIAEENIVSR (light) 
501.7769   2 Positive   27 TGLQEVEVK (light) 
668.369   2 Positive   27 APSTWLTAYVVK (light) 
645.3077   2 Positive   27 SGSDEVQVGQQR (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
Each isolation list was assayed with settings as described in Table 5.1, in triplex mode, and 
with a Max IT of 27 ms. List A was assessed using HAD_1 and POS_1, while HAD_2 and POS_2 
were analysed with precursors from list B. The cycle time for each analysis amounted to 
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approximately 1.5 seconds. Following PRM analysis, data files were imported into Skyline. 
Chromatograms were assessed for elimination of low-quality peptides. 
5.2.3.4. Round 4 
Optimally-performing precursors were brought to the next round of selection. A total of 53 
precursors were assessed in this round: 27 in List A (Table 5.7), and 26 in List B. 
TABLE 5.7: ISOLATION LIST A, ROUND 4 (UNSCHEDULED) 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
697.8435   2 Positive   27 NEDSLVFVQTDK (light) 
523.7977   2 Positive   27 FEVQVTVPK (light) 
558.806   2 Positive   27 QTVSWAVTPK (light) 
605.825   2 Positive   27 LPPNVVEESAR (light) 
628.3251   2 Positive   27 AIGYLNTGYQR (light) 
865.9258   2 Positive   27 SELEEQLTPVAEETR (light) 
474.7667   2 Positive   27 LAVYQAGAR (light) 
484.7798   2 Positive   27 LGPLVEQGR (light) 
749.4046   2 Positive   27 AATVGSLAGQPLQER (light) 
559.3086   2 Positive   27 TLLSNLEEAK (light) 
537.7749   2 Positive   27 IDSLLENDR (light) 
697.3515   2 Positive   27 ASSIIDELFQDR (light) 
937.4989   2 Positive   27 
LFDSDPITVTVPVEVSR 
(light) 
908.4251   2 Positive   27 
LGYVTADGETSGSITC[+57.0]
GK (light) 
532.2984   2 Positive   27 IDVHLVPDR (light) 
698.3957   2 Positive   27 SSNLIILEEHLK (light) 
595.269   2 Positive   27 LSYTC[+57.0]EGGFR (light) 
741.3583   2 Positive   27 
C[+57.0]FEGFGIDGPAIAK 
(light) 
827.8745   2 Positive   27 
AGEQVTYTC[+57.0]ATYYK 
(light) 
499.7745   2 Positive   27 EPGLQIWR (light) 
861.9223   2 Positive   27 EVQGFESATFLGYFK (light) 
915.4858   2 Positive   27 
QTQVSVLPEGGETPLFK 
(light) 
660.3513   2 Positive   27 AGALNSNDAFVLK (light) 
703.8386   2 Positive   27 AYSLFSYNTQGR (light) 
497.2662   2 Positive   27 DNELLVYK (light) 
578.8035   2 Positive   27 VGEYSLYIGR (light) 
697.3515   2 Positive   27 IVLGQEQDSYGGK (light) 
697.8435   2 Positive   27 NEDSLVFVQTDK (light) 
523.7977   2 Positive   27 FEVQVTVPK (light) 
558.806   2 Positive   27 QTVSWAVTPK (light) 
605.825   2 Positive   27 LPPNVVEESAR (light) 
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Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
628.3251   2 Positive   27 AIGYLNTGYQR (light) 
865.9258   2 Positive   27 SELEEQLTPVAEETR (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
TABLE 5.8: ISOLATION LIST B, ROUND 4 (UNSCHEDULED) 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
497.7638   2 Positive   27 TEDTIFLR (light) 
504.7535   2 Positive   27 QINDYVEK (light) 
461.7169   2 Positive   27 FLENEDR (light) 
508.3109   2 Positive   27 SVLGQLGITK (light) 
618.3477   2 Positive   27 DLATVYVDVLK (light) 
700.8383   2 Positive   27 DYVSQFEGSALGK (light) 
806.8963   2 Positive   27 LLDNWDSVTSTFSK (light) 
626.8141   2 Positive   27 VQPYLDDFQK (light) 
615.8583   2 Positive   27 QGLLPVLESFK (light) 
693.8612   2 Positive   27 VSFLSALEEYTK (light) 
602.2675   2 Positive   27 EYTDASFTNR (light) 
686.3852   2 Positive   27 GAYPLSIEPIGVR (light) 
952.4139   2 Positive   27 
NNEGTYYSPNYNPQSR 
(light) 
716.323   2 Positive   27 QSEDSTFYLGER (light) 
509.2354   2 Positive   27 QYTDSTFR (light) 
525.7587   2 Positive   27 AEFQDALEK (light) 
557.8144   2 Positive   27 VGDTLNLNLR (light) 
444.7578   2 Positive   27 KRLSC[+57.0]PK (light) 
492.2383   2 Positive   27 QGSFQGGFR (light) 
494.7824   2 Positive   27 PVQGVAYVR (light) 
685.8694   2 Positive   27 TIYTPGSTVLYR (light) 
735.8936   2 Positive   27 IPIEDGSGEVVLSR (light) 
490.9315   3 Positive   27 IPIEDGSGEVVLSR (light) 
908.9498   2 Positive   27 SNLDEDIIAEENIVSR (light) 
501.7769   2 Positive   27 TGLQEVEVK (light) 
645.3077   2 Positive   27 SGSDEVQVGQQR (light) 
497.7638   2 Positive   27 TEDTIFLR (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
Each isolation list was assayed with settings as described in Table 5.1, in duplex mode, and 
with a Max IT of 45 ms. Due to diminished sample volume at this stage of optimisation, 
samples HAD_1, HAD_2, MNI_1, POS_1 and POS_2 were combined into a single sample for 
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the remainder of optimisation. Both lists were assessed using the pooled sample. The cycle 
time for each analysis amounted to approximately 1.9 seconds. 
Following PRM analysis, data files were imported into Skyline. Chromatograms were assessed 
for elimination of low-quality peptides. Only high-quality precursors for inclusion in the final 
PRM assay now remain.  
5.2.3.5. Retention Time Scheduling 
In order to maximise the number of sampling points on the chromatogram, retention time 
scheduling windows of peptides were introduced. Skyline settings were modified such that a 
window of 5 minutes on either side of previously-established peak retention times would be 
integrated into the method. The isolation list was exported with this retention time scheduling 
(Table 5.9). Analysis was performed on the pooled sample with settings as described in Table 
5.1, in duplex mode, and with a Max IT of 45 ms. 
TABLE 5.9: SCHEDULED ISOLATION LIST FOR FINAL LIST OF PRM TARGET PEPTIDES 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
697.8435   2 Positive 24.87 29.87 27 NEDSLVFVQTDK (light) 
523.7977   2 Positive 24.61 29.61 27 FEVQVTVPK (light) 
628.3251   2 Positive 22.78 27.78 27 AIGYLNTGYQR (light) 
532.2984   2 Positive 22.06 27.06 27 IDVHLVPDR (light) 
595.269   2 Positive 22.1 27.1 27 LSYTC[+57.0]EGGFR (light) 
827.8745   2 Positive 21.5 26.5 27 
AGEQVTYTC[+57.0]ATYYK 
(light) 
474.7667   2 Positive 18.42 23.42 27 LAVYQAGAR (light) 
484.7798   2 Positive 20.42 25.42 27 LGPLVEQGR (light) 
749.4046   2 Positive 22.37 27.37 27 AATVGSLAGQPLQER (light) 
559.3086   2 Positive 26.96 31.96 27 TLLSNLEEAK (light) 
537.7749   2 Positive 22.08 27.08 27 IDSLLENDR (light) 
697.3515   2 Positive 33.91 38.91 27 ASSIIDELFQDR (light) 
499.7745   2 Positive 26.74 31.74 27 EPGLQIWR (light) 
915.4858   2 Positive 28.74 33.74 27 
QTQVSVLPEGGETPLFK 
(light) 
660.3513   2 Positive 25.47 30.47 27 AGALNSNDAFVLK (light) 
703.8386   2 Positive 26.9 31.9 27 AYSLFSYNTQGR (light) 
497.2662   2 Positive 24.19 29.19 27 DNELLVYK (light) 
578.8035   2 Positive 25.55 30.55 27 VGEYSLYIGR (light) 
497.7638   2 Positive 25.06 30.06 27 TEDTIFLR (light) 
461.7169   2 Positive 17.17 22.17 27 FLENEDR (light) 
508.3109   2 Positive 27.1 32.1 27 SVLGQLGITK (light) 
444.7555   2 Positive 20.48 25.48 27 AVLTIDEK (light) 
700.8383   2 Positive 28.19 33.19 27 DYVSQFEGSALGK (light) 
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Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
806.8963   2 Positive 30.67 35.67 27 LLDNWDSVTSTFSK (light) 
626.8141   2 Positive 24.55 29.55 27 VQPYLDDFQK (light) 
602.2675   2 Positive 19.62 24.62 27 EYTDASFTNR (light) 
686.3852   2 Positive 28.57 33.57 27 GAYPLSIEPIGVR (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
Following PRM analysis, data files were imported into Skyline. Chromatograms were assessed 
for correct application of retention time windows. Precursor measurement overlap was 
calculated to estimate average cycle time in the scheduled assay.  
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5.3. Results and Discussion 
5.3.1. Optimal Peptide Selection 
Optimal peptide selection during all rounds of optimisation was based on chromatogram 
quality. Examples of selection criteria are included in Figure 5.1.  Favourable peak shape was 
a basic requirement (A). Peptides with poor peak shape (B), significant transition misalignment 
(C), low number of transitions (D), low signal-to-noise ratio (E), and missing peaks (F) were 
eliminated. Peptides exhibiting low mass-accuracy (high parts per million [ppm] values, based 
on calculations by Skyline), were excluded. These selection criteria were applied at every stage 
of optimisation. 
A 
C 
D 
B 
E F 
FIGURE 5.1: EXAMPLES OF CHROMATOGRAMS OF VARYING QUALITY FOR OPTIMAL PEPTIDE SELECTION. 
A: Favourable chromatogram, B: Poor peak shape, C: Misaligned transitions, D: Few transitions, E: Low 
signal-to-noise ratio, F: Missing peak. 
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5.3.1.1. Round 1 
During data importation into Skyline, certain preselected peptides were excluded, probably 
due to automatic filtering of targets according to the predefined settings (the ‘automatically 
filter selected peptides’ option was selected in the settings dialog box). Due to the rapid nature 
of precursor selection and data quality analysis, this was recognised only after final peptide 
selection, contributing to disparity in transition numbers. 
The initial round of selection yielded mixed results, with 22 of 70 precursors from List A, and 
16 of 45 precursors from list B performing inadequately (Table 5.10). Low IT may have been 
responsible for the poor quality of peptides, or the analysed sample may have negatively 
impacted peptide detection. Thus, repeat analysis of low-quality peptides from List A (Table 
5.10: underlined entries) was conducted at a lowed multiplex level prior to continuing 
optimisation.  
TABLE 5.10: TALLY OF PEPTIDE PERFORMANCE FOR ROUND 1 
List Protein 
Precursors 
Analysed 
Precursors 
Accepted 
Precursors 
Rejected 
A 
A2M 15 15 0 
ApoE 6 0 6 
CLU  5 0 5 
C3  15 15 0 
CFH  17 17 0 
GSN 7 0 7 
SAP 5 0 5 
Subtotal 70  47 23 
B 
A1AG 2 1 1 
A1AT 13 6 7 
ApoA-I 8 7 0 
CERU 10 8 2 
C4A/B 12 6 6 
Subtotal 45 28 16 
TOTAL 115 75 39 
A2M: Alpha-2-macroglobulin, ApoE: Apolipoprotein E, CLU: Clusterin, C3: Complement Component C, 
CFH: Complement Factor H, GSN: Gelsolin, SAP: Serum Amyloid P, A1AG: Alpha-1-acid Glycoprotein 1, 
A1AT: Alpha-1-antitrypsin, ApoA-I: Apolipoprotein A1, CERU: Ceruloplasmin, C4A/B: Complement 
Component 4A/B 
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5.3.1.2. Round 2 
Repeat analysis of sample HAD_2 and verification with sample MNI_1 yielded largely 
favourable results. Both samples exhibited peptide peaks of comparable quality, precluding 
poor quality of the HAD_2 sample. 
A total of 23 precursors were assessed in Skyline, and six were eliminated (Table 5.11), 
including VEQAVETEPEPELR (ApoE), LEEQAQQIR (ApoE), EIQNAVNGVK (CLU), 
AQPVQVAEGSEPDGFWEALGGK (GSN), PALPAGTEDTAK (GSN), and QGYFVEAQPK (SAP). The 
remaining peptides were carried through to the next round of optimisation.  
TABLE 5.11: TALLY OF PEPTIDE PERFORMANCE FOR ROUND 2 
 
5.3.1.3. Round 3 
Analysis of recombined lists yielded favourable results. Most of the precursors analysed 
performed well in all samples assessed. Of the 65 precursors considered, 53 were selected for 
the next phase of optimisation while 12 were eliminated (Table 5.12). The eliminated peptides 
included: IAQWQSFQLEGGLK (A2M), LLIYAVLPTGDVIGDSAK (A2M), AAQVTIQSSGTFSSK (A2M), 
VSVLCQENYLIQEGEEITCK (CFH), TPSAAYLWVGTGASEAEK (GSN),  LSITGTYDLK (A1AT), 
VFSNGADLSGVTEEAPLK2+ (A1AT), VFSNGADLSGVTEEAPLK3+ (A1AT), TTNIQGINLLFSSR (C4), 
GSSTWLTAFVLK (C4), VPVAVQGEDTVQSLTQGDGVAK (C3), and APSTWLTAYVVK (C3). The 54 
peptides chosen for further optimisation were carried over to the next round. 
Peptide AVLTIDEK, derived from GSN, had been included in Round 2, but was not considered 
by Skyline for this list and was thus ignored at this stage of optimisation. 
 
List Protein 
Precursors 
Analysed 
Precursors 
Accepted 
Precursors 
Rejected 
A 
ApoE 6 4 2 
CLU  5 4 1 
GSN 7 5 2 
SAP 5 4 1 
TOTAL 23 17 6 
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TABLE 5.12: TALLY OF PEPTIDE PERFORMANCE FOR ROUND 3 
List Protein 
Precursors 
Analysed 
Precursors 
Accepted 
Precursors 
Rejected 
A 
A2M 8 5 3 
ApoE 4 4 0 
CLU  4 4 0 
CFH  7 6 1 
GSN 5 4 1 
SAP 4 4 0 
Subtotal 32 27 5 
B 
A1AG 1 1 0 
A1AT 6 3 3 
ApoA-I 6 6 0 
CERU 6 6 0 
C4A/B 7 5 2 
C3 7 5 2 
Subtotal 33 26 7 
TOTAL 65 53 12 
 
5.3.1.4. Round 4 
Of the 53 considered precursors, 20 were eliminated (Table 5.13) based on the criteria 
outlined in Section 5.3.1. For inclusion in the final PRM assay (patient sample analysis), a total 
of 33 precursors were selected - three per protein – except in the case of A1AG where only 
one peptide was of acceptable quality. In the case of GSN, two precursors were selected 
instead of the required three. It was decided to reincorporate the previously-overlooked 
AVLTIDEK peptide, given its favourable performance during the initial phase of optimisation, 
resulting in a total precursor count of 34. Mass accuracy measurements in ppm contributed 
to final peptide selection: acceptable ppm values for peak identifications did not exceed 
6.1ppm (average -0.26 ppm). 
TABLE 5.13: TALLY OF PEPTIDE PERFORMANCE FOR ROUND 4 
List Protein 
Precursors 
Analysed 
Precursors 
Accepted 
Precursors 
Rejected 
A A2M 5 3 2 
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List Protein 
Precursors 
Analysed 
Precursors 
Accepted 
Precursors 
Rejected 
ApoE 4 3 1 
CLU  4 3 1 
CFH  6 3 3 
GSN 4 3 1 
SAP 4 3 1 
Subtotal 27 18 9 
B 
A1AG 1 1 0 
A1AT 3 2 1 
ApoA-I 6 3 3 
CERU 6 3 3 
C4A/B 5 3 2 
C3 5 3 2 
Subtotal 26 15 11 
TOTAL 53 33 20 
 
The list of precursors for the final PRM assay to be conducted on patient samples is 
summarised in Table 5.13. The isolation list equated to approximately 4.7 seconds in single-
plex PRM mode at 35 000 resolution. In duplex mode, the overall cycle time was reduced to 
2.4 seconds. A higher MSX would not be acceptable for the purposes of patient sample 
analysis, due to the need for a sufficiently high sensitivity to detect low abundance analytes. 
Multiplexing may therefore not exceed a level of 2 (duplex), introducing the requirement for 
an excessively high cycle time. In order to maintain quantitative accuracy, cycle time should 
be less than 2 seconds to allow for at least six sampling points on the chromatographic curve.  
The cycle time of 2.4 seconds is thus acceptable, but not ideal. Sampling points on analyte 
chromatograms were, however, improved by the integration of retention time scheduling. 
TABLE 5.14: LIST OF OPTIMAL PEPTIDES FOR FINAL PRM ASSAY 
Protein Sequence m/z Charge 
Mass 
Accuracy 
(ppm) 
A2M 
NEDSLVFVQTDK (light) 697.8435 2 0.0 
FEVQVTVPK (light) 523.7977 2 0.0 
AIGYLNTGYQR (light) 628.3251 2 -0.6 
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Protein Sequence m/z Charge 
Mass 
Accuracy 
(ppm) 
CFH 
IDVHLVPDR (light) 532.2984 2 -0.2 
LSYTC[+57.0]EGGFR (light) 595.269 2 0.7 
AGEQVTYTC[+57.0]ATYYK (light) 827.8745 2 -1.7 
ApoE 
LAVYQAGAR (light) 474.7667 2 -0.1 
LGPLVEQGR (light) 484.7798 2 -0.7 
AATVGSLAGQPLQER (light) 749.4046 2 -0.9 
CLU 
TLLSNLEEAK (light) 559.3086 2 -0.4 
IDSLLENDR (light) 537.7749 2 0.2 
ASSIIDELFQDR (light) 697.3515 2 -1.4 
GSN 
EPGLQIWR (light) 499.7745 2 6.1 
QTQVSVLPEGGETPLFK (light) 915.4858 2 -0.3 
AGALNSNDAFVLK (light) 660.3513 2 -0.8 
SAP 
AYSLFSYNTQGR (light) 703.8386 2 -0.9 
DNELLVYK (light) 497.2662 2 -0.2 
VGEYSLYIGR (light) 578.8035 2 -3.2 
A1AG TEDTIFLR (light) 497.7638 2 -0.6 
A1AT 
FLENEDR (light) 461.7169 2 -0.1 
SVLGQLGITK (light) 508.3109 2 -0.4 
AVLTIDEK (light) 444.7555 2 -0.2 
ApoA-I 
DYVSQFEGSALGK (light) 700.8383 2 -0.6 
LLDNWDSVTSTFSK (light) 806.8963 2 -1.0 
VQPYLDDFQK (light) 626.8141 2 -0.4 
CERU 
EYTDASFTNR (light) 602.2675 2 0.0 
GAYPLSIEPIGVR (light) 686.3852 2 -0.1 
NNEGTYYSPNYNPQSR (light) 952.4139 2 -0.9 
C3 
AEFQDALEK (light) 525.7587 2 0.0 
VGDTLNLNLR (light) 557.8144 2 -0.1 
QGSFQGGFR (light) 492.2383 2 0.0 
C4 
TIYTPGSTVLYR (light) 685.8694 2 -0.5 
IPIEDGSGEVVLSR (light) 735.8936 2 0.0 
TGLQEVEVK (light) 501.7769 2 0.4 
m/z: Mass-to-charge ratio, ppm: Parts per Million 
 
5.3.1.5. Retention Time Scheduling 
As discussed, retention time scheduling was applied, and results assessed for retention time 
drift outside the specified window. The Skyline-generated transition distribution plot (Figure 
5.2) predicts that at most ~17 precursors can scanned concurrently when the 5-minute 
retention time window is used (as indicated in the figure legend).  This equates to an overall 
cycle time of 2.4 seconds, in single-plex mode at 35 000 resolution. In duplex mode, cycle time 
equates to 1.2 seconds. This results in 18 points on a 15-second peptide elution curve, which 
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is significantly higher that the eight recommended points.134 Since scheduling directs the 
instrument to scan for particular peptides in a window around their retention times, this 
minimises the number of peptides selected in each window.138 This is in contrast to non-
scheduled assays, which scan the entirety of the isolation list continually, leading to a waste 
of scanning time since all peptides are not present at all retention times. Scheduling restricts 
the size of the isolation list to the number of peptides eluting at that chromatographic 
retention time, allowing each peptide to be sampled more frequently during its elution and 
by extension, increases the total number of precursors that can be monitored in a single 
run.138 A higher number of points on each peptide’s chromatogram results in greater 
quantitative accuracy, since the peak shape would be a more accurate representation of the 
actual peptide elution.134  
 
  
FIGURE 5.2: TRANSITION DISTRIBUTION PLOT FOR ESTIMATION OF OVERLAPPING PRECURSORS IN FINAL 
SCHEDULED BIOMARKER LIST 
(min) 
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5.4. Conclusion 
The list of 106 prospective peptides, derived from shotgun analysis of pooled samples, was 
assessed to select optimal peptides for inclusion in the final high-throughput PRM assay of 
patient samples.  Highly-sensitive PRM assays facilitated identification of 33 optimal peptides 
for identification and quantitation of candidate biomarkers in patient samples (Table 5.14). As 
per established standards regarding representative peptides for proteomic MRM assays, three 
peptides were chosen as representatives of each protein.124 An exception was made in the 
case of A1AG: where there were only two prospective peptides, one of which performed 
optimally. Retention time scheduling in the final isolation list (Table 5.9) minimised cycle time 
to maximise quantitative capacity. The final isolation list was utilised in a targeted assay of 
patient samples. 
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Chapter 6  
Optimisation D: Selection of Reference 
Peptides for Normalisation 
6.1. Introduction 
A potential problem inherent in all sample preparation methods for MS-based quantitative 
proteomics is variability in peptide recovery.190 Differential peptide recovery could lead for 
example, to inconsistent sample loading between replicates, and in turn to inaccurate 
quantitation. During in-house shotgun proteomic analyses, peptide loading quantity is 
determined by MS1-TIC-based normalisation using short, data-dependent pilot analyses of all 
samples. The highest peptide peak of the MS1-TIC, representing summed ion intensity for all 
peptides eluting during that window, is used as a relative measure of the total peptide content 
of each sample. Sample loading volumes are then normalised based on differential MS1-TIC 
intensities. Another strategy employed is normalisation of individual peptide intensities by the 
ratio of total peptide intensities between samples. These methods of normalisation are, 
however, not feasible for targeted analyses as the total signal from all ions in the sample is 
not detected during typical targeted workflows.134 Additionally, the total ion chromatogram-
based method of normalisation was not feasible given the high number of samples as each 
sample would have to be analysed twice, first by shotgun and then by targeted analysis, in 
order to achieve normalisation by this means.  
Quantitation of recovered peptides by alternative means could be performed, followed by 
adjustment of the mass of loaded peptide prior to mass spectrometric analysis. Difficulties 
arise, however, due to lack of availability of rapid and accurate peptide quantitation 
techniques. Peptide quantitation using the Bradford or BCA protein assay is not suitable due 
to the limited mass of peptide sample available. Additionally, dye binding assays such as the 
Bradford assay lack the ability to detect small peptides (<3000 Da).191 Quantitation by HPLC-
UV (high performance liquid chromatography-ultraviolet) spectroscopy and amino acid 
analysis are time consuming, highly-specialised techniques, and were therefore not 
considered.98,192  
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The ideal method by which to assess variability in peptide recovery due to sample preparation 
involves addition of a known quantity of heavy-labelled protein (or a protein foreign to the 
organism) to samples, pre-normalised to total protein, prior to downstream processing.193 
Peptides belonging to this protein can later be quantified by the targeted assay, and used to 
normalise the signal of the remaining analytes. This method is analogous to protein standard 
absolute quantification (PSAQ), where a heavy-labelled version of the target protein is spiked 
into the unprocessed sample to attain absolute quantitation.194 
In the present study, addition of a protein standard to serum samples was not considered 
prior to commencement of sample processing. Here, we therefore opted to utilise a peptide 
derived from an endogenous protein as a reference to facilitate quantitative correction. 
Ideally, this peptide should be selected based on minimal variation across all samples, 
analogous to the common use of ‘housekeeping’ genes/proteins in DNA microarray and 
Western blot analyses.195  
This chapter focuses on application of the discovery proteomic data in selecting potential 
reference peptides for PRM assay construction. Peptides exhibiting the least variation during 
discovery analysis are considered as reference peptide candidates for PRM assay quantitation 
normalisation. This includes normalisation of shotgun peptide data, assessment of the quality 
of these peptides by PRM analysis, and concludes with selection of the best candidates to be 
included in the final PRM assay.  
6.2. Materials and Methods 
6.2.1. Normalisation of Shotgun Peptide Data 
6.2.1.1. Assessment of Peptide Raw Intensity Trends 
Intensity values for all peptides identified during discovery analysis (Section 3.3.1) were 
extracted from the peptides.txt MaxQuant output file (data not shown), and intensities were 
plotted (Section 6.3.1.1) across pooled samples. A line graph was constructed in Microsoft 
Excel and the y-axis was log10-transformed to aid in interpretation. Visualisation of intensity 
values for each peptide facilitated determination of loading irregularities.  
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6.2.1.2. Normalisation 
To correct for inconsistent sample loading during shotgun proteomic analysis, individual 
peptide intensities were normalised by the ratios of total peptide intensities across pooled 
samples. This strategy is analogous to MS1-TIC-based normalisation (vide supra); the 
difference being that the MS1-TIC constitutes all observed masses, at the MS1 level, and is not 
restricted to peptides exclusively. Briefly, the raw intensities for all peptides within each 
sample were summed; and the totals across all samples were averaged (See Table 6.1). This 
average was then divided by each sum to yield a normalisation factor for each sample. Finally, 
normalised values were calculated by multiplying each individual peptide’s intensity value by 
the factor for that particular sample. This normalisation method was performed to shift the 
data distributions of each sample relative to one another to bring them within comparable 
range. The intended result of this normalisation strategy was to emulate equal sample loading. 
TABLE 6.1: NORMALISATION FACTOR CALCULATION FOR SHOTGUN PROTEOMIC DATA 
Sample 
Sum of Peptide 
Intensities 
Average of Sums Normalisation factor  
HAD 1 49029730900 
29239527311 
0.596363202 
HAD 2 50709959600 0.576603246 
HAD 3 6439995100 4.540302726 
MNI 1 52986660200 0.551828087 
MNI 2 12747293200 2.293783225 
MNI 3 9951835900 2.938103844 
POS 1 40710368400 0.718232933 
POS 2 31754061700 0.920812197 
POS 3 8825840800 3.312945245 
 
The transformed peptide intensity values were plotted across pooled samples. A line graph 
was constructed in Microsoft Excel, and the y-axis was log10-transformed to aid in 
interpretation (Section 6.3.1.2). Boxplots were also constructed in the R programming 
language to confirm success of normalisation by comparing the shotgun proteomic data 
distribution before and after normalisation.196 
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6.2.2. Reference Peptide Selection 
The above normalisation method, however effective, was not applicable to PRM analyses. 
Where only a small portion of the total peptide component was measured, meaning that 
normalisation would have been highly subjective and would likely have suppressed true 
biological differences. Suitable internal reference peptides were thus identified from within 
the discovery analysis for inclusion in the final PRM method. Abundant peptides unlikely to 
fluctuate significantly between samples were deemed most suitable. 
Due to the relatively low number of proteins identified during the discovery analysis (due to 
the complexity of plasma, as discussed in Chapter 3), there were few candidate housekeeping 
proteins available to choose from (Appendix B: Table 9.2). It was hypothesised that 
immunoglobulin G subclass 4 (IgG4) would not fluctuate significantly between samples, given 
that all participants were HIV-positive, as well as the lack of IgG4 involvement in the immune 
response against HIV.197,198 Other IgG subclass peptides that did not fluctuate greatly across 
pooled samples following normalisation were additionally assessed in preparation for the 
possibility that IgG4 peptides proved suboptimal as a basis of normalisation. 
6.2.2.1. Preliminary Selection 
To determine the most suitable reference peptides, raw and normalised plots for each 
immunoglobulin (Ig) peptide were extracted from Figure 6.1 and Figure 6.2 respectively. 
Peptides were selected based on visual inspection of variation in their normalised intensity 
plots only. Peptides were rejected if they showed visually marked differences in intensity 
across samples after normalisation.  
6.2.2.2. Assessment and Final Selections 
The 18 preliminarily selected peptides were subjected to PRM analysis on the MNI_1 pooled 
sample to assess quality. A total of 28 precursors (Table 6.2) were analysed by unscheduled 
PRM at 35 000 resolution in duplex mode, with an IT of 45 ms. Remaining settings are outlined 
in Table 4.13. The LC gradient used was the default 72 minute gradient designed for PRM 
analyses, as described in Section 5.2.2. 
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TABLE 6.2: UNSCHEDULED ISOLATION LIST OF PROSPECTIVE IMMUNOGLOBULIN INTERNAL STANDARD PEPTIDES 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
607.3198   2 Positive   27 WLQGSQELPR (light) 
644.3293   2 Positive   27 GPSVFPLAPC[+57.0]SR (light) 
678.3223   2 Positive   27 TPLGDTTHTC[+57.0]PR (light) 
452.5506   3 Positive   27 TPLGDTTHTC[+57.0]PR (light) 
708.849   2 Positive   27 WYVDGVEVHNAK (light) 
472.9017   3 Positive   27 WYVDGVEVHNAK (light) 
643.8406   2 Positive   27 EPQVYTLPPSR (light) 
429.5628   3 Positive   27 EPQVYTLPPSR (light) 
581.3184   2 Positive   27 NQVSLTC[+57.0]LVK (light) 
712.3585   2 Positive   27 STSESTAALGC[+57.0]LVK (light) 
475.2414   3 Positive   27 STSESTAALGC[+57.0]LVK (light) 
981.8239   3 Positive   27 
YGPPC[+57.0]PSC[+57.0]PAPEFL
GGPSVFLFPPKPK (light) 
951.4676   2 Positive   27 TTPPVLDSDGSFFLYSR (light) 
942.5073   2 Positive   27 EIVLTQSPGTLSLSPGER (light) 
628.6739   3 Positive   27 EIVLTQSPGTLSLSPGER (light) 
610.3357   2 Positive   27 SGTSASLAISGLR (light) 
1002.505   2 Positive   27 SYELTQPPSVSVSPGQTAR (light) 
668.6726   3 Positive   27 SYELTQPPSVSVSPGQTAR (light) 
856.3832   2 Positive   27 
SYSC[+57.0]QVTHEGSTVEK 
(light) 
571.2579   3 Positive   27 
SYSC[+57.0]QVTHEGSTVEK 
(light) 
809.4076   2 Positive   27 QVGSGVTTDQVQAEAK (light) 
539.9408   3 Positive   27 QVGSGVTTDQVQAEAK (light) 
450.7687   2 Positive   27 VSVFVPPR (light) 
455.2143   2 Positive   27 DGFFGNPR (light) 
625.3215   2 Positive   27 LIC[+57.0]QATGFSPR (light) 
417.2168   3 Positive   27 LIC[+57.0]QATGFSPR (light) 
809.4076   2 Positive   27 QVGSGVTTDQVQAEAK (light) 
695.3101   2 Positive   27 SSEDPNEDIVER (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
Following PRM analysis of preliminary Ig peptides, data was imported into Skyline with 
settings identical to those outlined in Section 4.2.2.1. A consensus set of peptides was selected 
for inclusion in final clinical sample analysis, by qualitative assessment of variation in intensity 
across samples, as well as assessment of peak quality (desirable shape, high intensity, low 
background, and large number of product ions) from PRM results.  
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6.3. Results and Discussion 
6.3.1. Normalisation of Shotgun Peptide Data 
6.3.1.1. Assessment of Peptide Intensity Trends 
Loading consistency of shotgun proteomic analysis of pooled samples was evaluated by 
plotting raw peptide intensity values against pooled samples as shown in Figure 6.1(A) below, 
with an additional plot of log10-transformed intensity values (Figure 6.1(B)) for ease of 
interpretation.   
 
Peptide intensities appear to exhibit a sample-dependent trend, which implies inconsistent 
loading prior to mass spectrometric analysis. This suggests that inconsistent sample loading – 
rather than biological variation - is influencing the intensities of peptides across samples. 
Normalisation of these data to account for loading bias should reveal true quantitative trends. 
FIGURE 6.1: INTENSITY PLOT FOR ALL IDENTIFIED PEPTIDES ACROSS POOLED SAMPLES. EACH LINE 
REPRESENTS INDIVIDUAL PEPTIDE INTENSITY TRENDS. A: LOWER INTENSITIES APPEAR FLAT DUE TO 
SCALE OF PLOT, B: LOG10 TRANSFORMED PLOT FOR EASE OF INTERPRETATION. 
HAD: HIV Associated Dementia, MNI: Minor Neurocognitive Impairment, POS: HIV positive 
control.  
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6.3.1.2. Normalisation 
Following normalisation (based on pooled shotgun data; Table 6.1), peptide intensities were 
re-plotted across pooled samples as shown in Figure 6.2(A) below, with an additional plot of 
log10-transformed intensity values (Figure 6.2(B)) for ease of interpretation. 
 
Peptide intensities do not follow the same trends on a replicate-dependent basis, as is evident 
in non-normalised (raw) data. Boxplots of pre- and post-normalisation shotgun proteomic 
data (Figure 6.3) show the within-sample data distributions were not altered, and all sample 
distributions were shifted within range of one another. This normalisation strategy was 
deemed successful in emulating equal sample loading. These plots confirmed success of the 
normalisation strategy in alleviating loading bias effects; thus revealing true relative peptide 
levels on a ‘per µg total peptide’ basis, and facilitating selection of an internal reference 
peptide that remains relatively constant across biological replicates. 
 
FIGURE 6.2: NORMALISED INTENSITY PLOTS FOR EACH PEPTIDE ACROSS POOLED SAMPLES. EACH 
LINE REPRESENTS INDIVIDUAL PEPTIDE INTENSITY TRENDS. A: LOWER INTENSITIES APPEAR FLAT 
DUE TO SCALE OF PLOT, B: LOG10 TRANSFORMED PLOT FOR EASE OF INTERPRETATION. 
HAD: HIV Associated Dementia, MNI: Minor Neurocognitive Impairment, POS: HIV 
positive control. 
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6.3.2. Reference Peptide Selection 
6.3.2.1. Preliminary Selection 
Ig peptides were assessed for suitability as internal reference peptides based on their intensity 
profiles before and after normalisation. Of the total identified Ig peptides, 18 were chosen as 
prospective standards (Figure 6.4). 
A 
B 
FIGURE 6.3: BOXPLOTS OF PRE- AND POST-NORMALISATION SHOTGUN PROTEOMIC DATA. A: 
RAW DATA, B: NORMALISED DATA 
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FIGURE 6.4: RAW INTENSITY PLOTS OF PRELIMINARILY SELECTED IG PEPTIDES BEFORE AND AFTER NORMALISATION. INTENSITIES ARE LOG2-NORMALISED 
Before After 
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These peptides were chosen based on visual assessment of decrease in variation across 
samples following normalisation. As can be seen in the left panel of Figure 6.4, most peptides 
exhibited intensity profiles similar to the overall trend seen in Figure 6.1. Following 
normalisation, these profiles appeared to flatten suggesting that the concentrations of these 
peptides were actually consistent across samples (peptides GPSVFPLAPSSK and 
WYVDGEVHNAK being obvious exceptions). Peptide EPQVYTLPPSR in particular appeared to 
exhibit low variation following normalisation, and represented a likely candidate for use as 
the final internal reference peptide.  
The final list of prospective peptides is shown in Table 6.3 including charge states as identified 
by MaxQuant analysis. These peptides required verification by PRM analysis to be considered 
for use as internal references in the final PRM assay.  
 
TABLE 6.3: LIST OF INTERNAL REFERENCE PEPTIDE CANDIDATES 
Sequence Protein Charge 
DGFFGNPR Ig mu chain C region 2 
EIVLTQSPGTLSLSPGER Ig kappa chain V-III region WOL 2, 3 
EPQVYTLPPSR Ig gamma-3 chain C region 2, 3 
GPSVFPLAPC[+57.0]SR Ig gamma-1 chain C region 2 
LIC[+57.0]QATGFSPR Ig mu chain C region 2, 3 
NQVSLTC[+57.0]LVK Ig gamma-3 chain C region 2 
QVGSGVTTDQVQAEAK Ig mu chain C region 2, 3 
SGTSASLAISGLR Ig kappa chain C region 2 
SSEDPNEDIVER Immunoglobulin J chain 2 
STSESTAALGC[+57.0]LVK Ig gamma-4 chain C region 2, 3 
SYELTQPPSVSVSPGQTAR Ig lambda chain V-IV region Hil 2, 3 
SYSC[+57.0]QVTHEGSTVEK Ig lambda-2 chain C regions 2, 3 
TPLGDTTHTC[+57.0]PR Ig gamma-3 chain C region 2, 3 
TTPPVLDSDGSFFLYSR Ig gamma-4 chain C region 2 
VSVFVPPR Ig mu chain C region 2 
WLQGSQELPR Ig alpha-2 chain C region 2 
WYVDGVEVHNAK Ig gamma-3 chain C region 2, 3 
YGPPC[+57.0]PSC[+57.0]PAPEFLGGPSVFLFPPKPK Ig gamma-4 chain C region 3 
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6.3.2.2. Assessment and Final Selections 
Following PRM analysis of the set of preliminary Ig peptides, a final set of six were chosen to 
be included in the final analytical runs. The list of selected peptides included 
TPLGDTTHTC[+57.0]PR, WYVDGVEVHNAK, EPQVYTLPPSR, NQVSLTC[+57.0]LVK, 
STSESTAALGC[+57.0]LVK, and EIVLTQSPGTLSLSPGER. Figure 6.5 shows transition 
chromatograms extracted from Skyline for the selected peptides.  This selection was based on 
optimal peak characteristics (using exclusion criteria previously defined in Chapter 5, Section 
5.3.1), as well as ideal post-normalisation profiles. 
 
Precursor charge states of 2+ and 3+ were used for all peptides chosen for integration into the 
final PRM method, except NQVSLTC[+57.0]LVK (Table 6.4). Only one of the six peptides 
originated from IgG4, four were IgG3 peptides, and one belonged to the Ig kappa chain.  
 
 
FIGURE 6.5: SKYLINE CHROMATOGRAMS FOR SELECTED IMMUNOGLOBULIN PEPTIDES. NOTE THAT AXES FOR 
EACH PEPTIDE ARE NOT AT THE SAME SCALE. INTENSITY SHOWN ON EACH Y-AXIS, AND RETENTION TIME (IN 
MINUTES) ON EACH X-AXIS 
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TABLE 6.4: FINAL LIST OF INTERNAL REFERENCE PEPTIDES 
Sequence Protein m/z Charge 
EIVLTQSPGTLSLSPGER Ig kappa chain V-III region WOL 942.5073 2+ 
EIVLTQSPGTLSLSPGER Ig kappa chain V-III region WOL 628.6739 3+ 
EPQVYTLPPSR Ig gamma-3 chain C region 643.8406 2+ 
EPQVYTLPPSR Ig gamma-3 chain C region 429.5628 3+ 
NQVSLTC[+57.0]LVK Ig gamma-3 chain C region 581.3184 2+ 
STSESTAALGC[+57.0]LVK Ig gamma-4 chain C region 712.3585 2+ 
STSESTAALGC[+57.0]LVK Ig gamma-4 chain C region 475.2414 3+ 
TPLGDTTHTC[+57.0]PR Ig gamma-3 chain C region 678.3223 2+ 
TPLGDTTHTC[+57.0]PR Ig gamma-3 chain C region 452.5506 3+ 
WYVDGVEVHNAK Ig gamma-3 chain C region 708.849 2+ 
WYVDGVEVHNAK Ig gamma-3 chain C region 472.9017 3+ 
m/z: Mass-to-charge ratio 
 
The Skyline chromatograms shown in Figure 6.5 indicate high peak intensities for the selected 
peptides, with NQVSLTCLVK and EPQVYTLPPSR significantly dominating. Of the chosen 
peptides, EPQVYTLPPSR; NQVSLTCLVK; and TPLGDTTHTCPR appeared to be best suited for use 
as internal standards, based on their apparently low variation across samples following 
normalisation. The IgG4 peptide STSESTAALGC[+57.0]LVK was deemed the optimal internal 
reference, consistent with our original hypothesis. 
It was deemed prudent to include several potential reference peptides during clinical sample 
assays, however, in the case of sub-optimal performance of the single chosen peptide across 
all sample analysis runs. The final Scheduled IgG isolation list, including a final set of six 
peptides (11 precursors, Table 6.5), was generated for integration into the final analytical PRM 
method. Five minute retention time scheduling windows were used, based on analysis of the 
MNI_1 sample.  
TABLE 6.5: SCHEDULED ISOLATION LIST OF SELECTED INTERNAL REFERENCE PEPTIDES 
Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
678.3223   2 Positive 15.4 20.4 27 
TPLGDTTHTC[+57.0]PR 
(light) 
452.5506   3 Positive 15.4 20.4 27 
TPLGDTTHTC[+57.0]PR 
(light) 
708.849   2 Positive 22.47 27.47 27 WYVDGVEVHNAK (light) 
472.9017   3 Positive 22.47 27.47 27 WYVDGVEVHNAK (light) 
643.8406   2 Positive 21.46 26.46 27 EPQVYTLPPSR (light) 
429.5628   3 Positive 21.46 26.46 27 EPQVYTLPPSR (light) 
581.3184   2 Positive 25.07 30.07 27 NQVSLTC[+57.0]LVK (light) 
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Mass 
[m/z] 
Formula 
[M] Species 
CS 
[z] Polarity 
Start 
[min] 
End 
[min] NCE Comment 
712.3585   2 Positive 24.13 29.13 27 
STSESTAALGC[+57.0]LVK 
(light) 
475.2414   3 Positive 24.13 29.13 27 
STSESTAALGC[+57.0]LVK 
(light) 
942.5073   2 Positive 27 32 27 
EIVLTQSPGTLSLSPGER 
(light) 
628.6739   3 Positive 27 32 27 
EIVLTQSPGTLSLSPGER 
(light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur. 
 
6.4. Conclusions 
Internal reference peptides were required to control for variance in inter-replicate peptide 
abundances due to unavoidable sample preparation – and therefore peptide loading – 
inconsistencies. Prospective reference peptides were selected based on qualitative evaluation 
of their intensities across pooled samples analysed by discovery MS. Final peptide selection 
was based on qualitative assessment of inter-replicate variation following normalisation, as 
well as membership to IgG subclasses that do not vary greatly in HIV. Selection of the final list 
of reference peptides was also based on satisfactory performance in preliminary PRM analysis. 
For redundancy, six peptides were selected for use in the final assay, with a view to selecting 
the ultimate normalisation peptide once all samples had been analysed. 
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Chapter 7  
High-throughput Parallel Reaction 
Monitoring Assay of Clinical Samples 
7.1. Introduction 
Comprehensive development steps were required to build a PRM assay, de novo, for 
quantitative analysis of candidate Alzheimer’s protein biomarkers in blood serum. 
Development required extensive optimisation of instrument settings, as well as selection of 
representative peptides that would enable selective and sensitive quantitation of markers. 
Prospective representative peptides were selected based on shotgun proteomic analysis of 
patient serum pooled to enable unbiased detection of peptides (Chapter 3). Instrument 
parameters were optimised for PRM analysis on the Q Exactive Quadrupole-Orbitrap mass 
spectrometer as literature in this area was incomplete at the time of developing the assay 
(Chapter 4). Candidate peptides identified during the previous step were assessed by PRM 
analysis with optimised settings, to identify those optimal for identification and quantitation 
of parent proteins in the final analytical PRM assay utilising clinical samples (Chapter 5). 
Internal reference peptides were chosen from shotgun analysis and optimised by PRM analysis 
to correct for sample recovery inconsistencies evident during discovery analysis (Chapter 6). 
Regarding the applicability of Ig peptides as internal reference peptides (Chapter 3): As all 
patients were HIV positive, it was hypothesised that IgG levels may not fluctuate excessively 
within disease groups, and could thus be utilised post-hoc to correct for loading differences 
between samples within a group. Assessment of PRM data largely supports this hypothesis, 
although the literature suggests that HIV-positive patient total IgG levels do vary.197 IgG4 was 
considered the most likely candidate since its levels are not affected by HIV-infection.197 On 
these bases, it was decided to utilise IgG4 for normalisation of raw data, and to compare 
analysis outcomes with those from data normalised by total peptide quantitation (vide infra).  
Extensive assay development has culminated in a finalised PRM assay applicable to clinical 
samples. Indeed the optimised assay may be utilised to analyse the identified markers of 
interest in any sample set. This chapter discusses application of the final PRM assay to 81 
clinical samples in a high throughput manner to assess the major study hypothesis; that a 
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panel of AD biomarkers may also be applicable to the diagnosis of HAND, given the underlying 
molecular similarities between these two disease states. 
7.2. Materials and Methods 
7.2.1. Sample Preparation 
Stored serum peptide samples (preparation described in Chapter 2) were reconstituted in 25 
µl 2%ACN/0.1% FA to yield a stock solution with an estimated concentration of 0.4 µg/µl 
(assuming no loss during in-gel digest). A 25 ng/µl solution was prepared by 16-fold dilution 
of the stock solution. Samples were loaded into 2 ml autosampler vials with tapered 100 µl 
glass inserts (Macherey-Nagal), and stored at 4°C until mass spectrometric analysis using 
instruments and parameters described below. 
7.2.2. Analytical Parameters 
7.2.2.1. Isolation List Considerations 
The PRM assay isolation list was constructed by combining the final isolation lists from sample 
and internal standard method development (Table 7.1), and included RT scheduling. Analytical 
parameters such as MSX and Max IT were selected based on the consideration that a minimum 
cycle time of 2 seconds was required. All parameter changes are for a resolution setting of 
35 000.  
TABLE 7.1: SCHEDULED ISOLATION LIST FOR FINAL PRM ANALYSIS 
Mass [m/z] 
Formula 
[M] 
Species 
CS 
[z] 
Polarity 
Start 
[min] 
End 
[min] 
NCE Comment 
697.8435   2 Positive 24.5 29.5 27 NEDSLVFVQTDK (light) 
523.7977   2 Positive 24.19 29.19 27 FEVQVTVPK (light) 
628.3251   2 Positive 22.41 27.41 27 AIGYLNTGYQR (light) 
532.2984   2 Positive 21.63 26.63 27 IDVHLVPDR (light) 
595.269   2 Positive 21.81 26.81 27 LSYTC[+57.0]EGGFR (light) 
827.8745   2 Positive 21.13 26.13 27 AGEQVTYTC[+57.0]ATYYK (light) 
474.7667   2 Positive 18.08 23.08 27 LAVYQAGAR (light) 
484.7798   2 Positive 19.98 24.98 27 LGPLVEQGR (light) 
749.4046   2 Positive 21.96 26.96 27 AATVGSLAGQPLQER (light) 
559.3086   2 Positive 26.58 31.58 27 TLLSNLEEAK (light) 
537.7749   2 Positive 21.67 26.67 27 IDSLLENDR (light) 
697.3515   2 Positive 33.58 38.58 27 ASSIIDELFQDR (light) 
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Mass [m/z] 
Formula 
[M] 
Species 
CS 
[z] 
Polarity 
Start 
[min] 
End 
[min] 
NCE Comment 
499.7745   2 Positive 26.41 31.41 27 EPGLQIWR (light) 
915.4858   2 Positive 28.3 33.3 27 QTQVSVLPEGGETPLFK (light) 
660.3513   2 Positive 25.07 30.07 27 AGALNSNDAFVLK (light) 
703.8386   2 Positive 26.58 31.58 27 AYSLFSYNTQGR (light) 
497.2662   2 Positive 23.84 28.84 27 DNELLVYK (light) 
578.8035   2 Positive 25.22 30.22 27 VGEYSLYIGR (light) 
497.7638   2 Positive 24.68 29.68 27 TEDTIFLR (light) 
461.7169   2 Positive 17.04 22.04 27 FLENEDR (light) 
508.3109   2 Positive 26.72 31.72 27 SVLGQLGITK (light) 
444.7555   2 Positive 20.13 25.13 27 AVLTIDEK (light) 
700.8383   2 Positive 27.95 32.95 27 DYVSQFEGSALGK (light) 
806.8963   2 Positive 30.3 35.3 27 LLDNWDSVTSTFSK (light) 
626.8141   2 Positive 24.24 29.24 27 VQPYLDDFQK (light) 
602.2675   2 Positive 19.51 24.51 27 EYTDASFTNR (light) 
686.3852   2 Positive 28.11 33.11 27 GAYPLSIEPIGVR (light) 
952.4139   2 Positive 20 25 27 NNEGTYYSPNYNPQSR (light) 
525.7587   2 Positive 21.44 26.44 27 AEFQDALEK (light) 
557.8144   2 Positive 24.94 29.94 27 VGDTLNLNLR (light) 
492.2383   2 Positive 19.36 24.36 27 QGSFQGGFR (light) 
685.8694   2 Positive 24.66 29.66 27 TIYTPGSTVLYR (light) 
735.8936   2 Positive 24.13 29.13 27 IPIEDGSGEVVLSR (light) 
501.7769   2 Positive 19.61 24.61 27 TGLQEVEVK (light) 
678.3223   2 Positive 15.4 20.4 27 TPLGDTTHTC[+57.0]PR (light) 
452.5506   3 Positive 15.4 20.4 27 TPLGDTTHTC[+57.0]PR (light) 
708.849   2 Positive 22.47 27.47 27 WYVDGVEVHNAK (light) 
472.9017   3 Positive 22.47 27.47 27 WYVDGVEVHNAK (light) 
643.8406   2 Positive 21.46 26.46 27 EPQVYTLPPSR (light) 
429.5628   3 Positive 21.46 26.46 27 EPQVYTLPPSR (light) 
581.3184   2 Positive 25.07 30.07 27 NQVSLTC[+57.0]LVK (light) 
712.3585   2 Positive 24.13 29.13 27 STSESTAALGC[+57.0]LVK (light) 
475.2414   3 Positive 24.13 29.13 27 STSESTAALGC[+57.0]LVK (light) 
942.5073   2 Positive 27 32 27 EIVLTQSPGTLSLSPGER (light) 
628.6739   3 Positive 27 32 27 EIVLTQSPGTLSLSPGER (light) 
CS: Charge State, NCE: Normalised Collision Energy. 
* Isolation list columns left blank intentionally, as this is the required format from Xcalibur.  
 
7.2.2.2. Instrument Parameters  
Optimised instrument parameters developed in Chapter 4 were applied to the final PRM 
analysis at 35 000 resolution in duplex mode (Table 7.2). 
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TABLE 7.2: FINAL SETTINGS FOR PRM ANALYSES AT 35 000 RESOLUTION.  
Resolution 35000 
Lock masses Off 
Chrom peak width 15 s 
Charge state 2 
AGC Target 5.00E+06 
ISO Window 2 m/z 
NCE 27 
MSX 2 
Max IT 45 ms 
Precursors 45 
AGC: Automatic Gain Control, ISO: Isolation, NCE: Normalised Collision Energy, MSX: Multiplex level, 
Max IT: Maximum Injection time. 
 
7.2.3. LC/MS Instrumentation and Parameters 
Targeted proteomic analysis was performed on a Q Exactive Quadrupole-Orbitrap Mass 
Spectrometer, coupled to a Dionex UltiMate 3500 RSLC nano-LC system. Approximately 125 
ng of pooled peptide digest was injected by partial loop injection onto a trap column packed 
in-house with Luna C18 coated silica beads (75 µm x 2 cm, 5 µm). Separation was performed 
by reversed phase chromatography on a nanoscale analytical column, also packed in-house 
with Luna C18 resin (75 µm x 20 cm). Ionisation was attained by application of charge across 
a steel emitter tip fixed to the end of the analytical column. Solvent A was composed of 0.1% 
FA in UHPLC-grade H2O, while Solvent B (B) consisted of 0.1% FA in UHPLC-grade ACN. A 
shortened 72 minute linear gradient, developed for rapid targeted analysis, was applied at a 
constant flow rate of 300 nl/min as follows: 2% B for 5 minutes, 2-35% B over 35 minutes, 35-
80% B over 5 minutes, held at 80% B for 15 minutes, before returning to 2% B in 2 minutes, 
followed by re-equilibration at 2% B for 10 minutes. 
Samples were analysed in batches equivalent to those used during sample preparation 
(Appendix A: Table 8.1). Samples from within the same disease groups were analysed 
consecutively, followed by a blank, to prevent carryover (if any) between different sample 
types. An additional blank was added between batches. No technical replicates were analysed 
due to limitations on sample preparation time and mass spectrometric analysis time. The 
order of analysed samples is shown in Table 7.3. The discrepancies evident in batches five and 
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1 2 3 4 5 
6 7 8 9 
nine are due to sample mislabelling and subsequent correction, leading to disproportionate 
disease group distributions. This is not expected to negatively affect the analysis. 
TABLE 7.3: SEQUENCE OF SAMPLES FOR TARGETED ANALYSIS 
B3_32N B4_180N B8_68N B6_224N B7_26N 
B3_213N B4_203N B8_237N B6_142N B7_135N 
B3_231N B4_67N B8_215N B6_260N B7_35N 
Blank_Batch3_P1 Blank_Batch4_P1 Blank_Batch8_P1 Blank_Batch6_P1 Blank_Batch7_P1 
B3_156M B4_137M B8_183M B6_43M B7_152M 
B3_40M B4_214M B8_47M B6_167M B7_79M 
B3_125M B4_63M B8_74M B6_003M B7_201M 
Blank_Batch3_P2 Blank_Batch4_P2 Blank_Batch8_P2 Blank_Batch6_P2 Blank_Batch7_P2 
B3_25H B4_148H B8_16H B6_147H B7_005H 
B3_206H B4_38H B8_132H B6_50H B7_225H 
B3_126H B4_130H B8_24H B6_236H B7_198H 
Blank_Batch3_P3 Blank_Batch4_P3 Blank_Batch8_P3 Blank_Batch6_P3 Blank_Batch7_P3 
Wash_Batch3 Wash_Batch4 Wash_Batch8 Wash_Batch6 Wash_Batch7 
B9_207M B2_87N B5_09N B1_61N 
B9_36M B2_204N B5_81N B1_200N 
Blank_Batch9_P1-MID B2_31N Blank_Batch5_P1-MID B1_223N 
B9_239N Blank_Batch2_P1 B5_59M Blank_Batch1_P1 
Blank_Batch9_P1 B2_56M Blank_Batch5_P1 B1_179M 
B9_207M B2_193M B5_20M B1_27M 
B9_36M B2_146M B5_136M B1_209M 
Blank_Batch9_P2-MID Blank_Batch2_P2 B5_29M Blank_Batch1_P2 
B9_239N B2_229H Blank_Batch5_P2 B1_10H 
Blank_Batch9_P2 B2_166H B5_04H B1_149H 
B9_106H B2_30H B5_97H B1_104H 
B9_202H Blank_Batch2_P3 B5_172H Blank_Batch1_P3 
B9_216H Wash_Batch2 Blank_Batch5_P3 Wash_Batch1 
Blank_Batch9_P3 
 
Wash_Batch5 
 Wash_Batch9  
 
7.2.4. Preliminary Data and Repeat Analyses 
Following the first round of analyses, each data file was assessed for quality by viewing 
Thermo .raw files in Xcalibur Qual Browser (version 3.0, Thermo Scientific). Samples with 
irregular MS2-TIC profiles were marked for repeat analysis (Section 7.3.2). In the event that 
repeat analyses did not yield improved results, injection volumes were doubled and samples 
re-analysed. In cases where the MS2-TIC displayed unusually low intensity (in the original 
analysis), those samples were reanalysed with doubled injection volumes from the outset.  
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7.2.5. Data Curation 
All data files, including those with irregular MS2-TICs, were imported into Skyline (Section 
4.2.2.1) for evaluation. Annotations were set up in Skyline to categorise the samples based on 
disease status and patient identifier. The disease state (‘Condition’) consisted of CTRL, MNI, 
or HAD. Patient identifier (‘BioReplicate’) was populated with numerical patient identifiers 
linked to each sample. Each sample, once imported, was designated as belonging to one of 
the three disease groups, and numerical patient identifiers were entered. 
Skyline analysis, being more thorough than the initial MS2-TIC assessment (vide supra), was 
utilised to exclude sub-standard samples in order to prevent skewing of data. 
Chromatographic exclusion criteria included peak broadening and excessive drift, significantly 
misaligned transitions for the majority of peptides, and missing peaks for the majority of 
assessed peptides. Product ions were excluded from further analysis based on detection and 
signal consistency: regarding the former, ions not detected in all samples were excluded; 
regarding the latter, ions for which peak areas normalised to total signal still yielded unequal 
transition intensities across samples were excluded.199 Exceptions were made in cases where 
the varying ions were the only ions present in particular samples. 
Of the three peptides targeted per protein, two were used for quantitation, while the 
remaining peptide was employed for confirmation of identity.134 Quantitative peptides were 
selected based on similar average intensity trends across disease states, as well as ideal peak 
properties outlined in the exclusion criteria above.134 Measurement of three peptides also 
increased the likelihood that two peptides would be available for quantitation in the event 
that one performed sub-optimally. Five product ions per peptide were selected for 
quantitation purposes.134,189,199 
7.2.6. Power Analysis 
Sample size estimations for PRM analyses were based on coefficient of variation (CV) of the 
analytical method, and expected fold-change of the mean.200,201 Sample size estimations, 
developed by van Belle et al.201, were obtained from tabulated values corresponding to CV 
and fold changes. This calculation assumes a significance level (α) of 0.05, predicted power (1-
β) of 0.80, and applies to independent samples t-tests with unknown biological variance.201 
Data obtained from PRM analysis of repeated injection replicates using the final method 
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(Table 7.1), was used to calculate the average CV applicable to the PRM assay. Four replicate 
PRM analyses of sample 142N were performed, followed by selection of optimal product ions 
for each peptide as outlined in Section 7.2.5. All prospective internal reference peptides were 
removed except for STSESTAALGC[+57.0]LVK. Skyline-calculated CVs for each peptide were 
exported and the average CV calculated. This value was used to estimate the sample size 
required for a power of 0.8. 
7.2.7. Data Handling and Statistical Analyses 
7.2.7.1. Data Export and Manipulation 
Data was exported from Skyline in the form of a .csv report file, such that the total peak area 
for each peptide was calculated from the areas of their constituent ions. Data was then 
manually rearranged in Microsoft Excel, where the total peak area for the two peptides 
belonging to each protein were averaged to yield a final area value. Protein names were 
represented by UniProt identifiers, sample names were removed, and patient identifiers 
replaced by sequential numbering. The data were then split into separate .csv files according 
to disease group for downstream statistical analysis. 
7.2.7.2. Data Normalisation 
INTERNAL REFERENCE PEPTIDE NORMALISATION 
Protein intensities were normalised relative to the internal reference peptide 
(STSESTAALGC[+57.0]LVK) derived from the parent protein IgG4. Protein intensities in a given 
replicate were divided by the intensity of the reference peptide present in the same replicate, 
after which the quotient was multiplied by the average intensity of the internal reference 
peptide across all replicates, as described in Teleman et al.140  
NANODROP NORMALISATION 
In the event of substandard performance of the internal reference-based normalisation, total 
peptide-based normalisation was also conducted. Stock peptide samples (0.4 µg/µl) were 
measured using a NanoDrop 1000 Spectrophotometer (Thermo Scientific) at 214nm 
wavelength for quantitation of peptide bonds.98 Eight absorbance measurements were taken 
for each of the 55 samples selected for final analysis, and the average absorbance value 
calculated. Each sample absorbance was then divided by the average absorbance across all 
samples, to yield a normalisation factor for each sample (data not shown). Finally, each 
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protein intensity value was multiplied by the normalisation factor for its respective sample. 
(Appendix C: Table 11.2).   
7.2.7.3. Statistical Assessment 
An R-script, generously provided by Dr Janique Peyper (IDM, University of Cape Town), was 
used for normality assessment and statistical tests.196,202,203 All data were log2-transformed 
prior to visualisation and statistical analysis. Data were assessed for normality by visual 
inspection of histograms constructed for each peptide across all samples within each 
respective disease group.204 A Shapiro-Wilk test for normality was also conducted to confirm 
visual findings by evaluating normality of the data in an unbiased fashion.205  
Statistical tests comparing each protein between groups (Control vs MNI, MNI vs HAD, and 
Control vs HAD) were conducted on data normalised by the aforementioned methods, in the 
R statistical computing language.196 Samples were not stratified based on age, as analysed 
patient samples fell within a narrow age range (23-30 years). Additionally, sample 
stratification based on gender was not conducted as 83% of analysed samples were derived 
from female patients. Welch’s unequal variances t-tests were conducted on all proteins, but 
were most effective when applied to proteins that were normally distributed in all three 
patient groups.206,207 Welch’s t-test was used to account for potential heteroscedasticity, and 
unequal sample sizes.206,208 For peptides whose distributions were non-normal, a non-
parametric Wilcoxon rank sum test was appropriate to assess statistical significance of 
differences.209 Group comparisons were initially conducted without applying multiple testing 
correction in order to assess the data in a less stringent manner. In the event of proteins 
showing significant differences between disease groups, multiple testing correction using 
Bonferroni correction would be applied.210,211  Bar graphs plotting group means, with standard 
error of the mean (SEM) error bars were constructed to visually assess t-test data.204 
7.3. Results and Discussion 
7.3.1. Analytical Parameters 
7.3.1.1. Isolation List Considerations 
The final scheduled list included 45 peptides, 11 of which were considered internal reference 
peptides (Table 7.1). These 45 peptides represented a parent protein panel consisting of the 
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12 candidate AD biomarkers being evaluated here: A2M, CLU, C3, C4, CH, ApoE, SAP, ApoA-I, 
GSN, A1AG, A1AT, and CERU. This list size would result in an overall cycle time of 6.3 seconds, 
which is too long for acceptable quantitation as this would equate to two sampling points on 
an average 15 second chromatogram. With application of 5 minute scheduling windows, the 
overall cycle time would vary across different precursors within a sample. This is not 
detrimental, however, as consistent quantitation is only necessary between each precursor 
across samples. It can be observed from the transition distribution plot generated in Skyline 
(Figure 7.1), that during the 5 minute retention time window (blue graph) at most 25 
precursors are scanned concurrently. This equates to an overall maximum cycle time of 3.5 
seconds, which is still too high. Analysis in duplex mode would essentially halve the list length, 
yielding an overall cycle time of 1.75 seconds at the retention time where most precursors 
overlap. A cycle time of 1.75 seconds results in an average of 9 points on a 15 second 
chromatographic curve. This is acceptable, considering that peptides which do not have 
overlapping retention times with others will result in superior quantitation. Duplex mode was 
therefore employed during the final analysis.  
 
FIGURE 7.1: TRANSITION DISTRIBUTION PLOT FOR ESTIMATION OF OVERLAPPING PRECURSORS IN FINAL ASSAY 
(INCLUDING INTERNAL REFERENCE PEPTIDES) 
(min) 
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7.3.2. Preliminary Data and Repeat Analyses 
As outlined above, samples were selected for repeat analysis by assessment of MS2-TICs. 
Examples of samples exhibiting desirable MS2-TIC profiles are shown in Figure 7.2-A. Samples 
exhibiting poor MS2-TIC profiles (Figure 7.2-B-D) were reanalysed.  
 
  
A B 
C D 
FIGURE 7.2: EXAMPLES OF DESIRABLE AND POOR MS2-TICS FOR SAMPLE QUALITY ASSESSMENT. A: DESIRABLE 
CHROMATOGRAM, B-D: POOR CHROMATOGRAMS. 
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7.3.3. Data Curation  
Data quality was assessed based on criteria outlined in Section 7.2.5. Examples of samples 
possessing mostly good peaks are shown in Figure 7.3-A. Samples were excluded if a 
substantial number of their peptides were of poor quality based on: unsatisfactory peak shape 
(Figure 7.3-B), significant peak broadening (Figure 7.3-B and D), retention time drift (Figure 
7.3-C), missing transitions (Figure 7.3-E), or no peak detection (Figure 7.3-F).  
 
Determining satisfactory product ions for the remaining peptides was primarily based on 
consistency of relative product ion abundances across biological replicates. Ions exhibiting 
FIGURE 7.3: EXAMPLES OF PEAK QUALITY VARIATION. A: SATISFACTORY PEAK, B: UNSATISFACTORY PEAK 
SHAPE WITH BROADENING, C: UNSATISFACTORY PEAK SHAPE WITH SIGNIFICANT RETENTION TIME DRIFT, D: 
UNSATISFACTORY PEAK SHAPE WITH SIGNIFICANT BROADENING, E: PEAK WITH MISSING TRANSITIONS, F: NO 
TRANSITIONS DETECTED 
A B
D 
E F 
C 
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good consistency were retained, while product ions varying significantly between samples 
were excluded. Consistency of product ion abundances relative to total signal across samples 
confirm that there is no contribution to ion intensity by interfering species.212 For example, 
Figure 7.4 shows consistent peak area consistency following removal of ions y8, b10, and b11. 
The five most consistent ions were thus chosen for use in downstream quantitation. 
 
Samples chosen based on the above criteria are listed in Table 7.4, with 15; 19; and 21 samples 
in Control; MNI; and HAD groups, respectively. Of the 81 samples analysed, 26 were excluded 
(32%); with 12, 8, and 6 samples discarded from Control, MNI, and HAD groups, respectively.  
TABLE 7.4: SELECTED SAMPLES FOR FINAL STATISTICAL ANALYSIS 
Batch Group Patient Batch Group Patient Batch Group Patient 
1 Control 200 1 MNI 27 1 HAD 10 
2 Control 31 1 MNI 209 1 HAD 104 
2 Control 87 2 MNI 56 1 HAD 149 
2 Control 204 2 MNI 146 2 HAD 30 
3 Control 32 2 MNI 193 2 HAD 166 
3 Control 213 3 MNI 40 2 HAD 229 
3 Control 231 3 MNI 125 3 HAD 25 
4 Control 203 3 MNI 156 3 HAD 126 
5 Control 9 4 MNI 63 3 HAD 206 
5 Control 81 5 MNI 29 4 HAD 38 
6 Control 142 5 MNI 136 4 HAD 130 
6 Control 224 6 MNI 3 4 HAD 148 
6 Control 260 6 MNI 43 5 HAD 97 
7 Control 26 6 MNI 167 5 HAD 172 
FIGURE 7.4: PEAK INTENSITIES NORMALISED TO TOTAL PEAK AREA. BEFORE (LEFT) AND AFTER (RIGHT) REMOVAL 
OF INCONSISTENT PRODUCT IONS 
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Batch Group Patient Batch Group Patient Batch Group Patient 
9 Control 176 7 MNI 201 6 HAD 50 
 
8 MNI 47 6 HAD 236 
8 MNI 74 7 HAD 5 
9 MNI 36 7 HAD 225 
9 MNI 207 8 HAD 16 
 
8 HAD 132 
9 HAD 106 
 
Peptides selected for quantitation of their parent protein are shown in Table 7.5 below. 
Exceptions were made for sp|P02763|A1AG1 and sp|P01861|IGHG4, for which only one 
peptide was analysed per protein (vide supra). 
TABLE 7.5: PEPTIDES ASSIGNED TO EACH PROTEIN FOR THE PURPOSES OF PROTEIN INFERENCE 
Protein Name Peptide Sequence 
sp|P01023|A2MG 
NEDSLVFVQTDK 
AIGYLNTGYQR 
sp|P08603|CFAH 
IDVHLVPDR 
LSYTCEGGFR 
sp|P02649|APOE 
LGPLVEQGR 
AATVGSLAGQPLQER 
sp|P10909|CLUS 
TLLSNLEEAK 
IDSLLENDR 
sp|P06396|GELS 
QTQVSVLPEGGETPLFK 
AGALNSNDAFVLK 
sp|P02743|SAMP 
AYSLFSYNTQGR 
DNELLVYK 
sp|P02763|A1AG1 TEDTIFLR 
sp|P01009|A1AT 
SVLGQLGITK 
AVLTIDEK 
sp|P02647|APOA1 
DYVSQFEGSALGK 
VQPYLDDFQK 
sp|P00450|CERU 
EYTDASFTNR 
NNEGTYYSPNYNPQSR 
sp|P0C0L5|CO4 
AEFQDALEK 
QGSFQGGFR 
sp|P01024|CO3 
IPIEDGSGEVVLSR 
TGLQEVEVK 
sp|P01861|IGHG4 STSESTAALGCLVK 
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7.3.4. Power Analysis 
The average CV for the final PRM assay was found to be approximately 13.92% (±0.1411%, 
data not shown). This value was compared to Table 7.6 adapted from van Belle et al.201 This 
table shows sample number estimations according to measurement CV and fold change, for 
independent samples t-tests with unknown biological variance, assuming a significance level 
(α) of 0.05 and predicted power (1-β) of 0.80. A minimum power of 0.8, and α of 0.05 are 
conventionally used for statistical analyses.213 Following sample number reduction, Control; 
MNI; and HAD disease groups comprised 15; 19; and 21 samples, respectively. Detectable fold 
changes can be estimated based on these sample numbers. With a conservative CV estimate 
of 20%, despite the calculated CV being 13.92%, the lowest detectable mean difference would 
be 1.25-fold with 14 samples per group. Higher minimum fold changes can be detected with 
3-5 samples at this CV. Assuming a CV of 80% at worst case, the assay would be able to detect 
a mean difference of at least 2.5-fold using 11 samples per group. It can be concluded that, 
despite reduction in sample numbers, t-tests of PRM-quantified proteins would nevertheless 
be able to detect mean differences as low as 1.25-fold.  
TABLE 7.6: SAMPLE SIZE ESTIMATIONS FOR AN INDEPENDENT SAMPLES T-TEST, WHERE SIGNIFICANCE = 0.05, 
AND PREDICTED POWER = 0.8. ADAPTED FROM VAN BELLE ET AL.201 
CV (%) 
Fold change 
1.10 1.25 1.50 1.75 2.00 2.50 3.00 
10 19 5 3 3 3 3 4 
20 69 14 5 4 3 3 3 
30 150 29 10 6 4 3 3 
40 258 48 16 9 6 34 4 
50 387 72 23 13 9 6 5 
60 533 98 31 17 12 7 6 
70 691 127 40 22 15 9 7 
80 856 157 49 26 18 11 8 
90 >1000 189 58 31 21 13 9 
100 >1000 220 68 36 24 14 11 
200 >1000 509 155 82 54 32 22 
Shaded area shows applicable sample numbers for reduced samples assuming a CV of 20% 
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7.3.5. Data Handling and Statistical Analyses 
7.3.5.1. Data Export and Manipulation 
The data report exported from Skyline consisted of columns for Protein Name, Peptide 
Sequence, Replicate filename, Condition, BioReplicate, and total area calculated from the sum 
of ion peak areas (Table 7.7, All raw data: Appendix C: Table 10.1).  
TABLE 7.7: EXAMPLE OF SKYLINE DATA OUTPUT 
Protein Name Peptide 
Sequence 
Replicate Condition BioReplicate Total Area 
sp|P01023|A2MG NEDSLVFVQTDK 140802_BM_Dionex_B
3_32N_LSF_2plex_35K
_72min_25ngul_3ul 
Control 32 16947226 
sp|P01023|A2MG NEDSLVFVQTDK 140802_BM_Dionex_B
3_213N_LSF_2plex_35
K_72min_25ngul_3ul 
Control 213 37269700 
sp|P01023|A2MG NEDSLVFVQTDK 140802_BM_Dionex_B
3_231N_LSF_2plex_35
K_72min_25ngul_3ul 
Control 231 13608301 
sp|P01023|A2MG NEDSLVFVQTDK 140802_BM_Dionex_B
3_156M_LSF_2plex_35
K_72min_25ngul_3ul 
MNI 156 20031696 
sp|P01023|A2MG NEDSLVFVQTDK 140802_BM_Dionex_B
3_40M_LSF_2plex_35K
_72min_25ngul_3ul 
MNI 40 14586175 
sp|P01023|A2MG NEDSLVFVQTDK 140802_BM_Dionex_B
3_125M_LSF_2plex_35
K_72min_25ngul_3ul 
MNI 125 32799076 
For full raw data table see Appendix C: Table 10.1 
 
Data rearrangement yielded a result file formatted for downstream statistical analysis, with 
patient identifiers running down the rows and proteins across the columns (Table 7.8). 
TABLE 7.8: EXAMPLE OF DATA PREPARED FOR STATISTICAL ANALYSIS 
Patient Group sp_P01023_A2MG sp_P08603_CFAH sp_P02649_APOE sp_P10909_CLUS 
1 Control 71415240 7782003.5 3005355.5 28342590 
2 Control 52129109 4385080 2571627 11731742.5 
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Patient Group sp_P01023_A2MG sp_P08603_CFAH sp_P02649_APOE sp_P10909_CLUS 
3 Control 127857096 28001535.5 4515216.5 34542406 
4 Control 31038437 4951136.5 2378897.5 16315096 
 
7.3.5.2. Data Normalisation 
INTERNAL REFERENCE PEPTIDE NORMALISATION 
The first of two normalisation methods utilised in the present study was based on 
normalisation to the internal reference peptide. An example of the result of normalisation is 
depicted in Table 7.9 below, which includes the calculated average internal reference peptide 
intensity as well as the internal reference intensity for each respective sample. 
TABLE 7.9: EXAMPLE OF INTERNAL REFERENCE NORMALISED DATA 
Patient Group 
Average 
reference 
peptide 
intensity 
Sample reference 
peptide intensity 
sp|P01023|A2MG 
Pre-normalisation Post-normalisation 
1 Control 
186617596 
364794112 71415240 36533869 
2 Control 125390672 52129109 77583195 
3 Control 69829224 127857096 341696248 
4 Control 107740912 31038437 53761550 
 
NANODROP NORMALISATION 
The second normalisation method was based on total peptide quantitation measured by UV 
spectrophotometry. An example of the result of normalisation is depicted in Table 7.10 below, 
which includes the normalisation factors for each respective sample. 
TABLE 7.10: EXAMPLE OF TOTAL PEPTIDE NORMALISED DATA 
Patient Group Normalisation  factor 
sp|P01023|A2MG 
Pre-normalisation Post-normalisation 
1 Control 0.785853 71415240 56121866.67 
2 Control 0.940387 52129109 49021535.74 
3 Control 0.965005 127857096 123382698.5 
4 Control 1.391285 31038437 43183325.26 
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7.3.5.3. Statistical Assessment 
INTERNAL REFERENCE NORMALISED DATA 
The Shapiro-Wilk test for normality, as well as visual inspection of histograms (data not shown) 
confirmed normal distributions for several peptides in various samples (Table 7.11). Normality 
is inferred from Shapiro-Wilk output when W approaches 1, and p is large (in this case, p>0.2). 
The results of this test directed use of either the r test or non-parametric Wilcoxon rank-sum 
test. Only proteins exhibiting normal distributions in all disease groups were considered for 
analysis by t-test. Three of the 12 proteins exhibited normal distributions in all disease groups, 
and are indicated in bold in Table 7.11. 
TABLE 7.11: SHAPIRO-WILK NORMALITY TEST RESULTS ON INTERNAL REFERENCE-NORMALISED DATA 
Protein 
CTRL MNI HAD 
p W p W p W 
sp|P01023|A2MG 0.1125 0.9047 0.0286 0.8871 0.7556 0.9710 
sp|P08603|CFAH 0.1463 0.9122 0.8268 0.9726 0.5428 0.9613 
sp|P02649|APOE 0.1264 0.9080 0.4268 0.9520 0.0014 0.8208 
sp|P10909|CLUS 0.6704 0.9587 0.8580 0.9743 0.6002 0.9640 
sp|P06396|GELS 0.6906 0.9599 0.0846 0.9132 0.1515 0.9321 
sp|P02743|SAMP 0.6996 0.9604 0.2319 0.9369 0.8062 0.9734 
sp|P02763|A1AG1 0.7404 0.9628 0.0542 0.9026 0.4973 0.9591 
sp|P01009|A1AT 0.0583 0.8860 0.8047 0.9714 0.0907 0.9210 
sp|P02647|APOA1 0.3106 0.9338 0.1241 0.9222 0.0553 0.9102 
sp|P00450|CERU 0.0262 0.8624 0.0138 0.8688 0.0772 0.9175 
sp|P0C0L5|CO4 0.4670 0.9462 0.6185 0.9623 0.2964 0.9468 
sp|P01024|CO3 0.0858 0.8970 0.6924 0.9659 0.9870 0.9864 
Proteins with normally distributed values across all disease groups are indicated in bold. 
Normally distributed values highlighted in grey. 
 
These results facilitated use of the parametric Welch’s t-test (for unequal variances) to 
determine statistical significance of quantitative differences between disease groups for 
peptides with normally distributed values. Only those peptides exhibiting normal distributions 
across all disease groups may be assessed in this way. For remaining peptides with non-
normally distributed values, a non-parametric test of significance – the Wilcoxon rank-sum 
test – is appropriate. Results for both tests are shown, despite the t-test lacking power when 
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applied to non-normally distributed data (Table 7.12). Each between-group comparison was 
conducted: Control vs MNI, MNI vs HAD, and Control vs HAD. Upon implementation of both 
t-tests and Wilcoxon rank-sum tests no proteins were found to exhibit significant differences 
in quantity between disease groups (p > 0.05, Table 7.12). Considering this, it was deemed 
unnecessary for multiple testing correction to be applied to the results of these tests. 
TABLE 7.12: RESULTS FROM WELCH’S T-TEST AND WILCOXON TEST ON INTERNAL REFERENCE-NORMALISED 
DATA 
Protein 
MNI vs CTRL HAD vs MNI HAD vs CTRL 
p W/t p W/t p W/t 
Welch’s t-test 
sp|P01023|A2MG 0.7302 -0.3481 0.8691 -0.1659 0.6294 -0.4871 
sp|P08603|CFAH 0.2705 -1.1245 0.7892 -0.2692 0.1815 -1.3710 
sp|P02649|APOE 0.8947 0.1338 0.7454 0.3271 0.7015 0.3871 
sp|P10909|CLUS 0.4843 -0.7079 0.4883 -0.6999 0.1710 -1.4024 
sp|P06396|GELS 0.8707 -0.1642 0.4593 -0.7477 0.3053 -1.0419 
sp|P02743|SAMP 0.2439 -1.1876 0.9566 -0.0548 0.2711 -1.1187 
sp|P02763|A1AG1 0.6480 -0.4614 0.1989 1.3077 0.5057 0.6740 
sp|P01009|A1AT 0.4126 -0.8302 0.9912 0.0111 0.4021 -0.8489 
sp|P02647|APOA1 0.7638 -0.3032 0.9886 -0.0144 0.7642 -0.3025 
sp|P00450|CERU 0.4048 -0.8454 0.4080 0.8371 0.8864 -0.1442 
sp|P0C0L4/5|CO4 0.3305 -0.9881 0.1815 1.3613 0.6483 0.4602 
sp|P01024|CO3 0.2697 -1.1263 0.8417 -0.2012 0.2084 -1.2867 
Wilcoxon Rank Sum Test 
sp|P01023|A2MG 0.9727 144 0.9147 195 0.6804 144 
sp|P08603|CFAH 0.4505 120 0.8935 194 0.4089 131 
sp|P02649|APOE 0.6074 158 0.3471 235 0.2385 195 
sp|P10909|CLUS 0.6074 127 0.4207 169 0.1698 114 
sp|P06396|GELS 0.8373 149 0.4053 168 0.4461 133 
sp|P02743|SAMP 0.3024 112 0.8935 194 0.3242 126 
sp|P02763|A1AG1 0.8107 135 0.2363 244 0.4461 182 
sp|P01009|A1AT 0.5373 124 0.9147 204 0.6573 143 
sp|P02647|APOA1 0.9183 146 0.6681 216 0.7756 167 
sp|P00450|CERU 0.3538 115 0.0693 267 0.5468 177 
sp|P0C0L4/5|CO4 0.5602 125 0.1607 252 0.4273 183 
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Protein 
MNI vs CTRL HAD vs MNI HAD vs CTRL 
p W/t p W/t p W/t 
sp|P01024|CO3 0.5373 124 0.9786 198 0.4273 132 
Proteins with normally distributed values across all disease groups are indicated in bold. 
 
NANODROP NORMALISED DATA 
Statistical analysis of Nanodrop-normalised data progressed in much the same fashion as that 
for the internal reference-normalised data (vide supra). Results of the Shapiro-Wilk test for 
normality are shown in Table 7.13. Normality was assessed as previously discussed. The results 
of this test also directed use of either the t-test or non-parametric Wilcoxon rank-sum test. 
Only proteins exhibiting normal distributions in all disease groups were considered for analysis 
by t-test. Four of the 12 proteins exhibited normal distributions in all disease groups, and are 
indicated in bold in Table 7.13 
TABLE 7.13: SHAPIRO-WILK NORMALITY TEST RESULTS ON NANODROP-NORMALISED DATA 
Protein 
CTRL MNI HAD 
p W p W p W 
sp|P01023|A2MG 0.9863 0.9831 0.4405 0.9528 0.5437 0.9613 
sp|P08603|CFAH 0.1049 0.9028 0.7409 0.9682 0.7565 0.9711 
sp|P02649|APOE 0.1880 0.9193 0.1239 0.9221 0.0453 0.9058 
sp|P10909|CLUS 0.9213 0.9748 0.9901 0.9863 0.1293 0.9286 
sp|P06396|GELS 0.6215 0.9559 0.0309 0.8890 0.0395 0.9027 
sp|P02743|SAMP 0.9757 0.9810 0.7550 0.9689 0.0546 0.9099 
sp|P02763|A1AG1 0.2183 0.9236 0.7557 0.9690 0.6719 0.9673 
sp|P01009|A1AT 0.1197 0.9065 0.9036 0.9771 0.9779 0.9849 
sp|P02647|APOA1 0.4590 0.9457 0.6921 0.9659 0.0632 0.9131 
sp|P00450|CERU 0.2109 0.9226 0.1410 0.9252 0.1309 0.9289 
sp|P0C0L5|CO4 0.8809 0.9716 0.5064 0.9565 0.2783 0.9454 
sp|P01024|CO3 0.5964 0.9544 0.6729 0.9650 0.3199 0.9486 
Proteins with normally distributed values across all disease groups are indicated in bold. 
Normally distributed values highlighted in grey. 
 
Welch’s t-test was used to measure statistically significant differences between disease 
groups for proteins with normally distributed values, while Wilcoxon rank-sum tests were 
conducted for proteins that do not satisfy the normality criteria in all disease group samples. 
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Results for both tests are shown, despite the t-test lacking power when applied to non-
normally distributed data (Table 7.14). Each between-group comparison was conducted: 
Control vs MNI, MNI vs HAD, and Control vs HAD. Upon implementation of both t-tests and 
Wilcoxon rank-sum tests, no proteins were found to exhibit significant differences in quantity 
between disease groups (p > 0.05, Table 7.14). Considering this, it was deemed unnecessary 
for multiple testing correction to be applied to the results of these tests. 
TABLE 7.14: RESULTS FROM WELCH’S T-TEST AND WILCOXON TEST ON NANODROP-NORMALISED DATA 
Protein 
MNI vs CTRL HAD vs MNI HAD vs CTRL 
p W/t p W/t p W/t 
Welch’s t-test 
sp|P01023|A2MG 0.7375 -0.3382 0.6587 -0.4453 0.4658 -0.7378 
sp|P08603|CFAH 0.2885 -1.0817 0.5731 -0.5685 0.1187 -1.6116 
sp|P02649|APOE 0.9060 0.1191 0.9667 0.0421 0.8790 0.1536 
sp|P10909|CLUS 0.4821 -0.7124 0.3142 -1.0200 0.1199 -1.6025 
sp|P06396|GELS 0.8642 -0.1724 0.2490 -1.1736 0.1497 -1.4795 
sp|P02743|SAMP 0.2964 -1.0622 0.7889 -0.2697 0.2278 -1.2282 
sp|P02763|A1AG1 0.6465 -0.4633 0.3515 0.9437 0.7016 0.3871 
sp|P01009|A1AT 0.4234 -0.8112 0.8107 -0.2413 0.2871 -1.0831 
sp|P02647|APOA1 0.7363 -0.3398 0.7672 -0.2983 0.5156 -0.6577 
sp|P00450|CERU 0.3427 -0.9644 0.6121 0.5114 0.6643 -0.4380 
sp|P0C0L4/5|CO4 0.3920 -0.8679 0.3244 0.9985 0.8962 0.1315 
sp|P01024|CO3 0.2985 -1.0579 0.6498 -0.4577 0.1677 -1.4105 
Wilcoxon Rank Sum Test 
sp|P01023|A2MG 0.6562 129 0.4688 172 0.4654 134 
sp|P08603|CFAH 0.6074 127 0.4053 168 0.1599 113 
sp|P02649|APOE 0.7065 154 0.8513 192 0.4273 183 
sp|P10909|CLUS 0.4505 120 0.2363 155 0.0955 105 
sp|P06396|GELS 0.6316 157 0.0830 135 0.1414 111 
sp|P02743|SAMP 0.3361 114 0.8724 206 0.3567 128 
sp|P02763|A1AG1 0.7321 132 0.5735 221 0.7038 170 
sp|P01009|A1AT 0.4102 118 0.9573 197 0.3087 125 
sp|P02647|APOA1 1.0000 143 0.7479 187 0.7038 145 
sp|P00450|CERU 0.5149 123 0.7888 210 0.6120 141 
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Protein 
MNI vs CTRL HAD vs MNI HAD vs CTRL 
p W/t p W/t p W/t 
sp|P0C0L4/5|CO4 0.5836 126 0.5025 225 0.8992 162 
sp|P01024|CO3 0.4505 120 0.5374 176 0.1908 116 
Proteins with normally distributed values across all disease groups are indicated in bold. 
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7.3.6. Interpretation 
Most mean comparisons (Figure 7.5 - Figure 7.12) - apart from CERU (Figure 7.7), ApoA-I 
(Figure 7.13), GSN (Figure 7.10), and SAP (Figure 7.11) - exhibited similar trends across disease 
groups for both NanoDrop- and internal reference-normalised data. The similar trends 
observed using both normalisation approaches suggests that both methods perform equally 
well and yield similar results.  
Indeed, no significant differences were observed between the biomarker means of any groups 
compared. No significant quantitative difference – as assessed by representative peptide 
intensity - existed between HIV positive-control, MNI, and HAD groups for any of the 12 
biomarkers investigated. This suggests that levels of these serum proteins – individually or in 
combination - are not able to discriminate between HIV positivity and development of HIV-
related neurocognitive decline. Thus, the use of these Alzheimer’s biomarkers cannot be 
extended to identifying MNI or HAD. 
It is possible that systemic HIV infection and resulting systemic inflammatory changes are 
masking any smaller changes in levels of these non-specific inflammatory markers due to 
HAND-related processes. This could only be confirmed by inclusion of matched HIV-negative 
controls, which were not available during the present study. 
Interestingly, the lack of correlation between the present study and previous reports in the 
literature may also reflect the likely very different nature of the cohort studied here. For 
example: Tuberculosis (TB) is endemic to SA with a prevalence of 1.3% in 2013.214 As of 2013, 
an estimated 62% of TB-infected individuals have been found to be HIV-positive.214 Thus, 
analysis of markers that are primarily abundant acute phase proteins may be confounded by 
other co-infections such as TB, further supporting our conclusion that the set of 12 AD markers 
are not applicable to the diagnosis of HAND, particularly in developing countries such as SA. 
Given the satisfactory performance of normalisation and the likely-true observation of no 
significant differences in biomarker levels between disease groups, results for each biomarker 
are placed in biological context below.  
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7.3.6.1. Alpha-2-macroglobulin 
 
A2M functions primarily as an inhibitor of all four protease classes.215 It is able to inhibit such 
a wide array of proteases by irreversibly trapping them, following proteolytic attack of its ‘bait’ 
region, thereby sterically halting their activity.215 The complex is then cleared by binding to 
low-density lipoprotein receptor-related protein (LRP) on Kupffer cells and hepatocytes.216,217 
The study by Simon Lovestone, identifying A2M as a serum marker for AD, showed that its 
levels increase with increasing disease severity.157 Previous studies have implicated A2M in 
reduction of Aβ  aggregates via LRP receptor-mediated clearance in the CNS.218–221 
A study by Liu et al.222 suggests that, during CNS HIV infection, extracellular levels of A2M are 
increased due to competition by HIV-encoded Tat protein for LRP on the neuronal surface. 
Whether this increase in CNS levels of A2M is detectible in the serum compartment was not 
addressed by Liu et al.222 The present study found no statistically significant correlation 
between serum A2M levels and neurocognitive impairment (Table 7.12, Table 7.14, and Figure 
7.5).  
FIGURE 7.5: BAR GRAPHS COMPARING MEANS OF ALPHA-2-MACROGLOBULIN REPRESENTATIVE PEPTIDES 
ACROSS DISEASE GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD 
ERROR OF THE MEAN. A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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7.3.6.2. Clusterin 
 
CLU is a ubiquitously expressed mammalian glycoprotein found in a diverse array of tissues 
and biological fluids, including blood plasma.223 Although its main function has not been 
definitively identified, a crucial function is its ability to act as a chaperone that binds misfolded 
or stressed proteins for presentation to other proteins able to resolve misfolding, such as heat 
shock proteins.224,225  
This hypothesis is consistent with studies by Simon Lovestone which identify CLU as a serum 
marker for AD, showing an increase in levels of this protein with increasing cognitive decline 
and brain atrophy.154,155 
Increased levels of CLU have been found post-mortem in brains of HIV-positive patients, and 
in this setting it was hypothesised to serve a role in astrocyte protection.226 Rozek et al.78, 
however, observed a decrease in levels of CSF-localised CLU with increasing HAND severity. 
This apparent contradiction could be attributable to localisation of CLU at sites of astrocyte 
stress. The present study was unable to find any statistically significant correlation between 
serum CLU levels and neurocognitive impairment (Table 7.12, Table 7.14, and Figure 7.6); 
although there appears to be a reduction in serum CLU concentration as HAND severity 
increases (Figure 7.6), in line with Rozek et al.78, and in contrast to findings in AD. 
FIGURE 7.6: BAR GRAPHS COMPARING MEANS OF CLUSTERIN REPRESENTATIVE PEPTIDES ACROSS DISEASE 
GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR OF THE MEAN. 
A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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7.3.6.3. Ceruloplasmin 
 
CERU is a copper-containing protein that functions primarily in oxidation of Fe2+ to Fe3+, 
without concomitant release of reactive oxygen species, in order to facilitate Fe3+ binding to 
plasma transferrin.227–229 CERU is also able to facilitate iron efflux from cells as a result of cross-
membrane Fe2+ gradient modification when extracellular Fe2+ is oxidised and bound to 
transferrin.230 Of particular interest in the context of inflammatory disorders, CERU has also 
exhibited antioxidant abilities, and is regarded as an acute phase protein due to increase in 
serum levels during infection.231–233 
Simon Lovestone identified a decrease in plasma CERU as a marker of AD.157 Kessler et al.234 
confirmed these findings, measuring a significant decrease in CERU and copper levels between 
control and AD patients in both plasma and CSF.  
Rozek et al.79 detected a significant increase in serum CERU in HAD patients when compared 
to HIV-positive controls. Identification of differentially expressed proteins were conducted by 
LC-MS/MS, following abundant protein depletion and separation by 2-dimensional gel 
electrophoresis.79 Differential expression of CERU was validated by Western blot analysis. The 
present study, however, was unable to detect any significant differences in CERU levels across 
disease groups (Table 7.12, Table 7.14, and Figure 7.7); although the trend appears to be lower 
levels in HAND compared to controls, consistent with findings in AD and in contrast to Rozek 
et al.79 
FIGURE 7.7: BAR GRAPHS COMPARING MEANS OF CERULOPLASMIN REPRESENTATIVE PEPTIDES ACROSS DISEASE 
GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR OF THE MEAN. 
A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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7.3.6.4. Alpha-1-antitrypsin 
 
A1AT is the most abundant plasma protease inhibitor in human serum.235 Its primary substrate 
is neutrophil elastase, although it does possess minor specificity for trypsin and neutrophil 
Cathepsin G.235,236 Being an acute phase reactant, it is primarily involved in control of 
neutrophil-mediated tissue damage in acute inflammation.233,237 A1AT is unable to completely 
disrupt neutrophil-mediated tissue damage at inflammatory foci, since reactive oxygen 
species released by neutrophils and other innate inflammatory cells oxidise the methionine 
residue at the A1AT active site, and thereby render the protease inhibitor less active.236,238,239 
This interplay allows for controlled inflammatory processes at the site of infection, but 
prevents widespread tissue damage.  
Simon Lovestone identified an increase in plasma A1AT as a marker of AD severity.154 Studies 
by Nielson et al.240 and Sun et al.241 support this finding. 
A1AT has been implicated in the inhibition of both initial HIV entry and viral replication.242,243 
A study by Bryan et al.244 found a significant decrease in plasma A1AT in HIV positive patients 
when compared to uninfected controls. Ferreira et al.245 recently assessed the incidence of 
genetic A1AT deficiency in HIV positive and negative subjects, where it was observed that 
deleterious A1AT mutations were correlated with HIV positive status, and may in fact serve to 
increase susceptibility to HIV infection. This may explain the low levels of plasma A1AT 
previously found in HIV positive subjects.244  
FIGURE 7.8: BAR GRAPHS COMPARING MEANS OF ALPHA-1-ANTITRYPSIN REPRESENTATIVE PEPTIDES ACROSS 
DISEASE GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR OF THE 
MEAN. A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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The present study was unable to assess the effect of HIV on serum levels of A1AT due to lack 
of uninfected controls. There was no detectible correlation between serum A1AT levels and 
neurocognitive impairment (Table 7.12, Table 7.14, and Figure 7.8), although there does 
appear to be a trend of decreasing A1AT with increase in HAND severity. 
7.3.6.5. Alpha-1-acid glycoprotein 
 
A1AG, also known as Orosomucoid, is a plasma transport protein, primarily responsible for 
transport of basic and neutral drugs.246,247 It is also a positive acute phase protein, with 
increased plasma levels observed during inflammation.233,246  
Simon Lovestone observed a decrease in plasma A1AG in AD, which both predicted 
progression to dementia, as well indicated the degree of cognitive decline.154 
As a result of its acute phase induction, serum levels of A1AG are elevated in HIV positive 
individuals.248 No experimental evidence of A1AG differential regulation in relation to severity 
of HAND was found in the literature. Results of the present study showed no change in serum 
A1AG levels with increasing HAND severity (Table 7.12, Table 7.14, and Figure 7.9). Indeed, 
this agrees with the biological role of A1AG in context of HIV, wherein serum levels of this 
protein may have changed in relation to systemic infection.  
 
FIGURE 7.9: BAR GRAPHS COMPARING MEANS OF ALPHA-1-ACID GLYCOPROTEIN REPRESENTATIVE PEPTIDES 
ACROSS DISEASE GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR 
OF THE MEAN. A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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7.3.6.6. Gelsolin 
 
 
 
 
 
 
 
 
 
GSN functions primarily as a regulator of actin remodelling.249,250 It is involved in cell motility, 
apoptosis, and regulation of structural aspects of the cell.250–252 GSN functions to sever actin 
polymers, cap them to prevent polymerisation, as well as control nucleation of actin 
assembly.250,253–255 It is positively regulated by calcium ion binding, and inhibited by 
polyphosphoinositide 4,5-bisphosphate (PIP2).249,250,256–258 The plasma variant of GSN acts as 
an actin scavenger, collecting actin fragments generated from damaged tissue before they can 
damage blood capillaries and cause unwanted clot formation.259–262 
Simon Lovestone observed a decrease in plasma GSN correlating with progression of cognitive 
decline to AD.158 Studies have suggested a protective role by GSN in AD by inhibition of Aβ 
fibril formation and protection against apoptosis.263–266 
Studies have suggested a protective effect of GSN against excitotoxic damage in neurons, by 
means of actin depolymerisation and Ca2+ stabilisation.267,268 Indeed, excitotoxic damage by 
excessive extracellular CNS glutamate levels is a proposed mechanism by which HIV causes 
neuronal apoptosis.269 Liu et al.270 also proposed a mechanism of GSN-mediated inhibition of 
neuronal apoptosis that involved modulation of K+ exit from K+ channels in response to gp120-
mediated upregulation.  
Rozek et al.78 reported a decrease in CSF levels of GSN in patients with HAND. This is consistent 
with studies showing reduction in circulating gelsolin in individuals presenting with systemic 
FIGURE 7.10: BAR GRAPHS COMPARING MEANS OF GELSOLIN REPRESENTATIVE PEPTIDES ACROSS DISEASE 
GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR OF THE MEAN. 
A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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and CNS inflammatory pathologies.271,272 The NanoDrop-normalised data (Figure 7.10-B) does 
show a trend of decreasing GSN with increasing HAND severity, despite this trend not being 
mirrored by the IR-normalised data (Figure 7.10-A). It is possible that CNS-inflammation may 
cause a decrease in circulating GSN as seen in AD, HAND, and CNS inflammation. This trend 
would have to be confirmed due to the disparity between differentially-normalised data, as 
well as the lack of statistical significance. Despite any perceivable trend, the present study was 
unable to detect a significant change in GSN levels with increasing HAND severity (Table 7.12, 
Table 7.14, and Figure 7.10).  
7.3.6.7. Serum amyloid P 
 
SAP is a calcium-dependent DNA-binding protein found in human blood serum.273 It is 
primarily responsible for regulation of DNA degradation, and thereby prevents production of 
antibodies against ‘self’ DNA.274,275 It has been implicated in amyloidosis, the aggregation of 
insoluble plaques in systemic tissues, where it may impart resistance to degradation.276–278 
AD, being a form of amyloidosis, is the result of accumulation of Aβ proteins that form 
insoluble plaques.279 It has been found that SAP does in fact constitute a portion of AD plaques 
and neurofibrillary tangles, and is also responsible for resistance to degradation in this 
setting.278,280,281 Not surprisingly, Simon Lovestone observed an increase in circulating SAP 
correlating with increase in AD-related brain atrophy.159 
Studies have detected the presence of Aβ plaques in brains of HIV patients, alluding to possible 
similarities between HAND and AD pathogeneses.152,153,282 From the presence of SAP in Aβ 
FIGURE 7.11: BAR GRAPHS COMPARING MEANS OF SERUM AMYLOID P REPRESENTATIVE PEPTIDES ACROSS 
DISEASE GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR OF THE 
MEAN. A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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plaques found in AD, it would be reasonable to assume that SAP levels would indeed increase 
in HAND. The present study, however, did not detect a significant change in SAP level with 
increasing HAND severity (Table 7.12, Table 7.14, and Figure 7.11). Despite the lack of 
statistical significance, there appeared to be a decrease in SAP in HAND compared with the 
control (Figure 7.11), in contrast with the expected trend.  
7.3.6.8. Apolipoprotein E 
 
ApoE is a multifunctional variant of the apolipoprotein family, which comprise integral protein 
constituents of lipoproteins.283 Lipoproteins are integral to lipid transport and 
metabolism.283,284 ApoE has many functions, including: maintaining the structural integrity and 
solubility of very low density lipoproteins (VLDL), chylomicrons, and ApoE-containing high 
density lipoproteins (HDLc) in human blood plasma, and acting as a ligand for low density 
lipoprotein receptor-mediated tissue internalisation of HDLc and VLDL.284,285 ApoE has several 
variants: E2, E3, and E4; which are expressed by their respective alleles: ε2, ε3, and ε4.286,287 
Expression of different ApoE variants results in variable dietary lipid clearance, with E4 being 
the most efficient and E2 being the least.288 This variability has a direct effect on lipid levels in 
blood plasma.288 
In studies by Simon Lovestone, there were observed increases in plasma ApoE correlating with 
both increases in AD-related brain atrophy, as well as higher amounts of brain-localised Aβ in 
non-demented persons.154,156 Additionally, an increase in plasma levels of ApoE was observed 
to predict cognitive decline to AD.154 
FIGURE 7.12: BAR GRAPHS COMPARING MEANS OF APOLIPOPROTEIN E REPRESENTATIVE PEPTIDES ACROSS 
DISEASE GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR OF THE 
MEAN. A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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The ApoE ε4 allele is believed to heavily influence severity of AD, whereas studies conflict as 
to the effect of this mutation on severity of HAND.289–292 The study by Joska et al.171, from 
which the samples in the present study originate, shows no correlation between ApoE allele 
status and HAND severity in this South African cohort. 
In contrast to the ApoE allele, levels of plasma ApoE protein have not been widely assessed in 
the literature. Generally, the ApoE ε4 allele results in decreased circulating ApoE, whereas the 
converse is true for ApoE ε2.293 Regardless, the present study was not able to detect a 
significant correlation between serum ApoE protein levels and HAND disease severity (Table 
7.12, Table 7.14, and Figure 7.12). This may be explained by the lack of ApoE allele correlation 
with HAND-severity in this cohort.171 
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7.3.6.9. Apolipoprotein A-I 
 
ApoA-I is also a member of the apolipoprotein family, and is a structural element in HDL and 
chylomicrons.284 It is also a cofactor for the enzyme lecithin:cholesterol acyltransferase, which 
catalyses the conversion of HDL-localised cholesterol and lecithin to cholesteryl ester and 
lysolecithin.294–296 
Simon Lovestone observed increases in plasma ApoA-I correlating with an increase in AD-
related brain atrophy.154 
Decreased plasma ApoA-I levels have been observed in HIV-positive patients independent of 
HAART status.297–299 The antiretroviral drug nevirapine has been found to increase ApoA-I 
levels in HIV-infected individuals, whereas protease inhibitors decrease levels of this 
protein.297–302 This, however, is not applicable to the cohort used in the present study, as it 
consists of HAART-naïve patients.170 To the best of our knowledge, there are no studies 
assessing the levels of plasma ApoA-I in HAND. The present study was not able to detect a 
significant correlation between serum ApoA-I protein levels and HAND disease severity (Table 
7.12, Table 7.14, and Figure 7.13); although the trend appears to be lower levels in HAND 
compared to controls, in contrast to findings in AD. 
 
  
FIGURE 7.13: BAR GRAPHS COMPARING MEANS OF APOLIPOPROTEIN A-I REPRESENTATIVE PEPTIDES ACROSS 
DISEASE GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR OF THE 
MEAN. A: IR NORMALISED, B: NANODROP NORMALISED 
A B 
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7.3.6.10. Complement components 3, 4, and Factor H 
 
FIGURE 7.14: BAR GRAPHS COMPARING MEANS OF COMPLEMENT PROTEIN REPRESENTATIVE PEPTIDES ACROSS 
DISEASE GROUPS, USING BOTH NORMALISATION METHODS. ERROR BARS REPRESENT STANDARD ERROR OF THE 
MEAN. A.1: IR NORMALISED COMPLEMENT C3, A.2: NANODROP NORMALISED COMPLEMENT C3; B.1: IR 
NORMALISED COMPLEMENT C4, B.2: NANODROP NORMALISED COMPLEMENT C4; C.1: IR NORMALISED 
COMPLEMENT FACTOR H, C.2: NANODROP NORMALISED COMPLEMENT FACTOR H 
A.1 A.2 
B.1 B.2 
C.1 C.2 
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The complement system is a cascade-driven innate immunological response which results in 
pathogen and abnormal cell clearance.303 It may be activated via three pathways: the classical 
pathway is initiated by C-reactive protein or antigen-antibody complexes, the alternative 
pathway is activated by microbial surface macromolecules (e.g. lipopolysaccharides), and the 
lectin pathway is activated by lectins binding to carbohydrates on pathogen surfaces.303,304 
These pathways converge on activation of C3 convertase, which in turn cleaves C3 to C3a and 
the opsonin C3b, the main complement effectors.303  
Amplification cascades produce a large number of complement proteins, which ultimately 
result in four possible effects: opsonisation of pathogens for phagocytic engulfment, antibody 
production, chemotactic attraction of immune effector cells,  and the formation of a lytic 
membrane attack complex in target cells or pathogens.303,304 C3 is central to the cascade 
originating from all pathways, but is also constitutively cleaved in plasma to produce low levels 
of C3b in order to initiate the alternative pathway under the correct circumstances.303 
Component C4 is involved in the early activation of the classical and lectin pathways, as well 
as in chemotactic attraction.303 CFH is a major regulatory protein which protects host cells 
from complement activation, by binding preferentially to C3b on the host cell membrane.303 
This affinity for C3b is not applicable when it (C3b) is bound to bacterial cells.303  
A recent study suggests a role for C3 activation by NFκB in dendrite degeneration in the CNS, 
and therefore to cognitive decline during AD.305 Classical complement proteins, including C3d 
and C4d, were also found in senile plaques, suggesting a role for the innate immune response 
in AD-related neuropathy.306,307 Studies by Simon Lovestone, identifying C4 as a serum marker 
for AD, suggest a predictive role based on reduced levels of this protein in minor 
neurocognitive impairment.154,157 Increase in C3 and factor H have also been correlated with 
increasing disease severity.157,159 
HIV is able to subvert complement-mediated lysis, both by expression of surface proteins that 
regulate complement activity, and binding of CFH.308–310 Interestingly, HIV has also been 
observed to utilise complement to gain entry into target cells via complement receptor 
binding.311,312 Indeed, levels of C3 and C4 would be expected to increase in HIV infection 
considering their roles as positive acute phase proteins.233 In the CNS, HIV is able to upregulate 
expression of complement proteins, and thus potentiate infection.313,314 Thus, an 
inflammatory or HIV-related increase in complement proteins may be expected, both in the 
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CNS and in systemic circulation. Indeed, upregulation of complement proteins in the CNS of 
HAND patients has been observed in analysis of CSF levels of C3 and C4.315  
Rozek et al.78, however, observed significantly decreased C3 levels in CSF of individuals with 
HAD relative to non-demented individuals. Levels of C3 in serum were also observed to be 
lower in sera of HAD patients.79 These conflicting observations highlight the need for a 
comprehensive study on the effect of HAND on serum and CSF levels of complement factors. 
The present study was not able to detect a significant correlation between serum levels of C3, 
C4, or CFH and HAND disease severity (Table 7.12, Table 7.14, and Figure 7.14). Despite the 
lack of statistical significance, there appear to be potential decreases in CFH and C3 in HAND 
when compared with the controls (i.e.: Control vs MNI, Control vs HAD), in contrast to the 
trend observed in AD. Indeed, the observed decrease in C3 is in agreement with Rozek et al.79 
Regardless, lack of statistical significance renders these observations invalid. Further study is 
required to confirm changes in serum and CSF levels of these proteins in HAND. 
7.4. Conclusions and Future Prospects 
The present study has shown no significant effect of HAND on serum levels of the assessed 
markers. The possible lack of sufficient distinction between disease groupings, due to possible 
opportunistic infections or influence of systemic HIV infection, may have reduced the ability 
to discern applicable molecular differences. Regardless, results of the present study indicate 
that the primary hypothesis, that a candidate panel of AD biomarkers may also be applicable 
to the diagnosis of HAND, should be rejected.  
It is recommended that a repeat study be conducted to confirm the findings, and address 
identified shortcomings of the present study. Modifications to future protocols should 
include: an appropriate internal reference protein spiked into all samples prior to processing, 
a more consistent method of abundant protein depletion such as MARS, and a higher starting 
amount of protein which would yield sufficient sample for peptide quantitation and 
normalisation prior to mass spectrometric analysis. Analysis of post-translational 
modifications, such as phosphorylation and acetylation, should also be considered to assess 
changes in protein pathway dynamics that cannot be inferred directly from protein 
expression. This approach would require enrichment strategies at the peptide level to allow 
for reliable quantitation. Stratification by TB status, and exclusion of patients with other 
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opportunistic infections, should also be conducted to control for confounding effects on 
serum markers. Analysis of patient-matched cerebrospinal fluid samples would also lend 
credence to conclusions drawn from the serum analysis.  
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Chapter 8  
Appendix A: Sample Preparation 
 
 
TABLE 8.1: TABLE OF SERUM BATCHING AND DILUTIONS FOR MASS SPECTROMETRY ANALYSIS (FINAL 
CONCENTRATION: 1.53 µG/µL) 
Batch Group Samples 
Concentration 
(µg/µl) 
23 µg in 15 µl 
(1.53 µg/µl) 
Volume of 
Diluent 
 (23 µg) 
B
A
TC
H
 1
 
N J061 116 7 493 
N J200 100 8 492 
N J0223 100 8 492 
M J0179 105 7 493 
M J027 120 6 494 
M J0209 101 8 492 
H J010 77 10 490 
H J0149 91 8 492 
H J0104 68 11 489 
B
A
TC
H
 2
 
N J087 72 11 489 
N J204 100 8 492 
N J031 73 10 490 
M J056 91 8 492 
M J0193 73 10 490 
M J0146 85 9 491 
H J0229 108 7 493 
H J0166 73 11 489 
H J030 131 6 494 
B
A
TC
H
 3
 
N J032 80 10 490 
N J0213 69 11 489 
N J0231 131 6 494 
M J0156 122 6 494 
M J040 90 9 491 
M J0125 78 10 490 
H J025  73 11 489 
H J206 97 8 492 
161 
 
Batch Group Samples 
Concentration 
(µg/µl) 
23 µg in 15 µl 
(1.53 µg/µl) 
Volume of 
Diluent 
 (23 µg) 
H J0126 120 6 494 
B
A
TC
H
 4
 
N J180 83 9 491 
N J0203 70 11 489 
N J067 92 8 492 
M J0137 95 8 492 
M J0214 104 7 493 
M J063 105 7 493 
H J0148 96 8 492 
H J038 126 6 494 
H J0130 84 9 491 
B
A
TC
H
 5
 
N J009 89 9 491 
N J081 96 8 492 
N J059 127 6 494 
M J020 77 10 490 
M J0136 86 9 491 
M J029 90 8 492 
H J004 74 10 490 
H J097 132 6 494 
H J0172 80 10 490 
B
A
TC
H
 6
 
N J0224 98 8 492 
N J142 92 8 492 
N J0260 81 9 491 
M J043 72 11 489 
M J0167 89 9 491 
M J003 110 7 493 
H J0147 87 9 491 
H J050 112 7 493 
H J0236 87 9 491 
B
A
TC
H
 7
 
N J026 91 8 492 
N J0135 86 9 491 
N J035 81 9 491 
M J0152 98 8 492 
M J079 131 6 494 
M J0201 106 7 493 
H J005 94 8 492 
162 
 
Batch Group Samples 
Concentration 
(µg/µl) 
23 µg in 15 µl 
(1.53 µg/µl) 
Volume of 
Diluent 
 (23 µg) 
H J225 108 7 493 
H J0198 77 10 490 
B
A
TC
H
 8
 
N J068 82 9 491 
N J237 95 8 492 
N J0215 87 9 491 
M J0183 86 9 491 
M J047 104 7 493 
M J074 94 8 492 
H J016 90 9 491 
H J0132 102 7 493 
H J024 84 9 491 
B
A
TC
H
 9
 
N J0176 92 8 492 
N J0233 95 8 492 
N J0210 87 9 491 
N J0239 126 6 494 
M J0207 99 8 492 
M J036 90 8 492 
H J0106 90 8 492 
H J202 106 7 493 
H J216 117 7 493 
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(a) Batch 1 (b) Batch 2 (c) Batch 3 
(d) Batch 4 (e) Batch 5 (f) Batch 6 
(g) Batch 7 (h) Batch 8 (i) Batch 9 
FIGURE 8.1: FIGURE SHOWING IMAGES OF SDS-PAGE GELS STAINED WITH ZINC-IMIDAZOLE REVERSIBLE 
STAIN. GEL PHOTOGRAPHED AGAINST A DARK BACKGROUND. CLEAR PROTEIN BANDS APPEAR DARK. 
FIGURE 8.2: SCHEMATIC OF THERMO-
PIERCE SPIN COLUMN FOR C18-BASED 
SAMPLE CLEAN-UP 
164 
 
Chapter 9  
Appendix B: Optimisation A 
 
TABLE 9.1: MAXQUANT SETTINGS FOR SHOTGUN PROTEOMIC ANALYSIS OF POOLED SAMPLES 
Group-specific parameters 
Variable Mods Oxidation (M) Acetyl (Protein N-term) 
Multiplicity 1 
Enzyme Trypsin/P 
First search ppm 20 
Main search ppm 6 
Max number of  modifications per peptide 5 
Max. missed cleavages 2 
Max. charge 7 
Individual peptide mass tolerances yes 
Type Standard 
MS/MS Settings 
Mass Analyser 
MS/MS 
tolerance Unit 
Top peaks 
per 100 Da 
De-
isotoping 
Higher 
charge 
Water 
loss 
Ammonia 
loss 
Dependent 
loss 
FTMS 20 ppm 10 yes yes yes yes yes 
ITMS 0.5 Da 6 no yes yes yes yes 
TOF 0.1 Da 10 yes yes yes yes yes 
Unknown 0.5 Da 6 no yes yes yes yes 
Sequences 
Include contaminants yes 
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FASTA file Reverse 
Special Aas KR 
I=L yes 
Fixed modifications 
Fixed Mods Carbamidomethyl (C) 
Identification 
Peptide FDR 0.01 
Protein FDR 0.01 
Site FDR 0.01 
Apply site FDR separately yes 
Max. peptide PEP 1 
Min. peptide length 7 
Min. peptides 1 
Min. score 0 
Min. razor + unique peptides 1 
Filter labelled amino acids no 
Min. unique peptides no 
Second peptides yes 
Protein Quantitation 
Use only unmodified peptides and… Oxidation (M) Acetyl (Protein N-term) 
Use razor and unique peptides yes 
Discard unmodified counterpart peptides yes 
Min. ratio count 2 
Site quantitation 
Mode Use least modified peptides 
Use for occupancies Normalised ratios 
Miscellaneous 
Re-quantify yes 
Keep low-scoring versions of identified peptides No 
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Match between runs no 
Label-free quantitation yes 
LFQ min. ratio count 2 
Fast LFQ yes 
iBAQ yes 
Log fit yes 
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TABLE 9.2: TABLE OF DISCOVERY PROTEIN IDS FROM POOLED ANALYSIS. LEADING PROTEINS OF EACH GROUP ARE 
SHOWN FOR SIMPLICITY. PEP: POSTERIOR ERROR PROBABILITY 
# Protein ID Protein name Peptides 
Sequence 
coverage 
[%] 
PEP 
1 P43652 Afamin 2 3.5 0.00018149 
2 P02763 Alpha-1-acid glycoprotein 1 2 10.9 5.59E-15 
3 G3V5I3 Alpha-1-antichymotrypsin 9 23.4 4.65E-268 
4 P01009 Alpha-1-antitrypsin 18 47.8 0 
5 P04217 Alpha-1B-glycoprotein 7 18 2.66E-37 
6 C9JV77 Alpha-2-HS-glycoprotein 2 4.6 1.21E-08 
7 P01023 Alpha-2-macroglobulin 58 51.8 0 
8 P01019 Angiotensinogen 5 14.6 7.75E-50 
9 P01008 Antithrombin-III 4 10.3 7.02E-42 
10 P02647 Apolipoprotein A-I 12 48.3 0 
11 P02652 Apolipoprotein A-II 3 39 2.15E-27 
12 P06727 Apolipoprotein A-IV 9 26.5 1.01E-29 
13 P04114 Apolipoprotein B-100 127 34.1 0 
14 B0YIW2 Apolipoprotein C-III 1 13.7 4.50E-06 
15 P02649 Apolipoprotein E 7 27.8 0 
16 O14791-2 Apolipoprotein L1 2 5.6 3.08E-06 
17 P08519 Apolipoprotein(a) 2 8.6 2.71E-07 
18 O75882 Attractin 3 2.9 3.86E-06 
19 P02749 Beta-2-glycoprotein 1 5 22.3 6.55E-49 
20 Q9Y2P5 Bile acyl-CoA synthetase 1 2.6 0.043381 
21 P04003 C4b-binding protein alpha chain 10 19.1 2.61E-38 
22 Q9H257 Caspase recruitment domain-containing protein 9 1 2.2 0.0017862 
23 O43866 CD5 antigen-like 6 21.6 6.77E-114 
24 P00450 Ceruloplasmin 22 24.7 0 
25 P10909-2 Clusterin 7 19.4 8.77E-61 
26 P00748 Coagulation factor XII 3 5.7 7.31E-06 
27 P02747 Complement C1q subcomponent subunit C 4 21.2 2.92E-33 
28 P00736 Complement C1r subcomponent 4 8.1 2.73E-15 
29 P09871 Complement C1s subcomponent 2 4.2 0.00036161 
30 P01024 Complement C3 75 49.2 0 
31 P0C0L4 Complement C4-A 45 32.9 0 
32 P0C0L5 Complement C4-B 43 30.4 0 
33 P01031 Complement C5 20 13.5 3.97E-79 
34 P13671 Complement component C6 6 8.2 3.33E-90 
35 P10643 Complement component C7 3 4.9 3.97E-37 
36 P07357 Complement component C8 alpha chain 2 5.8 9.02E-09 
37 P07360 Complement component C8 gamma chain 1 7.4 0.0013995 
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# Protein ID Protein name Peptides 
Sequence 
coverage 
[%] 
PEP 
38 P02748 Complement component C9 8 15.9 1.19E-18 
39 B4E1Z4 Complement factor B 21 18.4 1.60E-89 
40 P08603 Complement factor H 21 24.1 6.41E-130 
41 E7ETH0 Complement factor I 3 6.1 1.40E-05 
42 P08185 Corticosteroid-binding globulin 3 8.4 1.88E-05 
43 P81605-2 Dermcidin 2 18.2 6.23E-05 
44 O75150 E3 ubiquitin-protein ligase BRE1B 1 1.1 0.00015515 
45 Q99814 Endothelial PAS domain-containing protein 1 1 1.8 0.014815 
46 Q8IWU5 Extracellular sulfatase Sulf-2 1 1.7 0.037666 
47 C9JC84 Fibrinogen gamma chain 1 2.6 0.0018074 
48 P02751 Fibronectin 29 17.9 1.07E-262 
49 Q08380 Galectin-3-binding protein 2 4.6 7.29E-06 
50 P06396 Gelsolin 10 19.1 3.50E-48 
51 P00738 Haptoglobin 24 47 0 
52 P00739-2 Haptoglobin-related protein 16 27 2.09E-188 
53 P68871 Hemoglobin subunit beta 5 40.1 1.93E-11 
54 P02790 Hemopexin 9 26 1.05E-149 
55 P05546 Heparin cofactor 2 7 14.8 6.68E-18 
56 P04196 Histidine-rich glycoprotein 4 10.1 8.43E-17 
57 P01876 Ig alpha-1 chain C region 10 39.4 0 
58 P01877 Ig alpha-2 chain C region 7 27.9 7.41E-250 
59 P01880-2 Ig delta chain C region 3 8.4 2.43E-08 
60 P01857 Ig gamma-1 chain C region 15 54.8 0 
61 P01859 Ig gamma-2 chain C region 11 39.3 7.01E-246 
62 P01860 Ig gamma-3 chain C region 13 45.9 0 
63 P01861 Ig gamma-4 chain C region 10 40.7 0 
64 P01743 Ig heavy chain V-I region HG3 2 22.2 1.47E-38 
65 P06326 Ig heavy chain V-I region Mot 1 9.6 0 
66 P06331 Ig heavy chain V-II region ARH-77 2 17.1 7.80E-129 
67 P01825 Ig heavy chain V-II region NEWM 2 24.8 5.08E-130 
68 P04438 Ig heavy chain V-II region SESS 1 4.8 2.05E-07 
69 P01824 Ig heavy chain V-II region WAH 3 22.5 2.00E-05 
70 P01766 Ig heavy chain V-III region BRO 2 25 3.31E-232 
71 P01773 Ig heavy chain V-III region BUR 1 9.2 0.00026232 
72 P01767 Ig heavy chain V-III region BUT 2 26.1 1.95E-85 
73 P01781 Ig heavy chain V-III region GAL 4 40.5 1.11E-24 
74 P80419 Ig heavy chain V-III region GAR 1 16.1 0.00048591 
75 P01771 Ig heavy chain V-III region HIL 1 9.1 9.41E-05 
76 P01780 Ig heavy chain V-III region JON 2 16.5 3.82E-05 
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# Protein ID Protein name Peptides 
Sequence 
coverage 
[%] 
PEP 
77 P01772 Ig heavy chain V-III region KOL 1 12.7 3.07E-07 
78 P01765 Ig heavy chain V-III region TIL 2 26.1 5.48E-145 
79 P01764 Ig heavy chain V-III region VH26 2 18.8 6.61E-17 
80 P01834 Ig kappa chain C region 6 80.2 0 
81 P01594 Ig kappa chain V-I region AU 2 31.5 9.49E-85 
82 P04430 Ig kappa chain V-I region BAN 1 16.7 2.13E-40 
83 P01597 Ig kappa chain V-I region DEE 2 10.2 1.38E-06 
84 P01598 Ig kappa chain V-I region EU 3 31.5 1.79E-117 
85 P01601 Ig kappa chain V-I region HK101 1 13.7 2.54E-20 
86 P01602 Ig kappa chain V-I region HK102 3 29.1 2.04E-78 
87 P01604 Ig kappa chain V-I region Kue 1 10.2 0.00021108 
88 P01613 Ig kappa chain V-I region Ni 2 30.4 5.37E-78 
89 P01608 Ig kappa chain V-I region Roy 2 24.1 1.22E-80 
90 P01609 Ig kappa chain V-I region Scw 3 42.6 2.88E-88 
91 P01610 Ig kappa chain V-I region WEA 2 30.6 6.55E-115 
92 P01611 Ig kappa chain V-I region Wes 2 31.5 1.57E-43 
93 P06309 Ig kappa chain V-II region GM607 2 31.6 1.06E-62 
94 P01619 Ig kappa chain V-III region B6 2 21.3 9.20E-09 
95 P04207 Ig kappa chain V-III region CLL 4 36.4 3.72E-20 
96 P04206 Ig kappa chain V-III region GOL 5 63.3 0 
97 P18135 Ig kappa chain V-III region HAH 5 41.9 3.63E-178 
98 P06311 Ig kappa chain V-III region IARC/BL41 2 24.2 2.82E-63 
99 P01621 Ig kappa chain V-III region NG9 5 54 1.13E-31 
100 P01620 Ig kappa chain V-III region SIE 6 66.1 0 
101 P04433 Ig kappa chain V-III region VG 3 27 9.72E-29 
102 P01623 Ig kappa chain V-III region WOL 5 60.6 0 
103 P06313 Ig kappa chain V-IV region JI 4 27.1 5.03E-42 
104 P01625 Ig kappa chain V-IV region Len 4 36.8 1.42E-101 
105 P04211 Ig lambda chain V region 4A 2 15.4 0.00078687 
106 P06316 Ig lambda chain V-I region BL2 1 6.2 5.02E-11 
107 P01701 Ig lambda chain V-I region NEW 3 34.2 4.41E-10 
108 P01703 Ig lambda chain V-I region NEWM 1 16.5 2.82E-05 
109 P01699 Ig lambda chain V-I region VOR 2 23.4 2.01E-09 
110 P04208 Ig lambda chain V-I region WAH 2 27.5 8.69E-32 
111 P80748 Ig lambda chain V-III region LOI 3 37.8 0 
112 P01714 Ig lambda chain V-III region SH 2 25 7.50E-56 
113 P01717 Ig lambda chain V-IV region Hil 1 17.8 1.47E-55 
114 P06319 Ig lambda chain V-VI region EB4 1 15.3 1.58E-20 
115 P0CG05 Ig lambda-2 chain C regions 5 74.5 0 
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# Protein ID Protein name Peptides 
Sequence 
coverage 
[%] 
PEP 
116 P01871-2 Ig mu chain C region 16 36.6 0 
117 P01591 Immunoglobulin J chain 4 26.4 5.34E-18 
118 B9A064 Immunoglobulin lambda-like polypeptide 5 5 36 0 
119 P35858-2 
Insulin-like growth factor-binding protein 
complex acid labile subunit 
3 7 2.37E-06 
120 P19827 Inter-alpha-trypsin inhibitor heavy chain H1 10 14.5 1.26E-47 
121 P19823 Inter-alpha-trypsin inhibitor heavy chain H2 14 18.2 2.61E-122 
122 Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 2 2.8 2.62E-07 
123 B7ZKJ8 Inter-alpha-trypsin inhibitor heavy chain H4 14 17.2 0 
124 CON__Q15323 Keratin, type I cuticular Ha1 5 11.3 6.43E-18 
125 CON__Q14525 Keratin, type I cuticular Ha3-II 5 10.6 2.33E-15 
126 CON__P13645 Keratin, type I cytoskeletal 10 21 35.8 0 
127 CON__P02533 Keratin, type I cytoskeletal 14 12 30.5 2.76E-39 
128 CON__P08779 Keratin, type I cytoskeletal 16 12 27.7 1.76E-45 
129 CON__P35527 Keratin, type I cytoskeletal 9 21 50.4 0 
130 CON__Q9NSB4 Keratin, type II cuticular Hb2 1 1.9 3.28E-07 
131 CON__P78385 Keratin, type II cuticular Hb3 3 5.5 7.06E-12 
132 CON__P04264 Keratin, type II cytoskeletal 1 27 44.1 0 
133 CON__P35908 Keratin, type II cytoskeletal 2 epidermal 16 28.8 0 
134 CON__P13647 Keratin, type II cytoskeletal 5 12 21.2 1.89E-65 
135 CON__P02538 Keratin, type II cytoskeletal 6A 13 24.5 4.14E-67 
136 P04259 Keratin, type II cytoskeletal 6B 13 24.5 1.38E-84 
137 CON__O95678 Keratin, type II cytoskeletal 75 5 8.7 1.80E-31 
138 P01042 Kininogen-1 5 10.6 3.81E-17 
139 P02750 Leucine-rich alpha-2-glycoprotein 2 8.1 2.30E-05 
140 P51884 Lumican 3 10.1 6.42E-05 
141 Q685J3 Mucin-17 1 0.2 7.94E-17 
142 P20916 Myelin-associated glycoprotein 1 1.9 0.025319 
143 Q96PD5-2 N-acetylmuramoyl-L-alanine amidase 3 6.6 1.85E-07 
144 P80108 
Phosphatidylinositol-glycan-specific 
phospholipase D 
1 1.8 0.00070946 
145 H0YAC1 Plasma kallikrein 2 2.9 1.99E-05 
146 B4E1F0 Plasma protease C1 inhibitor 8 18.2 3.07E-59 
147 P00747 Plasminogen 13 20.9 2.28E-36 
148 P20742 Pregnancy zone protein 10 9.4 3.96E-132 
149 P02760 Protein AMBP 8 27.6 3.88E-23 
150 P60903 Protein S100-A10 2 18.6 0.0005562 
151 Q16384 Protein SSX1 1 8 0.025058 
152 P00734 Prothrombin 6 10.1 3.63E-23 
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# Protein ID Protein name Peptides 
Sequence 
coverage 
[%] 
PEP 
153 P02787 Serotransferrin 32 46.8 0 
154 CON__P02768-1 Serum albumin 37 63.1 0 
155 P02743 Serum amyloid P-component 5 23.8 2.00E-13 
156 P27169 Serum paraoxonase/arylesterase 1 5 23.4 4.25E-20 
157 P61009 Signal peptidase complex subunit 3 1 3.9 0.038591 
158 Q17RD7 Synaptotagmin-16 1 2.5 0.023998 
159 P24821 Tenascin 1 0.8 1.65E-06 
160 Q6N022 Teneurin-4 1 0.4 6.91E-05 
161 P02766 Transthyretin 4 47.6 3.78E-144 
162 E7EQ64 Trypsin-1 1 7.7 0.00059298 
163 D6RF35 Vitamin D-binding protein 7 25.4 9.87E-25 
164 P07225 Vitamin K-dependent protein S 2 2.4 0.0017815 
165 P04004 Vitronectin 5 12.8 7.17E-23 
166 P04275 von Willebrand factor 5 2.3 1.33E-09 
167 C9JEE0  1 3.9 0.00017252 
168 
CON__REFSEQ:X
P_986630 
 5 10.9 6.35E-19 
169 CON__P00761  5 31.6 0 
170 CON__P02662  2 11.1 0.00017217 
171 CON__P02769  21 35.7 0 
172 E9PQP7  1 2.2 0.032163 
173 
REV__CON__Q6I
FZ6 
 1 2.1 0.0013335 
174 S4R394  1 13.8 7.15E-06 
175 S4R460  1 8.7 1.42E-07 
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TABLE 9.3: TABLE OF RAW PEPTIDE DATA FOR CANDIDATE BIOMARKERS. LEADING PROTEINS OF EACH GROUP ARE USED FOR SIMPLICITY.  
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A1AG 
TEDTIFLR 0 no no 2 4.28E-13 
1.73E+
07 
1.18E+
07 0 
9.07E+
06 0 0 
8.90E+
06 0 0 
A1AG 
EQLGEFYEALDCLR 0 yes yes 2 0.013071 
0 
5.60E+
06 0 0 0 0 0 0 0 
A1AT 
TLNQPDSQLQLTTGNGLFLSE
GLK 0 yes no 2,3 4.61E-188 
4.99E+
07 
6.70E+
07 
6.50E+
06 
5.57E+
07 
1.37E+
07 
1.64E+
06 
2.85E+
07 
1.28E+
07 
1.81E+
06 
A1AT 
VFSNGADLSGVTEEAPLK 0 yes no 2,3 1.54E-111 
2.69E+
08 
1.73E+
08 
2.51E+
07 
2.66E+
08 0 0 
2.26E+
08 
1.17E+
08 0 
A1AT 
DTEEEDFHVDQVTTVK 0 yes no 2,3 1.59E-107 
1.71E+
07 
4.20E+
07 
9.17E+
06 
1.05E+
08 
5.27E+
06 
2.59E+
06 
3.51E+
07 
4.18E+
07 
9.81E+
06 
A1AT 
AVLTIDEK 0 yes yes 2 1.03E-67 
1.93E+
08 0 0 0 0 
7.96E+
07 
1.49E+
08 
1.29E+
08 0 
A1AT 
LQHLENELTHDIITK 0 yes no 2,3,4 1.25E-61 
7.74E+
07 
2.19E+
08 
3.06E+
06 
1.89E+
08 
3.32E+
07 0 
1.53E+
08 
1.66E+
07 0 
A1AT 
LYHSEAFTVNFGDTEEAK 0 yes no 2,3 5.25E-31 
1.23E+
07 
5.11E+
07 0 
1.92E+
07 
2.94E+
06 0 
1.52E+
07 
2.75E+
06 0 
A1AT 
LYHSEAFTVNFGDTEEAKK 1 yes no 2,3,4 1.09E-16 
0 
7.50E+
07 0 
4.24E+
07 0 0 
4.01E+
07 0 0 
A1AT 
LSITGTYDLK 0 yes no 2 1.21E-15 
2.56E+
08 
2.49E+
08 
9.02E+
06 
2.48E+
08 
1.93E+
07 
8.25E+
06 
1.72E+
08 
1.29E+
08 0 
A1AT 
SASLHLPK 0 yes no 2 2.46E-09 
3.27E+
07 
1.21E+
07 
5.14E+
06 
2.50E+
07 
5.56E+
06 
8.10E+
06 
1.88E+
07 
1.09E+
07 
5.52E+
06 
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A1AT 
FLENEDRR 1 yes no 2,3 1.21E-08 
9.63E+
06 
6.08E+
06 0 
2.68E+
07 0 
1.57E+
07 
2.16E+
07 
1.43E+
07 0 
A1AT 
ITPNLAEFAFSLYR 0 yes no 2,3 6.61E-06 
1.81E+
07 
5.58E+
06 
1.23E+
06 
6.46E+
07 
2.57E+
06 0 
2.25E+
07 
4.46E+
06 0 
A1AT 
QINDYVEK 0 yes no 2 8.86E-05 
1.05E+
08 
6.60E+
07 
4.56E+
07 
9.94E+
07 
6.00E+
07 
7.14E+
07 
8.84E+
07 
6.98E+
07 
4.12E+
06 
A1AT 
SVLGQLGITK 0 yes no 2 0.000359 
3.57E+
08 
2.20E+
08 
1.77E+
07 
2.73E+
08 
2.24E+
07 
1.76E+
07 
2.21E+
08 
1.40E+
08 
2.75E+
07 
A1AT 
DTVFALVNYIFFK 0 yes no 2 0.000665 
0 0 0 0 0 0 
1.75E+
06 0 0 
A1AT 
LSSWVLLMK 0 yes no 2 0.003533 
0 
9.05E+
06 0 
6.26E+
06 0 0 
3.94E+
06 
1.71E+
06 0 
A1AT 
GKWERPFEVK 2 yes no 2 0.011852 
0 0 0 0 0 0 0 0 0 
A1AT 
FLENEDR 0 yes no 2 0.037749 
2.60E+
07 
9.73E+
06 0 0 
1.23E+
07 
1.58E+
07 
1.37E+
07 0 0 
A1AT 
LGMFNIQHCK 0 yes no 3 0.042353 
2.80E+
06 0 0 0 0 0 0 0 0 
A2M 
TEVSSNHVLIYLDK 0 yes yes 2,3 0 
4.77E+
07 
1.72E+
08 
5.62E+
06 
2.17E+
08 
1.65E+
07 
2.52E+
06 
8.59E+
07 
2.80E+
07 0 
A2M 
VYDYYETDEFAIAEYNAPCSK 0 yes yes 2,3 2.54E-180 
1.24E+
07 
3.84E+
07 
3.32E+
06 
4.72E+
07 
6.67E+
06 
2.66E+
06 
1.53E+
07 
1.90E+
07 
2.48E+
06 
A2M 
VTAAPQSVCALR 0 yes yes 2 4.60E-172 
1.55E+
08 
8.70E+
07 
1.99E+
07 
2.41E+
08 
1.17E+
07 
2.88E+
07 
1.19E+
08 
1.22E+
08 
1.19E+
07 
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A2M 
QFSFPLSSEPFQGSYK 0 yes yes 2,3 1.64E-145 
4.06E+
07 
9.02E+
07 
2.57E+
07 
7.58E+
07 
2.85E+
07 
1.89E+
07 
2.83E+
06 
3.82E+
06 
1.80E+
07 
A2M 
LHTEAQIQEEGTVVELTGR 0 yes yes 2,3 2.89E-132 
3.67E+
07 
1.45E+
08 0 
6.11E+
07 
9.65E+
05 
4.20E+
06 
2.70E+
07 
2.32E+
07 0 
A2M 
NEDSLVFVQTDK 0 yes no 2 8.08E-124 
1.52E+
08 
1.49E+
08 
1.92E+
07 
2.81E+
08 
2.52E+
07 
2.02E+
07 
1.24E+
08 
1.34E+
08 
2.43E+
07 
A2M 
HNVYINGITYTPVSSTNEK 0 yes yes 2,3 1.02E-82 
2.48E+
07 
4.40E+
07 
1.47E+
06 
4.61E+
07 
3.35E+
06 0 
2.40E+
07 
2.38E+
07 0 
A2M 
AAQVTIQSSGTFSSK 0 yes yes 2 5.71E-75 
2.96E+
07 
7.15E+
06 
1.51E+
07 
7.34E+
07 
1.07E+
07 
1.43E+
07 
3.59E+
07 
4.94E+
07 
3.87E+
06 
A2M 
YNILPEKEEFPFALGVQTLPQT
CDEPK 1 yes yes 3 1.63E-57 
9.29E+
06 
2.03E+
07 
2.36E+
06 
2.30E+
07 
8.35E+
06 0 
4.88E+
06 
5.35E+
06 0 
A2M 
AIGYLNTGYQR 0 yes yes 2 7.04E-52 
1.84E+
08 
1.77E+
08 
2.37E+
07 
3.15E+
08 
2.08E+
07 
2.85E+
07 
1.23E+
08 
2.05E+
08 
3.11E+
07 
A2M 
FSGQLNSHGCFYQQVK 0 yes yes 2,3 7.94E-49 
2.01E+
07 
2.80E+
07 0 
6.17E+
07 
3.28E+
06 0 
3.20E+
07 
9.21E+
06 0 
A2M 
DTVIKPLLVEPEGLEK 1 yes yes 2,3 1.64E-47 
7.26E+
07 
1.71E+
08 
3.15E+
07 
1.15E+
08 
2.60E+
07 
1.39E+
07 
6.93E+
07 
6.28E+
07 
3.86E+
07 
A2M 
IAQWQSFQLEGGLK 0 yes yes 2 2.91E-47 
7.03E+
06 
1.02E+
08 
1.13E+
07 
7.44E+
07 
1.70E+
07 
7.64E+
06 
2.22E+
07 
2.24E+
07 
6.04E+
06 
A2M 
VTGEGCVYLQTSLK 0 yes yes 2 4.44E-47 
8.02E+
06 
1.91E+
07 0 
1.96E+
07 
2.92E+
06 
1.04E+
06 
9.07E+
06 
9.76E+
06 
1.37E+
06 
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A2M 
VSVQLEASPAFLAVPVEK 0 yes no 2,3 3.59E-41 
2.11E+
07 
1.46E+
08 
1.70E+
07 
4.52E+
07 
1.75E+
07 
1.45E+
07 
1.28E+
07 
1.98E+
07 
1.13E+
07 
A2M 
GHFSISIPVK 0 yes no 2,3 3.52E-40 
2.74E+
07 
6.49E+
07 
6.37E+
06 
9.20E+
07 
1.54E+
07 
3.69E+
06 
3.71E+
07 
2.52E+
07 
1.40E+
06 
A2M 
YDVENCLANK 0 yes yes 2 6.88E-39 
1.28E+
08 
8.89E+
07 
1.60E+
07 
1.88E+
08 
1.40E+
07 
2.64E+
07 
8.30E+
07 
1.03E+
08 0 
A2M 
ALLAYAFALAGNQDK 0 yes yes 2,3 1.90E-36 
7.09E+
06 
1.37E+
07 0 
2.97E+
07 
2.59E+
06 
7.72E+
05 
1.15E+
07 
4.01E+
06 0 
A2M 
HYDGSYSTFGER 0 yes yes 2,3 9.62E-36 
2.20E+
07 
4.88E+
07 
5.47E+
06 
3.43E+
07 0 
2.51E+
06 
2.61E+
07 
4.71E+
07 
1.62E+
06 
A2M 
ETTFNSLLCPSGGEVSEELSLK 0 yes yes 2,3 7.53E-34 
4.56E+
06 0 0 
1.25E+
07 
2.17E+
06 0 0 0 0 
A2M 
QQNAQGGFSSTQDTVVALH
ALSK 0 yes yes 2,3 5.75E-30 
4.28E+
06 
5.54E+
07 
7.27E+
06 
7.65E+
07 
1.00E+
07 
5.86E+
06 
3.38E+
07 
1.60E+
07 
6.71E+
06 
A2M 
VDLSFSPSQSLPASHAHLR 0 yes yes 2,3,4 2.18E-27 
0 
7.25E+
07 0 
8.16E+
07 
9.70E+
06 0 
3.09E+
07 0 0 
A2M 
TEHPFTVEEFVLPK 0 yes yes 2,3 5.52E-27 
5.57E+
07 
1.19E+
08 
2.14E+
07 
1.33E+
08 
4.86E+
07 
1.68E+
07 
4.78E+
07 
2.19E+
07 
7.74E+
06 
A2M 
LVHVEEPHTETVR 0 yes yes 2,3,4 9.84E-27 
9.01E+
07 
7.63E+
07 
5.22E+
06 
1.71E+
08 
1.85E+
07 
2.52E+
06 
7.15E+
07 
6.15E+
07 0 
A2M 
FEVQVTVPK 0 yes yes 2 4.32E-22 
8.18E+
07 
1.01E+
08 
1.06E+
07 
1.77E+
08 
1.33E+
07 
6.15E+
06 
5.96E+
07 
7.32E+
07 
7.17E+
06 
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A2M 
FQVDNNNR 0 yes yes 2 1.93E-19 
1.56E+
07 
9.50E+
06 
1.37E+
07 
2.66E+
07 
1.29E+
07 
1.43E+
07 
9.87E+
06 
1.51E+
07 0 
A2M 
TGTHGLLVK 0 yes no 2,3 3.03E-15 
3.19E+
07 
1.80E+
07 
5.69E+
06 
5.14E+
07 
4.26E+
06 
1.20E+
07 
1.99E+
07 
2.74E+
07 
2.74E+
06 
A2M 
YSDASDCHGEDSQAFCEK 0 yes yes 2,3 8.84E-14 
1.24E+
07 
8.62E+
06 0 
2.72E+
07 0 
2.39E+
06 
9.70E+
06 
1.51E+
07 0 
A2M 
EEFPFALGVQTLPQTCDEPK 0 yes yes 2 1.93E-11 
3.37E+
06 
3.60E+
06 
1.42E+
06 
5.26E+
06 
2.79E+
06 
1.10E+
06 0 
2.74E+
06 
2.18E+
06 
A2M 
QTVSWAVTPK 0 yes no 2 1.74E-10 
9.14E+
07 
7.26E+
07 
1.67E+
07 
1.49E+
08 
1.42E+
07 
1.66E+
07 
5.76E+
07 
8.78E+
07 0 
A2M 
LLIYAVLPTGDVIGDSAK 0 yes yes 2,3 3.50E-10 
1.87E+
07 
8.60E+
07 
1.35E+
07 
6.46E+
07 
2.19E+
07 
7.84E+
06 
1.78E+
07 
1.51E+
07 
3.04E+
06 
A2M 
SIYKPGQTVK 1 yes no 2 1.50E-09 
1.70E+
07 
1.09E+
07 
6.81E+
06 
3.43E+
07 
5.47E+
06 
8.01E+
06 
1.28E+
07 
1.89E+
07 
6.34E+
06 
A2M 
LPPNVVEESAR 0 yes no 2 8.16E-06 
1.07E+
08 
8.60E+
07 
3.32E+
07 
1.71E+
08 
2.96E+
07 
3.29E+
07 
7.96E+
07 
1.35E+
08 
2.49E+
07 
A2M 
AVDQSVLLMKPDAELSASSVY
NLLPEK 1 yes yes 3 3.31E-05 
0 
2.84E+
06 0 
4.24E+
06 0 0 0 0 0 
A2M 
SSSNEEVMFLTVQVK 0 yes no 2 3.65E-05 
2.45E+
06 
2.59E+
06 0 
9.05E+
06 0 0 
2.18E+
06 0 0 
A2M 
NALFCLESAWK 0 yes yes 2 3.93E-05 
7.20E+
06 
2.38E+
07 
1.74E+
06 
1.60E+
07 
5.15E+
06 0 
6.13E+
06 0 0 
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A2M 
QGIPFFGQVR 0 yes yes 2 5.78E-05 
3.57E+
07 
4.27E+
07 
9.77E+
06 
9.69E+
07 
1.12E+
07 
8.62E+
06 
3.14E+
07 
1.46E+
07 
4.17E+
06 
A2M 
DLKPAIVK 1 yes no 2 0.000103 
4.97E+
07 
4.08E+
07 0 
9.23E+
07 0 
2.77E+
07 
3.22E+
07 
5.47E+
07 
1.86E+
07 
A2M 
PVPGHVTVSICR 0 yes yes 2,3 0.000155 
1.71E+
07 
3.16E+
07 0 
8.16E+
07 
4.24E+
06 0 
4.12E+
07 
1.36E+
07 0 
A2M 
SASNMAIVDVK 0 yes yes 2 0.000159 
1.61E+
06 0 
1.90E+
06 0 0 
4.35E+
06 0 
4.01E+
06 0 
A2M 
PLLVEPEGLEK 0 yes no 2 0.000229 
4.62E+
06 
4.74E+
06 0 
1.11E+
07 0 0 
3.84E+
06 
3.73E+
06 0 
A2M 
VGFYESDVMGR 0 yes yes 2 0.000373 
1.04E+
07 0 0 
2.32E+
07 0 0 
7.19E+
06 
4.85E+
06 0 
A2M 
SLFTDLEAENDVLHCVAFAVP
K 0 yes no 2,3 0.001512 
0 0 0 
1.07E+
07 0 0 0 0 0 
A2M 
SDIAPVAR 0 yes no 2 0.006611 
2.62E+
07 
1.63E+
07 
2.21E+
07 
4.67E+
07 
2.26E+
07 
2.36E+
07 
1.85E+
07 
2.86E+
07 0 
A2M 
SLNEEAVK 0 yes yes 2 0.007352 
0 0 0 0 0 
1.75E+
07 0 
2.07E+
07 0 
A2M 
GPTQEFK 0 yes no 2 0.013773 
0 0 0 0 0 0 
3.60E+
06 0 0 
A2M 
KDTVIKPLLVEPEGLEK 2 yes yes 3 0.019333 
0 0 0 0 
5.64E+
06 0 0 0 0 
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A2M 
VVSMDENFHPLNELIPLVYIQ
DPK 0 yes yes 3 0.02955 
0 0 0 
1.93E+
06 0 0 0 0 0 
A2M 
VSNQTLSLFFTVLQDVPVR 0 yes yes 3 0.0313 
0 0 0 
1.29E+
06 0 0 0 0 0 
A2M 
DMYSFLEDMGLK 0 yes yes 2 0.036487 
0 0 0 
7.11E+
05 0 0 0 0 0 
A2M 
GEAFTLK 0 yes no 2 0.038312 
0 0 
2.69E+
07 0 0 0 0 
4.58E+
07 
9.17E+
06 
A2M 
EQAPHCICANGR 0 yes no 3 0.043784 
3.38E+
06 0 0 0 0 0 0 0 0 
A2M 
SLNEEAVKK 1 yes yes 2 0.047426 
0 0 0 
2.98E+
06 0 0 0 0 0 
APOA-I 
DYVSQFEGSALGK 0 yes yes 2 7.99E-185 
1.05E+
08 
8.32E+
07 0 
1.32E+
08 0 0 
1.19E+
08 
7.47E+
07 0 
APOA-I 
LLDNWDSVTSTFSK 0 yes no 2 8.52E-74 
2.87E+
07 
7.32E+
07 
1.07E+
07 
4.28E+
07 
1.09E+
07 
1.35E+
07 
3.26E+
07 
1.57E+
07 
1.02E+
07 
APOA-I 
EQLGPVTQEFWDNLEK 0 yes no 2 3.04E-68 
1.55E+
07 0 
4.42E+
06 
1.81E+
07 
6.89E+
06 
6.61E+
06 
1.08E+
07 
5.13E+
06 
2.73E+
06 
APOA-I 
VSFLSALEEYTK 0 yes no 2 4.38E-47 
3.39E+
07 
7.55E+
07 
6.93E+
06 
6.20E+
07 
1.00E+
07 
6.29E+
06 
3.89E+
07 
1.22E+
07 
2.55E+
06 
APOA-I 
DLATVYVDVLK 0 yes yes 2 2.96E-14 
1.68E+
07 
4.96E+
07 
8.27E+
06 
5.74E+
07 0 
6.75E+
06 
2.51E+
07 
1.12E+
07 
2.80E+
06 
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APOA-I 
ATEHLSTLSEK 0 yes no 2,3 2.66E-13 
3.38E+
07 
1.95E+
07 
1.06E+
07 
3.75E+
07 
5.74E+
06 
1.29E+
07 
2.62E+
07 
1.44E+
07 
7.13E+
06 
APOA-I 
AKPALEDLR 1 yes no 2,3 1.40E-09 
5.03E+
07 
1.52E+
07 0 
2.29E+
07 0 0 
1.83E+
07 
1.71E+
07 0 
APOA-I 
THLAPYSDELR 0 yes no 2,3 1.59E-08 
1.33E+
08 
9.15E+
07 
4.73E+
06 
1.36E+
08 
3.43E+
06 
6.16E+
06 
5.63E+
07 0 
8.31E+
06 
APOA-I 
QGLLPVLESFK 0 yes no 2 0.000402 
2.83E+
07 
3.74E+
07 
1.53E+
07 
4.28E+
07 
1.69E+
07 
1.49E+
07 
2.69E+
07 
9.27E+
06 0 
APOA-I 
VQPYLDDFQK 0 yes no 2 0.000966 
1.16E+
08 
8.47E+
07 
8.08E+
06 
1.06E+
08 0 
9.30E+
06 
1.02E+
08 
6.06E+
07 
1.83E+
07 
APOA-I 
LSPLGEEMR 0 yes no 2 0.020836 
8.14E+
06 0 0 0 0 0 0 0 0 
APOA-I 
VKDLATVYVDVLK 1 yes yes 3 0.05691 
0 0 0 
6.07E+
06 0 0 0 0 0 
ApoE 
LEEQAQQIR 0 yes yes 2 0 
0 0 0 0 0 0 0 0 0 
ApoE 
SELEEQLTPVAEETR 0 yes no 2 4.25E-19 
1.05E+
07 
2.83E+
06 0 
7.17E+
06 0 0 
5.59E+
06 
3.98E+
06 0 
ApoE 
VQAAVGTSAAPVPSDNH 0 yes yes 2 0.000696 
0 0 0 0 0 0 
4.13E+
06 0 0 
ApoE 
AATVGSLAGQPLQER 0 yes no 2 0.001296 
1.04E+
07 
5.92E+
06 0 
6.99E+
06 
8.87E+
05 0 
6.59E+
06 
6.45E+
06 0 
ApoE 
VEQAVETEPEPELR 0 yes no 2 0.020221 
0 0 0 0 0 0 0 0 0 
ApoE 
LGPLVEQGR 0 yes no 2 0.020788 
0 0 0 0 0 0 0 0 0 
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ApoE 
LAVYQAGAR 0 yes no 2 0.027538 
4.61E+
06 0 0 0 0 0 0 0 0 
CERU 
VNKDDEEFIESNK 1 yes no 2,3 2.00E-122 
6.21E+
07 
3.79E+
07 0 
4.70E+
07 0 0 
4.45E+
07 
5.34E+
07 0 
CERU 
NNEGTYYSPNYNPQSR 0 yes no 2 1.62E-61 
2.42E+
07 
1.39E+
07 
4.02E+
06 
1.74E+
07 
6.17E+
06 
6.77E+
06 
2.46E+
07 
1.60E+
07 
2.19E+
06 
CERU 
DIASGLIGPLIICK 0 yes no 2,3 2.51E-48 
2.46E+
07 
4.04E+
07 
1.39E+
07 
2.46E+
07 
1.43E+
07 
1.46E+
07 
1.77E+
07 
1.30E+
07 
9.40E+
06 
CERU 
ALYLQYTDETFR 0 yes no 2 2.07E-36 
1.45E+
07 
6.81E+
07 
2.73E+
06 
3.47E+
07 
4.07E+
06 
2.62E+
06 
3.38E+
07 
1.10E+
07 0 
CERU 
SGAGTEDSACIPWAYYSTVD
QVK 0 yes no 2,3 4.32E-35 
9.09E+
06 
1.19E+
07 
2.15E+
06 
1.12E+
07 
2.73E+
06 
3.28E+
06 
8.75E+
06 
5.61E+
06 
2.96E+
06 
CERU 
EYTDASFTNR 0 yes no 2 3.12E-29 
6.26E+
07 
4.66E+
07 
2.20E+
07 
5.28E+
07 
2.57E+
07 
4.17E+
07 
6.41E+
07 
5.22E+
07 
3.30E+
06 
CERU 
LISVDTEHSNIYLQNGPDR 0 yes no 2,3 5.17E-27 
6.16E+
06 
2.62E+
07 0 
2.39E+
07 0 0 
2.90E+
07 
7.61E+
06 0 
CERU 
GAYPLSIEPIGVR 0 yes no 2 3.51E-26 
5.08E+
07 
5.18E+
07 
9.49E+
06 
6.05E+
07 
1.09E+
07 
1.12E+
07 
6.92E+
07 
2.70E+
07 
1.50E+
07 
CERU 
EVGPTNADPVCLAK 0 yes no 2 6.20E-26 
7.80E+
07 
6.12E+
07 
2.17E+
07 
6.45E+
07 
1.09E+
07 
2.22E+
07 
7.10E+
07 
6.37E+
07 
6.59E+
06 
CERU 
DLYSGLIGPLIVCR 0 yes no 2,3 1.53E-19 
1.40E+
07 
2.23E+
07 
4.67E+
06 
1.61E+
07 
8.22E+
06 
3.43E+
06 
1.18E+
07 
4.73E+
06 
1.50E+
06 
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CERU 
DDEEFIESNK 0 yes no 2 4.86E-11 
0 0 0 0 
1.07E+
06 0 0 0 0 
CERU 
SVPPSASHVAPTETFTYEWTV
PK 0 yes no 2,3 1.26E-06 
0 
1.61E+
07 0 0 0 0 
3.54E+
06 0 0 
CERU 
QSEDSTFYLGER 0 yes no 2 1.97E-05 
4.25E+
07 
3.54E+
07 
1.59E+
06 
3.69E+
07 
2.01E+
06 
2.05E+
06 
4.05E+
07 
3.75E+
07 
8.92E+
05 
CERU 
TTIEKPVWLGFLGPIIK 1 yes no 2,3 0.001087 
0 
8.83E+
06 0 
6.66E+
06 0 0 
5.26E+
06 0 0 
CERU 
RQSEDSTFYLGER 1 yes no 3 0.008378 
0 0 0 0 0 0 0 0 0 
CERU 
DIFTGLIGPMK 0 yes no 2 0.009039 
0 
3.46E+
06 0 0 0 0 0 0 0 
CERU 
QYTDSTFR 0 yes no 2 0.010863 
2.47E+
07 
1.69E+
07 
1.36E+
07 
2.44E+
07 
1.69E+
07 
2.48E+
07 
2.24E+
07 
2.29E+
07 0 
CERU 
AEEEHLGILGPQLHADVGDK 0 yes no 3,4 0.015779 
0 
2.93E+
06 0 
4.79E+
06 0 0 
3.41E+
06 0 0 
CERU 
AGLQAFFQVQECNK 0 yes no 2 0.018401 
0 0 0 
2.17E+
06 0 0 
2.51E+
06 0 0 
CERU 
GEFYIGSK 0 yes no 2 0.024898 
2.01E+
07 0 0 0 0 0 0 0 0 
CERU 
KAEEEHLGILGPQLHADVGDK 1 yes no 3 0.037227 
0 0 0 0 0 0 
2.82E+
06 0 0 
CERU 
PVWLGFLGPIIK 0 yes no 2 0.046533 
0 0 0 
1.46E+
06 0 0 0 0 0 
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CLU 
ASSIIDELFQDR 0 yes no 2 2.65E-26 
5.99E+
06 
2.16E+
07 
2.98E+
06 
1.48E+
07 
5.04E+
06 
2.64E+
06 
6.16E+
06 
3.43E+
06 0 
CLU 
LFDSDPITVTVPVEVSR 0 yes no 2 8.44E-12 
0 
1.48E+
07 0 
8.71E+
06 
1.86E+
06 0 
3.72E+
06 0 0 
CLU 
EILSVDCSTNNPSQAK 0 yes no 2 2.34E-09 
7.29E+
06 
4.62E+
06 0 
1.18E+
07 0 0 
5.87E+
06 0 0 
CLU 
VTTVASHTSDSDVPSGVTEVV
VK 0 yes no 3 7.60E-07 
7.22E+
06 
7.48E+
06 0 
1.86E+
07 0 0 
1.54E+
07 
4.75E+
06 
2.19E+
06 
CLU 
EIQNAVNGVK 0 yes no 2 0.0002 
2.72E+
06 0 0 
4.74E+
06 
2.87E+
06 
2.85E+
06 
3.03E+
06 
2.96E+
06 0 
CLU 
IDSLLENDR 0 yes no 2 0.001805 
1.52E+
07 
1.08E+
07 
4.19E+
06 
1.95E+
07 
5.59E+
06 
7.77E+
06 
1.51E+
07 
1.07E+
07 0 
CLU 
TLLSNLEEAK 0 yes no 2 0.006125 
1.00E+
07 
8.72E+
06 
1.55E+
06 0 0 0 0 0 
2.15E+
06 
C3 
APSTWLTAYVVK 0 yes yes 2 0 
9.09E+
06 
6.82E+
07 0 
3.12E+
07 0 0 
2.09E+
07 
2.35E+
07 0 
C3 
GVFVLNK 0 no no 1,2 0 
2.39E+
07 
3.02E+
07 
7.54E+
06 
5.33E+
07 
1.23E+
07 
7.79E+
06 
3.46E+
07 
7.24E+
07 0 
C3 
VPVAVQGEDTVQSLTQGDGV
AK 0 yes yes 2,3 1.02E-285 
1.88E+
07 
1.06E+
08 0 
1.06E+
08 
3.21E+
07 0 
1.12E+
08 
4.64E+
07 
4.10E+
07 
C3 
DYAGVFSDAGLTFTSSSGQQT
AQR 0 yes yes 2,3 1.15E-145 
1.62E+
07 
3.98E+
07 
4.85E+
06 
2.70E+
07 
6.73E+
06 
5.37E+
06 
1.97E+
07 
2.58E+
07 
2.86E+
06 
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C3 
AYYENSPQQVFSTEFEVK 0 yes yes 2 3.44E-94 
0 
3.26E+
07 
7.74E+
06 
2.17E+
07 
1.33E+
07 
8.60E+
06 
1.58E+
07 
2.16E+
07 
1.01E+
07 
C3 
CAEENCFIQK 0 yes yes 2 1.37E-91 
1.75E+
07 
1.47E+
07 
8.22E+
06 
3.24E+
07 
1.27E+
07 
1.27E+
07 
2.91E+
07 
2.60E+
07 
3.60E+
06 
C3 
SGSDEVQVGQQR 0 yes no 2 2.07E-89 
1.09E+
07 
1.06E+
07 
1.21E+
07 
1.92E+
07 
2.30E+
07 
1.92E+
07 
2.05E+
07 
2.35E+
07 
2.21E+
06 
C3 
SNLDEDIIAEENIVSR 0 yes yes 2,3 5.71E-76 
3.43E+
07 
1.10E+
08 
1.26E+
07 
8.53E+
07 
2.58E+
07 
3.13E+
06 
6.94E+
07 
6.50E+
07 
1.88E+
07 
C3 
QELSEAEQATR 0 yes yes 2 3.98E-61 
1.68E+
07 
1.50E+
07 
1.05E+
07 
2.22E+
07 
2.22E+
07 
1.90E+
07 
2.62E+
07 
2.93E+
07 0 
C3 
DICEEQVNSLPGSITK 0 yes no 2 6.06E-57 
1.02E+
07 
9.30E+
06 
2.00E+
06 
2.19E+
07 
4.45E+
06 
2.06E+
06 
1.44E+
07 
1.90E+
07 0 
C3 
SEETKENEGFTVTAEGK 1 yes no 2,3 5.43E-50 
1.05E+
07 0 0 
2.04E+
07 0 0 
2.89E+
07 
3.09E+
07 
6.05E+
06 
C3 
VHQYFNVELIQPGAVK 0 yes no 2,3 2.45E-48 
5.41E+
06 
7.06E+
07 
2.54E+
06 
5.18E+
07 
2.03E+
07 0 
3.83E+
07 
1.24E+
07 0 
C3 
TIYTPGSTVLYR 0 no no 2 2.06E-47 
1.12E+
08 
1.54E+
08 0 
1.66E+
08 
2.16E+
07 
1.34E+
07 
1.64E+
08 
1.87E+
08 
2.70E+
07 
C3 
EDIPPADLSDQVPDTESETR 0 yes yes 2 9.42E-36 
4.16E+
06 
6.76E+
06 
2.65E+
06 
6.90E+
06 
7.88E+
06 
4.03E+
06 
5.46E+
06 
1.11E+
07 
5.35E+
06 
C3 
IPIEDGSGEVVLSR 0 yes yes 2,3 1.39E-35 
1.01E+
08 
1.18E+
08 
1.15E+
07 
1.56E+
08 
2.38E+
07 
1.21E+
07 
1.46E+
08 
1.72E+
08 
2.20E+
07 
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C3 
TGLQEVEVK 0 yes yes 2 1.22E-33 
8.35E+
07 
8.54E+
07 
4.67E+
07 
1.21E+
08 
7.68E+
07 
7.88E+
07 
1.23E+
08 
1.41E+
08 
8.86E+
06 
C3 
GYTQQLAFR 0 no no 2 2.70E-30 
5.52E+
07 
6.92E+
07 
6.03E+
06 
8.22E+
07 
1.12E+
07 
9.25E+
06 
8.59E+
07 
9.96E+
07 
1.21E+
07 
C3 
KGYTQQLAFR 1 no no 3 7.00E-30 
0 
5.27E+
06 0 
6.43E+
06 
1.21E+
06 0 
7.72E+
06 
8.82E+
06 0 
C3 
VELLHNPAFCSLATTK 0 yes yes 2,3 6.91E-28 
1.04E+
07 
4.51E+
07 0 
4.00E+
07 
1.43E+
07 0 
3.54E+
07 
1.70E+
07 
1.80E+
06 
C3 
LVAYYTLIGASGQR 0 yes yes 2,3 4.68E-26 
1.23E+
07 
8.29E+
07 
3.07E+
06 
8.30E+
07 
1.28E+
07 
2.74E+
06 
7.89E+
07 
3.77E+
07 0 
C3 
VFLDCCNYITELR 0 yes yes 2 7.73E-26 
9.06E+
06 
2.41E+
07 0 
1.36E+
07 
5.38E+
06 
1.55E+
06 
9.63E+
06 
8.11E+
06 
1.38E+
06 
C3 
VYAYYNLEESCTR 0 yes yes 2 1.62E-24 
2.92E+
07 0 
1.02E+
06 
5.66E+
07 0 
1.60E+
06 
4.59E+
07 
4.24E+
07 
1.03E+
06 
C3 
GLEVTITAR 0 yes yes 2 3.64E-24 
0 
4.52E+
07 0 
3.93E+
07 0 0 
3.05E+
07 0 0 
C3 
IHWESASLLR 0 yes no 2,3 1.50E-22 
1.12E+
07 
1.78E+
07 0 
4.30E+
07 
5.43E+
06 0 
1.77E+
07 
1.22E+
07 0 
C3 
EVVADSVWVDVK 0 no no 2 1.00E-21 
2.56E+
07 
5.62E+
07 0 
6.27E+
07 0 
2.32E+
06 
4.10E+
07 
4.66E+
07 
2.78E+
06 
C3 
VTIKPAPETEK 1 yes yes 2,3 2.00E-18 
2.20E+
07 
1.83E+
07 
1.24E+
07 
3.93E+
07 
2.42E+
07 
2.44E+
07 
4.18E+
07 
5.21E+
07 
1.20E+
07 
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C3 
KQELSEAEQATR 1 yes yes 2,3 4.63E-18 
5.20E+
06 
1.11E+
07 0 
2.15E+
07 
6.00E+
06 
1.30E+
07 
2.09E+
07 
2.58E+
07 0 
C3 
VLLDGVQNPR 0 yes yes 2 2.21E-15 
6.68E+
07 
6.69E+
07 
1.37E+
07 
9.15E+
07 
2.62E+
07 
1.76E+
07 
9.29E+
07 
1.10E+
08 
1.45E+
07 
C3 
SDDKVTLEER 1 yes no 2,3 3.78E-15 
5.76E+
06 0 
4.56E+
06 
1.65E+
07 
8.45E+
06 
1.28E+
07 
1.31E+
07 
1.89E+
07 0 
C3 
HQQTVTIPPK 0 yes yes 2,3 3.83E-15 
6.17E+
06 
5.61E+
06 
2.99E+
06 
1.48E+
07 
7.80E+
06 
6.02E+
06 
1.64E+
07 
2.59E+
07 0 
C3 
FVTVQATFGTQVVEK 0 yes no 2 1.27E-14 
4.33E+
06 
2.23E+
07 0 
1.42E+
07 
4.48E+
06 0 
1.28E+
07 
9.77E+
06 0 
C3 
FYYIYNEK 0 yes yes 2 4.83E-13 
4.68E+
07 
5.91E+
07 
3.64E+
06 
7.35E+
07 
8.87E+
06 
2.34E+
06 
7.85E+
07 
8.34E+
07 
3.90E+
06 
C3 
EPGQDLVVLPLSITTDFIPSFR 0 yes yes 2,3 7.97E-13 
4.04E+
06 
1.46E+
07 0 
1.05E+
07 
1.16E+
06 0 
7.72E+
06 0 0 
C3 
EYVLPSFEVIVEPTEK 0 yes yes 2 3.70E-10 
1.65E+
07 
5.60E+
07 
6.88E+
06 
2.35E+
07 
2.09E+
07 
6.56E+
06 
1.54E+
07 
1.72E+
07 
2.88E+
06 
C3 
ADIGCTPGSGK 0 yes yes 2 2.37E-09 
5.84E+
06 
5.68E+
06 
7.42E+
06 
9.61E+
06 
1.31E+
07 
9.98E+
06 
1.06E+
07 
1.50E+
07 
1.32E+
06 
C3 
LSINTHPSQKPLSITVR 1 yes yes 3,4 4.66E-09 
0 
4.16E+
07 0 
4.24E+
07 
5.34E+
06 0 
4.41E+
07 0 0 
C3 
ENEGFTVTAEGK 0 yes no 2 2.06E-08 
4.45E+
07 
4.09E+
07 
1.50E+
07 
4.17E+
07 
2.78E+
07 
2.99E+
07 
5.97E+
07 
6.91E+
07 
3.81E+
06 
186 
 
P
ro
te
in
s 
Se
q
u
en
ce
 
M
is
se
d
 
cl
ea
va
ge
s 
U
n
iq
u
e 
(G
ro
u
p
s)
 
U
n
iq
u
e 
(P
ro
te
in
s)
 
C
h
ar
ge
 
P
EP
 
H
A
D
 1
 
H
A
D
 2
 
H
A
D
 3
 
M
N
I 1
 
M
N
I 2
 
M
N
I 3
 
P
O
S 
1
 
P
O
S 
2
 
P
O
S 
3
 
C3 
EALKLEEK 1 yes no 2,3 1.00E-07 
0 0 0 
5.08E+
06 0 
4.32E+
06 
4.02E+
06 
2.73E+
06 0 
C3 
DFDFVPPVVR 0 yes yes 2 2.47E-07 
4.83E+
07 
1.48E+
08 
2.49E+
07 
1.21E+
08 
4.60E+
07 
2.47E+
07 
9.34E+
07 
8.50E+
07 
3.38E+
07 
C3 
SEFPESWLWNVEDLKEPPK 1 yes yes 3 8.75E-07 
2.49E+
06 
4.31E+
06 0 
5.05E+
06 0 0 
3.13E+
06 0 0 
C3 
SGIPIVTSPYQIHFTK 0 yes yes 2,3 1.43E-06 
8.41E+
06 
5.63E+
07 
7.19E+
06 
3.23E+
07 
3.15E+
07 
7.87E+
06 
2.91E+
07 
1.17E+
07 
3.74E+
06 
C3 
ILLQGTPVAQMTEDAVDAER 0 yes yes 2 2.69E-06 
0 0 0 
4.06E+
06 0 0 
2.24E+
06 0 
3.38E+
06 
C3 
ISLPESLK 0 yes yes 2 3.51E-06 
9.52E+
07 
9.99E+
07 0 
1.19E+
08 0 0 
1.14E+
08 
1.66E+
08 
2.31E+
07 
C3 
VSHSEDDCLAFK 0 yes no 2,3 3.03E-05 
5.11E+
06 
4.03E+
06 0 
2.53E+
07 0 0 
2.08E+
07 
1.90E+
07 
3.91E+
06 
C3 
TVMVNIENPEGIPVK 0 yes yes 2 3.71E-05 
4.09E+
06 0 0 
7.22E+
06 0 0 
8.80E+
06 
6.29E+
06 
2.07E+
06 
C3 
TELRPGETLNVNFLLR 1 yes yes 3 4.09E-05 
4.03E+
06 0 0 
6.83E+
06 0 0 0 0 0 
C3 
DSCVGSLVVK 0 yes yes 2 6.19E-05 
7.11E+
07 
6.55E+
07 
2.37E+
07 
8.23E+
07 
4.24E+
07 
3.65E+
07 
8.95E+
07 
9.80E+
07 
7.39E+
06 
C3 
RIPIEDGSGEVVLSR 1 yes yes 3 0.000131 
0 
3.34E+
06 0 
3.34E+
06 0 0 0 
3.02E+
06 0 
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C3 
KVEGTAFVIFGIQDGEQR 1 yes yes 2,3 0.000327 
0 
1.19E+
07 0 
6.64E+
06 0 0 
6.10E+
06 0 0 
C3 
QPSSAFAAFVK 0 yes yes 2 0.000371 
2.90E+
07 
3.27E+
07 0 
4.76E+
07 
7.39E+
06 0 
4.81E+
07 
4.81E+
07 
9.38E+
06 
C3 
AAVYHHFISDGVR 0 yes yes 2,3,4 0.000645 
1.39E+
06 
1.36E+
07 0 
3.03E+
07 0 0 
3.59E+
07 
4.97E+
06 0 
C3 
SSLSVPYVIVPLK 0 yes yes 2 0.000735 
2.39E+
07 
1.20E+
08 
2.30E+
07 
3.81E+
07 
4.55E+
07 
2.32E+
07 
3.86E+
07 
3.58E+
07 
3.94E+
07 
C3 
NTLIIYLDK 0 no no 2 0.000927 
3.45E+
07 
4.58E+
07 
1.49E+
06 
8.43E+
07 
5.63E+
06 0 
5.35E+
07 
3.99E+
07 0 
C3 
RQGALELIK 1 yes yes 3 0.001155 
0 0 0 0 0 0 
2.30E+
06 0 0 
C3 
VEGTAFVIFGIQDGEQR 0 yes yes 2 0.001238 
0 
4.22E+
06 0 
2.20E+
06 0 0 
8.42E+
05 0 0 
C3 
ACEPGVDYVYK 0 no no 2 0.001645 
7.26E+
07 
6.91E+
07 
9.50E+
06 
9.22E+
07 
3.03E+
07 
1.35E+
07 
9.29E+
07 
1.27E+
08 
6.98E+
06 
C3 
SYTVAIAGYALAQMGR 0 yes no 2 0.001897 
0 
1.86E+
06 0 0 0 0 0 0 0 
C3 
FISLGEACK 0 yes yes 2 0.002504 
2.35E+
07 
1.65E+
07 0 
4.58E+
07 
2.12E+
06 0 
4.49E+
07 
2.87E+
07 
5.44E+
06 
C3 
YYTYLIMNK 0 yes yes 2 0.002989 
9.48E+
06 
6.70E+
06 0 
1.71E+
07 0 0 
1.18E+
07 
9.80E+
06 0 
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C3 
KVLLDGVQNPR 1 yes yes 2 0.004021 
4.65E+
06 0 0 
6.23E+
06 0 0 
5.15E+
06 
5.89E+
06 0 
C3 
LPYSVVR 0 no no 2 0.005779 
0 0 0 0 0 0 
1.15E+
08 
1.34E+
08 
1.44E+
07 
C3 
VQLSNDFDEYIMAIEQTIK 0 yes no 2 0.007734 
0 0 0 
9.95E+
05 0 0 0 0 0 
C3 
NTMILEICTR 0 yes no 2 0.008338 
0 0 0 
4.56E+
06 0 0 0 0 0 
C3 
LSINTHPSQK 0 yes yes 2,3 0.008726 
0 0 0 0 0 0 
1.36E+
06 
2.84E+
06 0 
C3 
AGDFLEANYMNLQR 0 yes no 2 0.010457 
3.00E+
06 0 0 
5.52E+
06 0 0 0 0 0 
C3 
ISLPESLKR 1 yes yes 3 0.01151 
6.51E+
06 0 0 
6.89E+
06 0 0 
8.52E+
06 0 0 
C3 
QGALELIK 0 yes yes 2 0.012758 
0 0 0 
8.11E+
07 0 0 
8.09E+
07 
7.93E+
07 0 
C3 
IFTVNHK 0 yes yes 2 0.012853 
3.06E+
06 0 0 0 0 
2.50E+
06 
4.73E+
06 
5.40E+
06 0 
C3 
VVPEGIR 0 yes yes 2 0.022027 
6.33E+
06 0 
5.88E+
06 
1.13E+
07 
1.10E+
07 0 
9.73E+
06 
1.30E+
07 0 
C3 
LMNIFLK 0 yes yes 2 0.022874 
6.64E+
06 0 0 
1.27E+
07 0 0 
1.06E+
07 
9.62E+
06 0 
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C3 
IWDVVEK 0 no no 2 0.032481 
6.14E+
07 0 0 0 0 0 0 
8.35E+
07 0 
C3 
LVLSSEK 0 yes no 2 0.033095 
7.53E+
06 0 
9.11E+
06 0 0 
1.09E+
07 
1.51E+
07 
1.75E+
07 0 
C3 
SEFPESWLWNVEDLK 0 yes yes 2 0.051115 
0 0 0 0 
1.62E+
06 0 0 0 0 
C3 
VVLVAVDK 0 yes yes 2 0.056084 
0 0 0 0 0 0 0 0 
5.23E+
06 
C3 
NEQVEIR 0 no no 2 0.061346 
0 0 0 0 0 
1.62E+
07 0 0 0 
C4-A 
PVAFSVVPTAAAAVSLK 0 yes no 2,3 2.47E-50 
1.85E+
06 
2.08E+
07 
2.09E+
06 
5.25E+
06 
2.66E+
06 
3.02E+
06 
4.99E+
06 
3.11E+
06 
1.46E+
06 
C4-A 
LQETSNWLLSQQQADGSFQD
PCPVLDR 0 yes no 3 7.10E-08 
0 
4.85E+
06 0 0 0 0 0 0 0 
C4-A 
DSSTWLTAFVLK 0 yes no 2 0.020117 
0 
3.15E+
06 0 
3.50E+
06 
2.62E+
06 0 
3.66E+
06 0 0 
C4-B 
VLSLAQEQVGGSPEK 0 no no 2 6.66E-175 
6.75E+
07 
7.22E+
07 
1.50E+
07 
7.51E+
07 
4.78E+
06 
1.02E+
07 
6.58E+
07 
7.39E+
07 0 
C4-B 
VTASDPLDTLGSEGALSPGGV
ASLLR 0 no no 2,3 4.29E-106 
1.72E+
07 
4.68E+
07 
7.58E+
06 
1.84E+
07 
4.58E+
06 
1.16E+
07 
9.88E+
06 
1.09E+
07 
9.75E+
06 
C4-B 
LLATLCSAEVCQCAEGK 0 no no 2,3 2.97E-66 
1.90E+
07 
3.48E+
07 
2.92E+
06 
4.33E+
07 
3.46E+
06 
1.64E+
06 
2.98E+
07 
3.22E+
07 
4.40E+
06 
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C4-B 
TTNIQGINLLFSSR 0 no no 2 1.75E-60 
2.78E+
06 
4.51E+
07 
6.00E+
06 
1.26E+
07 
5.29E+
06 
3.74E+
06 
8.64E+
06 
7.81E+
06 
1.30E+
06 
C4-B 
ALEILQEEDLIDEDDIPVR 0 no no 2 1.31E-44 
0 0 
2.77E+
06 0 0 0 0 
6.79E+
06 0 
C4-B 
DHAVDLIQK 0 no no 2 5.73E-40 
2.02E+
07 
1.93E+
07 
8.44E+
06 
2.50E+
07 
5.26E+
06 
8.70E+
06 
2.00E+
07 
2.09E+
07 
3.68E+
06 
C4-B 
EELVYELNPLDHR 0 no no 2,3 1.31E-35 
6.72E+
06 
2.92E+
07 
2.77E+
06 
1.82E+
07 
6.74E+
06 0 
1.35E+
07 
3.62E+
06 0 
C4-B 
STQDTVIALDALSAYWIASHT
TEER 0 no no 2,3 7.49E-27 
0 
4.61E+
06 0 
1.29E+
07 0 0 
1.02E+
07 0 0 
C4-B 
GHLFLQTDQPIYNPGQR 0 no no 2,3 1.99E-22 
0 
4.79E+
06 0 
1.17E+
07 0 0 
1.66E+
06 0 0 
C4-B 
AACAQLNDFLQEYGTQGCQV 0 no no 2 6.00E-22 
7.42E+
06 
8.54E+
06 
6.26E+
06 
1.17E+
07 
5.12E+
06 
6.14E+
06 
6.06E+
06 
1.01E+
07 0 
C4-B 
QGSFQGGFR 0 no no 2 2.49E-15 
1.54E+
07 
1.16E+
07 
8.41E+
06 
1.89E+
07 
5.55E+
06 
9.53E+
06 
1.54E+
07 
1.61E+
07 0 
C4-B 
DFALLSLQVPLK 0 no no 2 2.64E-13 
8.41E+
06 
2.19E+
07 
5.30E+
06 
1.10E+
07 
6.02E+
06 
2.12E+
06 
8.27E+
06 
4.31E+
06 
6.71E+
05 
C4-B 
VGDTLNLNLR 0 no no 2 1.71E-11 
0 
6.24E+
07 0 
8.45E+
07 
5.08E+
06 0 
4.76E+
07 
3.43E+
07 
4.53E+
06 
C4-B 
CSVFYGAPSK 0 no no 2 2.17E-07 
6.38E+
06 0 
2.07E+
06 0 
1.97E+
06 
2.56E+
06 
9.29E+
06 
6.81E+
06 0 
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C4-B 
SCGLHQLLR 0 no no 2,3 2.55E-06 
1.03E+
07 
9.07E+
06 0 
3.15E+
07 0 0 
1.24E+
07 0 0 
C4-B 
AEFQDALEK 0 no no 2 3.09E-06 
3.29E+
07 
3.10E+
07 
1.42E+
07 
3.99E+
07 
9.99E+
06 
1.62E+
07 
3.04E+
07 
3.79E+
07 0 
C4-B 
PVQGVAYVR 0 no no 2 3.35E-06 
8.55E+
06 
1.03E+
07 
3.37E+
06 
2.02E+
07 
3.26E+
06 
2.94E+
06 
1.16E+
07 
1.35E+
07 0 
C4-B 
HLVPGAPFLLQALVR 0 no no 3 1.74E-05 
5.92E+
05 
5.06E+
06 0 
2.28E+
06 0 0 
8.86E+
05 0 0 
C4-B 
GPEVQLVAHSPWLK 0 no no 2,3 4.71E-05 
0 
1.56E+
07 0 
6.13E+
06 0 0 
7.44E+
06 0 0 
C4-B 
LGQYASPTAK 0 no no 2 0.000324 
6.94E+
06 
6.72E+
06 
8.09E+
06 
1.28E+
07 
6.17E+
06 
7.39E+
06 
7.26E+
06 
8.87E+
06 0 
C4-B 
GLQDEDGYR 0 no no 2 0.000327 
5.76E+
06 
6.06E+
06 
5.74E+
06 
1.08E+
07 
4.66E+
06 
5.67E+
06 
6.01E+
06 
8.42E+
06 0 
C4-B 
VDFTLSSER 0 no no 2 0.000359 
2.85E+
07 
3.24E+
07 
6.00E+
06 
3.53E+
07 0 0 
2.68E+
07 
2.87E+
07 0 
C4-B 
KADGSYAAWLSR 1 no no 3 0.000379 
0 0 0 0 0 0 0 0 0 
C4-B 
TEQWSTLPPETK 0 no no 2 0.00054 
7.50E+
06 0 0 0 0 0 
6.02E+
06 
6.88E+
06 0 
C4-B 
GSFEFPVGDAVSK 0 no no 2 0.000868 
2.62E+
07 
2.62E+
07 0 
3.57E+
07 0 0 
2.68E+
07 
3.04E+
07 0 
C4-B 
LTVAAPPSGGPGFLSIERPDSR
PPR 2 no no 4 0.001097 
0 
9.92E+
06 0 0 0 0 0 0 0 
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C4-B 
ITQVLHFTK 0 no no 2,3 0.001421 
1.20E+
07 
1.37E+
07 0 
2.10E+
07 0 0 
1.94E+
07 
1.35E+
07 0 
C4-B 
GLCVATPVQLR 0 no no 2 0.001456 
0 0 0 0 0 0 
2.51E+
07 
2.45E+
07 
2.57E+
06 
C4-B 
FGLLDEDGKK 1 no no 2,3 0.002211 
7.34E+
06 
8.50E+
06 0 
8.20E+
06 0 0 
2.24E+
07 0 0 
C4-B 
YVLPNFEVK 0 no no 2 0.002692 
0 0 
3.44E+
06 0 
2.71E+
06 
2.30E+
06 
2.27E+
07 
1.68E+
07 0 
C4-B 
ASAGLLGAHAAAITAYALTLTK 0 no no 3 0.003771 
0 
1.86E+
06 0 0 0 0 
4.48E+
06 0 0 
C4-B 
LELSVDGAK 0 no no 1,2 0.00404 
1.93E+
07 
1.91E+
07 0 
3.49E+
07 0 0 
1.68E+
07 
2.00E+
07 0 
C4-B 
FGLLDEDGK 0 no no 2 0.005188 
9.85E+
06 0 0 
1.71E+
07 0 0 0 0 0 
C4-B 
VDVQAGACEGK 0 no no 2 0.0083 
0 0 
3.23E+
06 
4.80E+
06 
2.56E+
06 0 
3.67E+
06 
4.58E+
06 0 
C4-B 
VEYGFQVK 0 no no 2 0.011353 
2.02E+
07 
2.62E+
07 0 
3.11E+
07 0 0 
1.97E+
07 0 0 
C4-B 
LTVAAPPSGGPGFLSIER 0 no no 2 0.013815 
0 
9.91E+
06 0 
9.59E+
06 0 0 0 0 0 
C4-B 
LVNGQSHISLSK 0 no no 2,3 0.017968 
0 
5.58E+
06 0 
2.62E+
06 0 0 
6.04E+
06 
4.71E+
06 0 
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C4-B 
LNMGITDLQGLR 0 no no 2 0.019475 
0 0 0 
6.36E+
06 0 0 
1.75E+
06 0 0 
C4-B 
SHALQLNNR 0 no no 2,3 0.029639 
1.03E+
06 0 0 
4.64E+
06 0 0 
1.35E+
06 0 0 
C4-B 
EPFLSCCQFAESLR 0 no no 2 0.031572 
0 0 0 
2.17E+
06 0 0 0 0 0 
C4-B 
FACYYPR 0 no no 2 0.054082 
0 0 0 0 0 0 
1.09E+
07 
1.29E+
07 0 
C4-B 
GLEEELQFSLGSK 0 no no 2 0.058066 
0 0 0 
3.96E+
06 0 0 0 0 0 
C4-B 
GSSTWLTAFVLK 0 yes no 2 0.058978 
0 0 0 0 0 0 
4.25E+
06 0 0 
CFH 
LGYVTADGETSGSITCGK 0 yes yes 2 1.66E-40 
7.43E+
06 
1.25E+
07 0 
1.29E+
07 
3.35E+
06 
1.69E+
06 
1.29E+
07 
1.13E+
07 0 
CFH 
AGEQVTYTCATYYK 0 yes yes 2 1.33E-26 
1.21E+
07 
2.34E+
07 0 
2.19E+
07 
2.93E+
06 
1.12E+
06 
1.96E+
07 
2.33E+
07 
7.34E+
05 
CFH 
VSVLCQENYLIQEGEEITCK 0 yes yes 2,3 1.58E-15 
2.83E+
06 
1.33E+
07 
2.97E+
06 
1.25E+
07 
3.05E+
06 
3.30E+
06 
9.27E+
06 
6.16E+
06 
1.29E+
06 
CFH 
AVYTCNEGYQLLGEINYR 0 yes no 2 1.49E-06 
0 
1.02E+
07 0 
3.54E+
06 
2.08E+
06 0 
2.20E+
06 
2.79E+
06 0 
CFH 
SSIDIENGFISESQYTYALK 0 yes yes 2 1.94E-06 
0 
2.80E+
06 0 
2.88E+
06 0 0 0 
1.16E+
06 0 
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CFH 
LSYTCEGGFR 0 yes yes 2 9.26E-05 
2.20E+
07 
2.16E+
07 0 
2.48E+
07 
4.80E+
06 0 
2.34E+
07 
2.53E+
07 
2.10E+
06 
CFH 
SSNLIILEEHLK 0 yes yes 2,3 0.000662 
0 0 0 
1.58E+
07 0 0 
1.65E+
07 0 0 
CFH 
EQVQSCGPPPELLNGNVK 0 yes yes 2 0.00172 
8.15E+
05 
7.63E+
05 0 
1.71E+
06 0 0 
1.20E+
06 
1.31E+
06 0 
CFH 
WSSPPQCEGLPCK 0 yes yes 2 0.002179 
4.04E+
06 
6.20E+
06 0 
5.28E+
06 0 0 
5.00E+
06 
7.18E+
06 0 
CFH 
CFEGFGIDGPAIAK 0 yes yes 2 0.003203 
4.76E+
06 
8.66E+
06 
1.26E+
06 
2.54E+
06 
2.98E+
06 
3.77E+
06 
9.18E+
06 
1.56E+
06 0 
CFH 
IDVHLVPDR 0 yes yes 2 0.003643 
7.37E+
06 
8.93E+
06 0 
8.12E+
06 0 0 0 0 0 
CFH 
NTEILTGSWSDQTYPEGTQAI
YK 0 yes no 2 0.004231 
0 0 0 
1.76E+
06 0 0 0 0 0 
CFH 
DTSCVNPPTVQNAYIVSR 0 yes yes 2 0.004345 
0 0 0 
1.58E+
06 0 0 0 0 0 
CFH 
SCDNPYIPNGDYSPLR 0 yes no 2 0.005497 
2.14E+
06 0 0 
2.37E+
06 0 0 
2.12E+
06 0 0 
CFH 
KGEWVALNPLR 1 yes no 3 0.005629 
0 
6.66E+
06 0 0 0 0 0 0 0 
CFH 
SIDVACHPGYALPK 0 yes no 3 0.011134 
9.48E+
06 0 0 0 0 0 
1.21E+
07 
8.42E+
06 0 
CFH 
TGESVEFVCK 0 yes yes 2 0.013467 
0 0 0 0 0 0 0 0 0 
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CFH 
WQSIPLCVEK 0 yes yes 2 0.030882 
7.14E+
06 0 0 0 0 0 
9.51E+
06 
1.22E+
07 0 
CFH 
FVCNSGYK 0 yes no 2 0.049407 
0 0 0 0 0 
2.98E+
06 0 0 0 
GSN 
TPSAAYLWVGTGASEAEK 0 yes no 2 4.20E-16 
0 
5.43E+
06 0 
5.78E+
06 0 0 
5.17E+
06 0 0 
GSN 
QTQVSVLPEGGETPLFK 0 yes no 2 3.62E-08 
2.62E+
06 
6.26E+
06 0 
8.74E+
06 
2.76E+
06 
1.48E+
06 
6.08E+
06 
1.96E+
06 
1.99E+
06 
GSN 
EVQGFESATFLGYFK 0 yes no 2 7.65E-07 
1.50E+
06 
5.17E+
06 0 
4.19E+
06 
1.64E+
06 0 
3.03E+
06 
9.55E+
05 0 
GSN 
AQPVQVAEGSEPDGFWEAL
GGK 0 yes no 2 1.78E-06 
0 
1.88E+
06 0 
1.87E+
06 0 0 0 0 0 
GSN 
AGALNSNDAFVLK 0 yes no 2 0.000408 
0 
1.11E+
07 0 
1.35E+
07 0 0 
1.23E+
07 
7.21E+
06 0 
GSN 
HVVPNEVVVQR 0 yes no 2,3 0.000929 
2.87E+
06 
9.48E+
06 0 
4.78E+
06 0 0 
4.68E+
06 
2.97E+
06 0 
GSN 
PALPAGTEDTAK 0 yes no 2 0.007971 
0 
1.03E+
06 0 
3.18E+
06 0 0 
3.45E+
06 0 0 
GSN 
DPDQTDGLGLSYLSSHIANVE
R 0 yes no 3 0.033608 
0 
3.62E+
06 0 0 0 0 0 0 0 
GSN 
EPGLQIWR 0 yes no 2 0.037589 
0 0 0 
4.82E+
06 0 0 0 0 0 
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GSN 
SEDCFILDHGK 0 yes no 3 0.044182 
0 0 0 
5.05E+
06 0 0 
3.44E+
06 0 0 
SAP 
IVLGQEQDSYGGK 0 yes yes 2 0.00064 
0 
9.38E+
06 0 
7.40E+
06 0 0 0 
8.68E+
06 0 
SAP 
AYSLFSYNTQGR 0 yes yes 2 0.001124 
7.95E+
06 
1.02E+
07 0 0 0 0 
3.48E+
06 
9.08E+
06 0 
SAP 
QGYFVEAQPK 0 yes yes 2 0.005256 
8.02E+
06 
6.10E+
06 0 
5.57E+
06 0 0 
2.09E+
06 0 0 
SAP 
VGEYSLYIGR 0 yes yes 2 0.005256 
0 0 0 
6.48E+
06 0 0 0 
4.80E+
06 0 
SAP 
DNELLVYK 0 yes yes 2 0.010095 
4.69E+
06 0 0 
4.09E+
06 0 0 
2.25E+
06 
2.61E+
06 0 
A1AG: Alpha-1-acid Glycoprotein 1, Alpha-1-antitrypsin, A2M: Alpha-2-macroglobulin, APOA-I: Apolipoprotein A-I, ApoE: Apolipoprotein E, CERU: Ceruloplasmin, 
CLU: Clusterin, C3: Complement C3, C4-A: Complement C4-A, C4-B: Complement C4-B, CFH: Complement Factor H, GSN: Gelsolin, SAP: Serum Amyloid P, PEP: 
Posterior Error Probability, HAD: HIV Associated Dementia, MNI: Minor Neurocognitive Impairment, POS: HIV Positive Control.
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Chapter 10  
Appendix C: Final High Throughput PRM Assay 
 
TABLE 10.1: RAW PRM PEPTIDE DATA AVERAGED TO GIVE REPRESENTATIVE PROTEIN VALUES 
P
at
ie
n
t 
G
ro
u
p
 
sp
|P
0
1
02
3
|A
2
M
G
 
sp
|P
0
8
60
3
|C
FA
H
 
sp
|P
0
2
64
9
|A
P
O
E 
sp
|P
1
0
90
9
|C
LU
S 
sp
|P
0
6
39
6
|G
EL
S 
sp
|P
0
2
74
3
|S
A
M
P
 
sp
|P
0
2
76
3
|A
1
A
G
1 
sp
|P
0
1
00
9
|A
1
A
T 
sp
|P
0
2
64
7
|A
P
O
A
1 
sp
|P
0
0
45
0
|C
ER
U
 
sp
|P
0
C
0
L4
/5
|C
O
4 
sp
|P
0
1
02
4
|C
O
3 
sp
|P
0
1
86
1
|I
G
H
G
4 
1 Control 71415240 7782003.5 3005355.5 28342590 1976906 5459729 16087954 162214952 24498716 14719187 13581328 109646488 364794112 
2 Control 52129109 4385080 2571627 11731742.5 1791102.5 974658.5 2978098 43001348 20283971.5 8391309 8885475 51170122 125390672 
3 Control 127857096 28001535.5 4515216.5 34542406 2969473.5 3281467.5 8087178 370852104 120183592 68558466 21229840 175824432 69829224 
4 Control 31038437 4951136.5 2378897.5 16315096 1228586.5 1580298.5 2673960 53969152 18746663.5 9124818.5 4577692 34658233 107740912 
5 Control 76752152 11372512.5 19642228.5 21359258 2677493.5 3787371.5 10446998 128273852 83526428 19062201.5 12107538.5 108438652 116419552 
6 Control 139099216 24346128 6209569.5 33012315 7868341 4913925 7974155 339105928 90043424 28399462.5 25744344.5 120121712 278351744 
7 Control 118268156 8251494.5 3051418 16911857.5 4446138 2812805.5 3846511 121708816 63961296 15666995 14109685 78038792 187938144 
8 Control 40971485 4671514.5 2527727.5 3833214.5 1140821 426361.5 3482209 52822860.5 29146965 20133176 8785312.5 48358052 83294096 
9 Control 186723108 7429973 3024476.5 17131421 5917342.5 2435026.5 4185877 121318896 76642656 16167725.5 10149872 86233520 460260288 
10 Control 30600575 5264585.5 331081 2228899.5 333533 219455 266995 17813551 5434796.5 6770917.5 3502921.5 30999221 47338588 
11 Control 62875034 13070363 3778758 29855144 4477281 2120263 9786252 207387764 61891420 24773361.5 20581086 101192244 322006336 
12 Control 47720084 5397422 847515 8501861.5 1395505.5 1792274 6061244 113427948 10308760.5 6641527 7040750 31753697 187952416 
13 Control 74276900 8980958.5 1435482.5 14394037 4419215 2374187 4171083 102854760 43535230 14837424 16652011 79516444 303216544 
14 Control 15808946.5 2359398 665491 5844688.5 551203.5 410623.5 1500618 30298256 16610541 4211243 1910304 16860396 78688216 
15 Control 120247584 6759115 3223988 6852747.5 1953956.5 1023690.5 2439245 66121876 73446776 20474389 25649003 99313522 408156736 
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16 MNI 88291824 7620870 1493390.5 21169530 4758269 2006419 4286864 116800936 37773016 16185603.5 14379728 76327432 155389136 
17 MNI 53544132 7337609 2441690 17908449 2083936.5 1867961.5 7952100 93523060 45873736 10045208.5 6324152 68423628 179910640 
18 MNI 47672056 5488237.5 3112809.5 15978493 2512214 978790.5 3519266 100915548 41580204 11176691.5 4321570.5 51875911 102396912 
19 MNI 69228184 3664150 2016456.5 4579725 1269919.5 644324 1090137 56661637 47418528 13862198 10593164 48490256 252821088 
20 MNI 20262673.5 2635658 1773659 4464641.5 286336 680871.5 2744753 18835456.5 35002434 8966417.5 4308796.5 24933156 340503168 
21 MNI 117708460 10168868.5 5709580.5 11839329 3874366.5 4234713 11342191 152095680 46896716 13967214 29646386 111102890 398986560 
22 MNI 66804868 6769401 6102588.5 13057389.5 3934892.5 1247721.5 4046640 58185862 25832714 10464291.5 3839362 43134483 133165632 
23 MNI 134680188 15959997 5195610 32392362 3120948 4343323 6229029 450204768 113495916 66014988 17803499 114117580 101900992 
24 MNI 29963433.5 3579147 700875 4001824 186940.5 150254.5 479414 14531012 2021808 4829164 3734617 27716160 130550624 
25 MNI 48911861.5 4139702 3501762.5 4306121 1215172 283623.5 2120573 30138193.5 33004678 11815181 15534560 43292248 128076048 
26 MNI 38714812 4423493 1361706 9242173 1100106.5 2141258.5 2282136 52862528 24472652 7156103.5 23468479 47997062 152971296 
27 MNI 68494746 9211729 3979955.5 12957829 3992021.5 2302753.5 6065798 132553744 40494978 16038148.5 8426071 76753120 177657616 
28 MNI 143961544 13548344.5 3667905 10435447.5 7924100 2941204.5 9171624 201714520 94025928 19669716 20893720 82611320 256112528 
29 MNI 25386745 1507772 513909.5 10822541.5 377264 348190.5 1324898 24678678 10351605.5 3760096.5 1436296.5 14426151 86584272 
30 MNI 91805160 9049173 4337352.5 16458916 5421910 1004962 6038602 98058144 34488036 10753532.5 8883311.5 98318448 235977520 
31 MNI 189187896 12475102 5610050 37524168 6397663 2902836.5 5342622 241858456 87412308 20016506 9543129.5 93353770 295328448 
32 MNI 60121362 2140080 1408479.5 4146871.5 1799490 966303.5 3755979 51346934 13057015 5100867 11669926 25850538 151998000 
33 MNI 34436701 6400458 3344146.5 6731984.5 4120149 686112 3049857 79989896 46082434 20858918 6681812.5 38925167 62998372 
34 MNI 57967822 3870003 3438583.5 14764470 2263790.5 1041401 4597926 45204798 39410417 6011602 3149905.5 38055560 226230304 
35 HAD 51663995 1218220.5 1478444.5 2855886.5 838789.5 260533.5 2258124 16502588.5 20741299 8248530 15473913 33093102 59543972 
36 HAD 101879098 6695897 4453699 11954896 2152749.5 1080419 8107634 85693580 81421648 21496135.5 9649306 54215179 169055216 
37 HAD 36286189 4408163 4281051 7784639 2055526.5 1884295 6796799 39666368 28578644 7183159 5119908 26851710 145633104 
38 HAD 69952882 3490371.5 3068845 5637284 1101445 1292262 3222662 170576264 45031175 22465446 19926566.5 61244850 175132496 
39 HAD 45795688.5 3946849.5 4500845.5 3610073.5 584933 614984 10875511 88743229 23511536.5 23452458 9237182.5 37613059 377994240 
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40 HAD 16993130 639493 113651 2850656.5 41431.5 213251 442980 3442754 1227566 1190016 930737.5 9153840 127574400 
41 HAD 84107122 9717010 3382701.5 45512672 3402831.5 1827378.5 6276358 168346184 29069894 14899599 10115792 93675354 473510720 
42 HAD 40185817 3730220 1445284 10911724 2762519.5 715564.5 3155959 79287800 21648663 10030367 6061592.5 24861771 25087292 
43 HAD 102602756 5067124 3221815 6991871.5 1318362.5 1831027 6590752 80696956 74732576 8380369 23423117 63255314 110797592 
44 HAD 13831621.5 4323035.5 3587371.5 5616585.5 2249925.5 539033.5 2699763 60205885 23157904 16165624.5 6651118.5 28448224 127471664 
45 HAD 10962366 2313828.5 1027276 6401974 431793 701535 1689882 33528150 25229709 4511380 2005976.5 12960586 76192208 
46 HAD 15875901.5 1599381 468258.5 885080.5 154803 94207 1534472 7519493 2607760.5 2886735 4680470 18593668.5 27886574 
47 HAD 50184458 2659655.5 2895260 3757791 757118.5 644755 3883461 37076222.5 30419750 11278870 11749858.5 27163198 191662496 
48 HAD 24527972 2421385.5 124044.5 2327620 110601 19655 799932 8191831.5 2494018 2657487.5 4448834.5 13065813 47137068 
49 HAD 68607036 4866749 4876377 14879189 1889519 2793653 6083366 85035396 46753664 23337234 12760288 53114288 140024896 
50 HAD 125255456 23605346 12722663.5 18609392 9971867 2964539 22348520 569511504 64718892 55524336 51808254 180579332 529726080 
51 HAD 112982948 8172602.5 4178825 14764597 2210517.5 2976913 2991793 180976224 73767740 31658604 23077656 109146452 252886208 
52 HAD 20710982 4625799.5 3244832 6972436 1722401 3072159 3354974 58307678 34587680 6116484 7215073 18505733 65128100 
53 HAD 35989406 1892619.5 1255688 3001321 1476131 529710.5 2475604 41195249 20810329 3769935 2541726.5 14668839.5 74167632 
54 HAD 52099989 8334503 2756482.5 6530325 2129374 1173244.5 2303642 69593258 42438433 28433389 18772659 81470712 171216880 
55 HAD 89279406 10465974 4766587.5 23714767 5879800 6488826.5 14747374 172278784 64634224 17661993 21735459 90282218 185202192 
A2MG: Alpha-2-macroglobulin, CFAH: Complement factor H, APOE: Apolipoprotein E, CLUS: Clusterin, GELS: Gelsolin, SAMP: Serum Amyloid P, A1AG1: Alpha-1-acid 
glycoprotein 1, A1AT: Alpha-1antitrypsin, APOA1: Apolipoprotein A-I, CERU: Ceruloplasmin, CO4: Complement C component 4, CO3: Complement component 3, 
IGHG4: IgG4 (Peptide STSESTAALGC[+57.0]LV) 
